id	sid	tid	token	lemma	pos
cord-315453-mbv8vb2r	1	1	key	key	JJ
cord-315453-mbv8vb2r	1	2	:	:	:
cord-315453-mbv8vb2r	1	3	cord-315453-mbv8vb2r	cord-315453-mbv8vb2r	NNP
cord-315453-mbv8vb2r	1	4	authors	author	NNS
cord-315453-mbv8vb2r	1	5	:	:	:
cord-315453-mbv8vb2r	1	6	Jean	Jean	NNP
cord-315453-mbv8vb2r	1	7	,	,	,
cord-315453-mbv8vb2r	1	8	Shio	Shio	NNP
cord-315453-mbv8vb2r	1	9	-	-	HYPH
cord-315453-mbv8vb2r	1	10	Shin	Shin	NNP
cord-315453-mbv8vb2r	1	11	;	;	:
cord-315453-mbv8vb2r	1	12	Hsueh	Hsueh	NNP
cord-315453-mbv8vb2r	1	13	,	,	,
cord-315453-mbv8vb2r	1	14	Po	Po	NNP
cord-315453-mbv8vb2r	1	15	-	-	HYPH
cord-315453-mbv8vb2r	1	16	Ren	Ren	NNP
cord-315453-mbv8vb2r	1	17	title	title	NN
cord-315453-mbv8vb2r	1	18	:	:	:
cord-315453-mbv8vb2r	2	1	Old	old	JJ
cord-315453-mbv8vb2r	2	2	and	and	CC
cord-315453-mbv8vb2r	2	3	re	re	JJ
cord-315453-mbv8vb2r	2	4	-	-	JJ
cord-315453-mbv8vb2r	2	5	purposed	purpose	VBN
cord-315453-mbv8vb2r	2	6	drugs	drug	NNS
cord-315453-mbv8vb2r	2	7	for	for	IN
cord-315453-mbv8vb2r	2	8	the	the	DT
cord-315453-mbv8vb2r	2	9	treatment	treatment	NN
cord-315453-mbv8vb2r	2	10	of	of	IN
cord-315453-mbv8vb2r	2	11	COVID-19	covid-19	CD
cord-315453-mbv8vb2r	2	12	date	date	NN
cord-315453-mbv8vb2r	2	13	:	:	:
cord-315453-mbv8vb2r	2	14	2020	2020	CD
cord-315453-mbv8vb2r	2	15	-	-	HYPH
cord-315453-mbv8vb2r	2	16	06	06	CD
cord-315453-mbv8vb2r	2	17	-	-	HYPH
cord-315453-mbv8vb2r	2	18	01	01	CD
cord-315453-mbv8vb2r	2	19	journal	journal	NN
cord-315453-mbv8vb2r	2	20	:	:	:
cord-315453-mbv8vb2r	3	1	Expert	expert	NN
cord-315453-mbv8vb2r	3	2	review	review	NN
cord-315453-mbv8vb2r	3	3	of	of	IN
cord-315453-mbv8vb2r	3	4	anti	anti	JJ
cord-315453-mbv8vb2r	3	5	-	-	JJ
cord-315453-mbv8vb2r	3	6	infective	infective	JJ
cord-315453-mbv8vb2r	3	7	therapy	therapy	NN
cord-315453-mbv8vb2r	3	8	DOI	doi	NN
cord-315453-mbv8vb2r	3	9	:	:	:
cord-315453-mbv8vb2r	4	1	10.1080/14787210.2020.1771181	10.1080/14787210.2020.1771181	NNP
cord-315453-mbv8vb2r	4	2	sha	sha	NNP
cord-315453-mbv8vb2r	4	3	:	:	:
cord-315453-mbv8vb2r	4	4	ef211de460af75536bf00e0a0a3735e2670c236a	ef211de460af75536bf00e0a0a3735e2670c236a	NNS
cord-315453-mbv8vb2r	4	5	doc_id	doc_id	CD
cord-315453-mbv8vb2r	4	6	:	:	:
cord-315453-mbv8vb2r	4	7	315453	315453	CD
cord-315453-mbv8vb2r	4	8	cord_uid	cord_uid	NNS
cord-315453-mbv8vb2r	4	9	:	:	:
cord-315453-mbv8vb2r	4	10	mbv8vb2r	mbv8vb2r	CD
cord-315453-mbv8vb2r	4	11	INTRODUCTION	introduction	NN
cord-315453-mbv8vb2r	4	12	:	:	:
cord-315453-mbv8vb2r	5	1	The	the	DT
cord-315453-mbv8vb2r	5	2	coronavirus	coronavirus	NN
cord-315453-mbv8vb2r	5	3	disease	disease	NN
cord-315453-mbv8vb2r	5	4	2019	2019	CD
cord-315453-mbv8vb2r	5	5	(	(	-LRB-
cord-315453-mbv8vb2r	5	6	COVID-19	COVID-19	NNP
cord-315453-mbv8vb2r	5	7	)	)	-RRB-
cord-315453-mbv8vb2r	5	8	caused	cause	VBN
cord-315453-mbv8vb2r	5	9	by	by	IN
cord-315453-mbv8vb2r	5	10	the	the	DT
cord-315453-mbv8vb2r	5	11	novel	novel	JJ
cord-315453-mbv8vb2r	5	12	severe	severe	JJ
cord-315453-mbv8vb2r	5	13	acute	acute	JJ
cord-315453-mbv8vb2r	5	14	respiratory	respiratory	JJ
cord-315453-mbv8vb2r	5	15	syndrome	syndrome	NN
cord-315453-mbv8vb2r	5	16	coronavirus	coronavirus	NN
cord-315453-mbv8vb2r	5	17	2	2	CD
cord-315453-mbv8vb2r	5	18	(	(	-LRB-
cord-315453-mbv8vb2r	5	19	SARS	SARS	NNP
cord-315453-mbv8vb2r	5	20	-	-	HYPH
cord-315453-mbv8vb2r	5	21	CoV-2	CoV-2	NNP
cord-315453-mbv8vb2r	5	22	)	)	-RRB-
cord-315453-mbv8vb2r	5	23	has	have	VBZ
cord-315453-mbv8vb2r	5	24	developed	develop	VBN
cord-315453-mbv8vb2r	5	25	since	since	IN
cord-315453-mbv8vb2r	5	26	December	December	NNP
cord-315453-mbv8vb2r	5	27	2019	2019	CD
cord-315453-mbv8vb2r	5	28	.	.	.
cord-315453-mbv8vb2r	6	1	It	-PRON-	PRP
cord-315453-mbv8vb2r	6	2	has	have	VBZ
cord-315453-mbv8vb2r	6	3	caused	cause	VBN
cord-315453-mbv8vb2r	6	4	a	a	DT
cord-315453-mbv8vb2r	6	5	global	global	JJ
cord-315453-mbv8vb2r	6	6	pandemic	pandemic	NN
cord-315453-mbv8vb2r	6	7	with	with	IN
cord-315453-mbv8vb2r	6	8	more	more	JJR
cord-315453-mbv8vb2r	6	9	than	than	IN
cord-315453-mbv8vb2r	6	10	three	three	CD
cord-315453-mbv8vb2r	6	11	hundred	hundred	CD
cord-315453-mbv8vb2r	6	12	thousand	thousand	CD
cord-315453-mbv8vb2r	6	13	case	case	NN
cord-315453-mbv8vb2r	6	14	fatalities	fatality	NNS
cord-315453-mbv8vb2r	6	15	.	.	.
cord-315453-mbv8vb2r	7	1	However	however	RB
cord-315453-mbv8vb2r	7	2	,	,	,
cord-315453-mbv8vb2r	7	3	apart	apart	RB
cord-315453-mbv8vb2r	7	4	from	from	IN
cord-315453-mbv8vb2r	7	5	supportive	supportive	JJ
cord-315453-mbv8vb2r	7	6	care	care	NN
cord-315453-mbv8vb2r	7	7	by	by	IN
cord-315453-mbv8vb2r	7	8	respirators	respirator	NNS
cord-315453-mbv8vb2r	7	9	,	,	,
cord-315453-mbv8vb2r	7	10	no	no	DT
cord-315453-mbv8vb2r	7	11	standard	standard	JJ
cord-315453-mbv8vb2r	7	12	medical	medical	JJ
cord-315453-mbv8vb2r	7	13	therapy	therapy	NN
cord-315453-mbv8vb2r	7	14	is	be	VBZ
cord-315453-mbv8vb2r	7	15	validated	validate	VBN
cord-315453-mbv8vb2r	7	16	.	.	.
cord-315453-mbv8vb2r	8	1	AREAS	area	NNS
cord-315453-mbv8vb2r	8	2	COVERED	cover	VBN
cord-315453-mbv8vb2r	8	3	:	:	:
cord-315453-mbv8vb2r	9	1	This	this	DT
cord-315453-mbv8vb2r	9	2	paper	paper	NN
cord-315453-mbv8vb2r	9	3	presents	present	VBZ
cord-315453-mbv8vb2r	9	4	old	old	JJ
cord-315453-mbv8vb2r	9	5	drugs	drug	NNS
cord-315453-mbv8vb2r	9	6	with	with	IN
cord-315453-mbv8vb2r	9	7	potential	potential	NN
cord-315453-mbv8vb2r	9	8	in	in	FW
cord-315453-mbv8vb2r	9	9	vitro	vitro	FW
cord-315453-mbv8vb2r	9	10	efficacy	efficacy	NN
cord-315453-mbv8vb2r	9	11	against	against	IN
cord-315453-mbv8vb2r	9	12	SARS	SARS	NNP
cord-315453-mbv8vb2r	9	13	-	-	HYPH
cord-315453-mbv8vb2r	9	14	CoV-2	CoV-2	NNP
cord-315453-mbv8vb2r	9	15	.	.	.
cord-315453-mbv8vb2r	10	1	The	the	DT
cord-315453-mbv8vb2r	10	2	in	in	FW
cord-315453-mbv8vb2r	10	3	vitro	vitro	FW
cord-315453-mbv8vb2r	10	4	database	database	NN
cord-315453-mbv8vb2r	10	5	,	,	,
cord-315453-mbv8vb2r	10	6	adverse	adverse	JJ
cord-315453-mbv8vb2r	10	7	effects	effect	NNS
cord-315453-mbv8vb2r	10	8	,	,	,
cord-315453-mbv8vb2r	10	9	and	and	CC
cord-315453-mbv8vb2r	10	10	potential	potential	JJ
cord-315453-mbv8vb2r	10	11	toxicities	toxicity	NNS
cord-315453-mbv8vb2r	10	12	of	of	IN
cord-315453-mbv8vb2r	10	13	these	these	DT
cord-315453-mbv8vb2r	10	14	drugs	drug	NNS
cord-315453-mbv8vb2r	10	15	are	be	VBP
cord-315453-mbv8vb2r	10	16	reviewed	review	VBN
cord-315453-mbv8vb2r	10	17	regarding	regard	VBG
cord-315453-mbv8vb2r	10	18	their	-PRON-	PRP$
cord-315453-mbv8vb2r	10	19	feasibility	feasibility	NN
cord-315453-mbv8vb2r	10	20	of	of	IN
cord-315453-mbv8vb2r	10	21	clinical	clinical	JJ
cord-315453-mbv8vb2r	10	22	prescription	prescription	NN
cord-315453-mbv8vb2r	10	23	for	for	IN
cord-315453-mbv8vb2r	10	24	the	the	DT
cord-315453-mbv8vb2r	10	25	treatment	treatment	NN
cord-315453-mbv8vb2r	10	26	of	of	IN
cord-315453-mbv8vb2r	10	27	patients	patient	NNS
cord-315453-mbv8vb2r	10	28	with	with	IN
cord-315453-mbv8vb2r	10	29	COVID-19	COVID-19	NNP
cord-315453-mbv8vb2r	10	30	.	.	.
cord-315453-mbv8vb2r	11	1	To	to	TO
cord-315453-mbv8vb2r	11	2	obtain	obtain	VB
cord-315453-mbv8vb2r	11	3	convincing	convincing	JJ
cord-315453-mbv8vb2r	11	4	recommendations	recommendation	NNS
cord-315453-mbv8vb2r	11	5	,	,	,
cord-315453-mbv8vb2r	11	6	we	-PRON-	PRP
cord-315453-mbv8vb2r	11	7	referred	refer	VBD
cord-315453-mbv8vb2r	11	8	to	to	IN
cord-315453-mbv8vb2r	11	9	opinions	opinion	NNS
cord-315453-mbv8vb2r	11	10	from	from	IN
cord-315453-mbv8vb2r	11	11	the	the	DT
cord-315453-mbv8vb2r	11	12	US	US	NNP
cord-315453-mbv8vb2r	11	13	National	National	NNP
cord-315453-mbv8vb2r	11	14	Institute	Institute	NNP
cord-315453-mbv8vb2r	11	15	of	of	IN
cord-315453-mbv8vb2r	11	16	Health	Health	NNP
cord-315453-mbv8vb2r	11	17	regarding	regard	VBG
cord-315453-mbv8vb2r	11	18	drugs	drug	NNS
cord-315453-mbv8vb2r	11	19	repurposed	repurpose	VBN
cord-315453-mbv8vb2r	11	20	for	for	IN
cord-315453-mbv8vb2r	11	21	COVID-19	covid-19	NN
cord-315453-mbv8vb2r	11	22	therapy	therapy	NN
cord-315453-mbv8vb2r	11	23	.	.	.
cord-315453-mbv8vb2r	12	1	EXPERT	EXPERT	NNP
cord-315453-mbv8vb2r	12	2	OPINION	OPINION	NNP
cord-315453-mbv8vb2r	12	3	:	:	:
cord-315453-mbv8vb2r	13	1	Although	although	IN
cord-315453-mbv8vb2r	13	2	strong	strong	JJ
cord-315453-mbv8vb2r	13	3	evidence	evidence	NN
cord-315453-mbv8vb2r	13	4	of	of	IN
cord-315453-mbv8vb2r	13	5	well	well	RB
cord-315453-mbv8vb2r	13	6	-	-	HYPH
cord-315453-mbv8vb2r	13	7	designed	design	VBN
cord-315453-mbv8vb2r	13	8	randomized	randomized	JJ
cord-315453-mbv8vb2r	13	9	controlled	control	VBN
cord-315453-mbv8vb2r	13	10	studies	study	NNS
cord-315453-mbv8vb2r	13	11	regarding	regard	VBG
cord-315453-mbv8vb2r	13	12	COVID-19	COVID-19	NNP
cord-315453-mbv8vb2r	13	13	therapy	therapy	NN
cord-315453-mbv8vb2r	13	14	is	be	VBZ
cord-315453-mbv8vb2r	13	15	presently	presently	RB
cord-315453-mbv8vb2r	13	16	lacking	lack	VBG
cord-315453-mbv8vb2r	13	17	,	,	,
cord-315453-mbv8vb2r	13	18	remdesivir	remdesivir	NNP
cord-315453-mbv8vb2r	13	19	,	,	,
cord-315453-mbv8vb2r	13	20	teicoplanin	teicoplanin	NNP
cord-315453-mbv8vb2r	13	21	,	,	,
cord-315453-mbv8vb2r	13	22	hydroxychloroquine	hydroxychloroquine	NNP
cord-315453-mbv8vb2r	13	23	(	(	-LRB-
cord-315453-mbv8vb2r	13	24	not	not	RB
cord-315453-mbv8vb2r	13	25	in	in	IN
cord-315453-mbv8vb2r	13	26	combination	combination	NN
cord-315453-mbv8vb2r	13	27	with	with	IN
cord-315453-mbv8vb2r	13	28	azithromycin	azithromycin	NNP
cord-315453-mbv8vb2r	13	29	)	)	-RRB-
cord-315453-mbv8vb2r	13	30	,	,	,
cord-315453-mbv8vb2r	13	31	and	and	CC
cord-315453-mbv8vb2r	13	32	ivermectin	ivermectin	NNP
cord-315453-mbv8vb2r	13	33	might	may	MD
cord-315453-mbv8vb2r	13	34	be	be	VB
cord-315453-mbv8vb2r	13	35	effective	effective	JJ
cord-315453-mbv8vb2r	13	36	antiviral	antiviral	JJ
cord-315453-mbv8vb2r	13	37	drugs	drug	NNS
cord-315453-mbv8vb2r	13	38	and	and	CC
cord-315453-mbv8vb2r	13	39	are	be	VBP
cord-315453-mbv8vb2r	13	40	deemed	deem	VBN
cord-315453-mbv8vb2r	13	41	promising	promising	JJ
cord-315453-mbv8vb2r	13	42	candidates	candidate	NNS
cord-315453-mbv8vb2r	13	43	for	for	IN
cord-315453-mbv8vb2r	13	44	controlling	control	VBG
cord-315453-mbv8vb2r	13	45	SARS	SARS	NNP
cord-315453-mbv8vb2r	13	46	-	-	HYPH
cord-315453-mbv8vb2r	13	47	CoV-2	CoV-2	NNP
cord-315453-mbv8vb2r	13	48	.	.	.
cord-315453-mbv8vb2r	14	1	In	in	IN
cord-315453-mbv8vb2r	14	2	addition	addition	NN
cord-315453-mbv8vb2r	14	3	,	,	,
cord-315453-mbv8vb2r	14	4	tocilizumab	tocilizumab	NNP
cord-315453-mbv8vb2r	14	5	might	may	MD
cord-315453-mbv8vb2r	14	6	be	be	VB
cord-315453-mbv8vb2r	14	7	considered	consider	VBN
cord-315453-mbv8vb2r	14	8	as	as	IN
cord-315453-mbv8vb2r	14	9	the	the	DT
cord-315453-mbv8vb2r	14	10	supplementary	supplementary	JJ
cord-315453-mbv8vb2r	14	11	treatment	treatment	NN
cord-315453-mbv8vb2r	14	12	for	for	IN
cord-315453-mbv8vb2r	14	13	COVID-19	covid-19	JJ
cord-315453-mbv8vb2r	14	14	patients	patient	NNS
cord-315453-mbv8vb2r	14	15	with	with	IN
cord-315453-mbv8vb2r	14	16	cytokine	cytokine	NN
cord-315453-mbv8vb2r	14	17	release	release	NN
cord-315453-mbv8vb2r	14	18	syndrome	syndrome	NN
cord-315453-mbv8vb2r	14	19	.	.	.
cord-315453-mbv8vb2r	15	1	In	in	IN
cord-315453-mbv8vb2r	15	2	future	future	JJ
cord-315453-mbv8vb2r	15	3	,	,	,
cord-315453-mbv8vb2r	15	4	clinical	clinical	JJ
cord-315453-mbv8vb2r	15	5	trials	trial	NNS
cord-315453-mbv8vb2r	15	6	regarding	regard	VBG
cord-315453-mbv8vb2r	15	7	a	a	DT
cord-315453-mbv8vb2r	15	8	combination	combination	NN
cord-315453-mbv8vb2r	15	9	of	of	IN
cord-315453-mbv8vb2r	15	10	potentially	potentially	RB
cord-315453-mbv8vb2r	15	11	effective	effective	JJ
cord-315453-mbv8vb2r	15	12	drugs	drug	NNS
cord-315453-mbv8vb2r	15	13	against	against	IN
cord-315453-mbv8vb2r	15	14	SARS	SARS	NNP
cord-315453-mbv8vb2r	15	15	-	-	HYPH
cord-315453-mbv8vb2r	15	16	CoV-2	CoV-2	NNP
cord-315453-mbv8vb2r	15	17	need	need	VB
cord-315453-mbv8vb2r	15	18	to	to	TO
cord-315453-mbv8vb2r	15	19	be	be	VB
cord-315453-mbv8vb2r	15	20	conducted	conduct	VBN
cord-315453-mbv8vb2r	15	21	to	to	TO
cord-315453-mbv8vb2r	15	22	establish	establish	VB
cord-315453-mbv8vb2r	15	23	the	the	DT
cord-315453-mbv8vb2r	15	24	optimal	optimal	JJ
cord-315453-mbv8vb2r	15	25	regimen	regimen	NN
cord-315453-mbv8vb2r	15	26	for	for	IN
cord-315453-mbv8vb2r	15	27	the	the	DT
cord-315453-mbv8vb2r	15	28	treatment	treatment	NN
cord-315453-mbv8vb2r	15	29	of	of	IN
cord-315453-mbv8vb2r	15	30	patients	patient	NNS
cord-315453-mbv8vb2r	15	31	with	with	IN
cord-315453-mbv8vb2r	15	32	moderate	moderate	JJ
cord-315453-mbv8vb2r	15	33	-	-	HYPH
cord-315453-mbv8vb2r	15	34	to	to	IN
cord-315453-mbv8vb2r	15	35	-	-	HYPH
cord-315453-mbv8vb2r	15	36	severe	severe	JJ
cord-315453-mbv8vb2r	15	37	COVID-19	covid-19	NN
cord-315453-mbv8vb2r	15	38	.	.	.
cord-315453-mbv8vb2r	16	1	Since	since	IN
cord-315453-mbv8vb2r	16	2	December	December	NNP
cord-315453-mbv8vb2r	16	3	2019	2019	CD
cord-315453-mbv8vb2r	16	4	,	,	,
cord-315453-mbv8vb2r	16	5	Wuhan	Wuhan	NNP
cord-315453-mbv8vb2r	16	6	city	city	NN
cord-315453-mbv8vb2r	16	7	(	(	-LRB-
cord-315453-mbv8vb2r	16	8	the	the	DT
cord-315453-mbv8vb2r	16	9	capital	capital	NN
cord-315453-mbv8vb2r	16	10	city	city	NN
cord-315453-mbv8vb2r	16	11	of	of	IN
cord-315453-mbv8vb2r	16	12	Hubei	Hubei	NNP
cord-315453-mbv8vb2r	16	13	province	province	NN
cord-315453-mbv8vb2r	16	14	,	,	,
cord-315453-mbv8vb2r	16	15	China	China	NNP
cord-315453-mbv8vb2r	16	16	)	)	-RRB-
cord-315453-mbv8vb2r	16	17	experienced	experience	VBD
cord-315453-mbv8vb2r	16	18	a	a	DT
cord-315453-mbv8vb2r	16	19	major	major	JJ
cord-315453-mbv8vb2r	16	20	outbreak	outbreak	NN
cord-315453-mbv8vb2r	16	21	caused	cause	VBN
cord-315453-mbv8vb2r	16	22	by	by	IN
cord-315453-mbv8vb2r	16	23	the	the	DT
cord-315453-mbv8vb2r	16	24	severe	severe	JJ
cord-315453-mbv8vb2r	16	25	acute	acute	JJ
cord-315453-mbv8vb2r	16	26	respiratory	respiratory	JJ
cord-315453-mbv8vb2r	16	27	syndrome	syndrome	NN
cord-315453-mbv8vb2r	16	28	coronavirus	coronavirus	NN
cord-315453-mbv8vb2r	16	29	2	2	CD
cord-315453-mbv8vb2r	16	30	(	(	-LRB-
cord-315453-mbv8vb2r	16	31	SARS	SARS	NNP
cord-315453-mbv8vb2r	16	32	-	-	HYPH
cord-315453-mbv8vb2r	16	33	CoV-2	CoV-2	NNP
cord-315453-mbv8vb2r	16	34	)	)	-RRB-
cord-315453-mbv8vb2r	16	35	[	[	-LRB-
cord-315453-mbv8vb2r	16	36	1	1	CD
cord-315453-mbv8vb2r	16	37	,	,	,
cord-315453-mbv8vb2r	16	38	2	2	CD
cord-315453-mbv8vb2r	16	39	]	]	-RRB-
cord-315453-mbv8vb2r	16	40	.	.	.
cord-315453-mbv8vb2r	17	1	Owing	owe	VBG
cord-315453-mbv8vb2r	17	2	to	to	IN
cord-315453-mbv8vb2r	17	3	its	-PRON-	PRP$
cord-315453-mbv8vb2r	17	4	high	high	JJ
cord-315453-mbv8vb2r	17	5	transmission	transmission	NN
cord-315453-mbv8vb2r	17	6	potential	potential	NN
cord-315453-mbv8vb2r	17	7	,	,	,
cord-315453-mbv8vb2r	17	8	the	the	DT
cord-315453-mbv8vb2r	17	9	SARS	SARS	NNP
cord-315453-mbv8vb2r	17	10	-	-	HYPH
cord-315453-mbv8vb2r	17	11	CoV-2	CoV-2	NNP
cord-315453-mbv8vb2r	17	12	infection	infection	NN
cord-315453-mbv8vb2r	17	13	has	have	VBZ
cord-315453-mbv8vb2r	17	14	become	become	VBN
cord-315453-mbv8vb2r	17	15	a	a	DT
cord-315453-mbv8vb2r	17	16	global	global	JJ
cord-315453-mbv8vb2r	17	17	public	public	JJ
cord-315453-mbv8vb2r	17	18	health	health	NN
cord-315453-mbv8vb2r	17	19	menace	menace	NN
cord-315453-mbv8vb2r	17	20	[	[	-LRB-
cord-315453-mbv8vb2r	17	21	3	3	CD
cord-315453-mbv8vb2r	17	22	]	]	-RRB-
cord-315453-mbv8vb2r	17	23	.	.	.
cord-315453-mbv8vb2r	18	1	According	accord	VBG
cord-315453-mbv8vb2r	18	2	to	to	IN
cord-315453-mbv8vb2r	18	3	the	the	DT
cord-315453-mbv8vb2r	18	4	COVID-19	COVID-19	NNP
cord-315453-mbv8vb2r	18	5	research	research	NN
cord-315453-mbv8vb2r	18	6	information	information	NN
cord-315453-mbv8vb2r	18	7	published	publish	VBN
cord-315453-mbv8vb2r	18	8	in	in	IN
cord-315453-mbv8vb2r	18	9	the	the	DT
cord-315453-mbv8vb2r	18	10	PubMed	PubMed	NNP
cord-315453-mbv8vb2r	18	11	database	database	NN
cord-315453-mbv8vb2r	18	12	,	,	,
cord-315453-mbv8vb2r	18	13	fever	fever	NN
cord-315453-mbv8vb2r	18	14	(	(	-LRB-
cord-315453-mbv8vb2r	18	15	67	67	CD
cord-315453-mbv8vb2r	18	16	-	-	SYM
cord-315453-mbv8vb2r	18	17	89	89	CD
cord-315453-mbv8vb2r	18	18	%	%	NN
cord-315453-mbv8vb2r	18	19	)	)	-RRB-
cord-315453-mbv8vb2r	18	20	,	,	,
cord-315453-mbv8vb2r	18	21	cough	cough	NN
cord-315453-mbv8vb2r	18	22	(	(	-LRB-
cord-315453-mbv8vb2r	18	23	43	43	CD
cord-315453-mbv8vb2r	18	24	-	-	SYM
cord-315453-mbv8vb2r	18	25	81	81	CD
cord-315453-mbv8vb2r	18	26	%	%	NN
cord-315453-mbv8vb2r	18	27	)	)	-RRB-
cord-315453-mbv8vb2r	18	28	,	,	,
cord-315453-mbv8vb2r	18	29	dyspnea	dyspnea	NN
cord-315453-mbv8vb2r	18	30	(	(	-LRB-
cord-315453-mbv8vb2r	18	31	31	31	CD
cord-315453-mbv8vb2r	18	32	-	-	SYM
cord-315453-mbv8vb2r	18	33	55	55	CD
cord-315453-mbv8vb2r	18	34	%	%	NN
cord-315453-mbv8vb2r	18	35	)	)	-RRB-
cord-315453-mbv8vb2r	18	36	and	and	CC
cord-315453-mbv8vb2r	18	37	myalgia	myalgia	NN
cord-315453-mbv8vb2r	18	38	(	(	-LRB-
cord-315453-mbv8vb2r	18	39	3	3	CD
cord-315453-mbv8vb2r	18	40	-	-	SYM
cord-315453-mbv8vb2r	18	41	44	44	CD
cord-315453-mbv8vb2r	18	42	%	%	NN
cord-315453-mbv8vb2r	18	43	)	)	-RRB-
cord-315453-mbv8vb2r	18	44	were	be	VBD
cord-315453-mbv8vb2r	18	45	the	the	DT
cord-315453-mbv8vb2r	18	46	most	most	RBS
cord-315453-mbv8vb2r	18	47	prevalent	prevalent	JJ
cord-315453-mbv8vb2r	18	48	manifestations	manifestation	NNS
cord-315453-mbv8vb2r	18	49	among	among	IN
cord-315453-mbv8vb2r	18	50	patients	patient	NNS
cord-315453-mbv8vb2r	18	51	with	with	IN
cord-315453-mbv8vb2r	18	52	COVID-19	COVID-19	NNP
cord-315453-mbv8vb2r	18	53	.	.	.
cord-315453-mbv8vb2r	19	1	Elevation	elevation	NN
cord-315453-mbv8vb2r	19	2	of	of	IN
cord-315453-mbv8vb2r	19	3	serum	serum	NN
cord-315453-mbv8vb2r	19	4	aspartate	aspartate	NN
cord-315453-mbv8vb2r	19	5	aminotransferase	aminotransferase	NN
cord-315453-mbv8vb2r	19	6	,	,	,
cord-315453-mbv8vb2r	19	7	creatine	creatine	NN
cord-315453-mbv8vb2r	19	8	kinase	kinase	NN
cord-315453-mbv8vb2r	19	9	,	,	,
cord-315453-mbv8vb2r	19	10	creatinine	creatinine	NN
cord-315453-mbv8vb2r	19	11	,	,	,
cord-315453-mbv8vb2r	19	12	and	and	CC
cord-315453-mbv8vb2r	19	13	C	c	NN
cord-315453-mbv8vb2r	19	14	-	-	HYPH
cord-315453-mbv8vb2r	19	15	reactive	reactive	JJ
cord-315453-mbv8vb2r	19	16	protein	protein	NN
cord-315453-mbv8vb2r	19	17	levels	level	NNS
cord-315453-mbv8vb2r	19	18	were	be	VBD
cord-315453-mbv8vb2r	19	19	more	more	RBR
cord-315453-mbv8vb2r	19	20	frequently	frequently	RB
cord-315453-mbv8vb2r	19	21	seen	see	VBN
cord-315453-mbv8vb2r	19	22	in	in	IN
cord-315453-mbv8vb2r	19	23	the	the	DT
cord-315453-mbv8vb2r	19	24	complicated	complicated	JJ
cord-315453-mbv8vb2r	19	25	COVID-19	COVID-19	NNP
cord-315453-mbv8vb2r	19	26	patients	patient	NNS
cord-315453-mbv8vb2r	19	27	than	than	IN
cord-315453-mbv8vb2r	19	28	the	the	DT
cord-315453-mbv8vb2r	19	29	uncomplicated	uncomplicated	JJ
cord-315453-mbv8vb2r	19	30	group	group	NN
cord-315453-mbv8vb2r	19	31	,	,	,
cord-315453-mbv8vb2r	19	32	while	while	IN
cord-315453-mbv8vb2r	19	33	a	a	DT
cord-315453-mbv8vb2r	19	34	normal	normal	JJ
cord-315453-mbv8vb2r	19	35	serum	serum	NN
cord-315453-mbv8vb2r	19	36	procalcitonin	procalcitonin	NNS
cord-315453-mbv8vb2r	19	37	concentration	concentration	NN
cord-315453-mbv8vb2r	19	38	was	be	VBD
cord-315453-mbv8vb2r	19	39	noticed	notice	VBN
cord-315453-mbv8vb2r	19	40	among	among	IN
cord-315453-mbv8vb2r	19	41	most	most	JJS
cord-315453-mbv8vb2r	19	42	COVID-19	covid-19	CD
cord-315453-mbv8vb2r	19	43	patients	patient	NNS
cord-315453-mbv8vb2r	19	44	[	[	-LRB-
cord-315453-mbv8vb2r	19	45	4	4	CD
cord-315453-mbv8vb2r	19	46	,	,	,
cord-315453-mbv8vb2r	19	47	5	5	CD
cord-315453-mbv8vb2r	19	48	]	]	-RRB-
cord-315453-mbv8vb2r	19	49	.	.	.
cord-315453-mbv8vb2r	20	1	Additionally	additionally	RB
cord-315453-mbv8vb2r	20	2	,	,	,
cord-315453-mbv8vb2r	20	3	20.3	20.3	CD
cord-315453-mbv8vb2r	20	4	%	%	NN
cord-315453-mbv8vb2r	20	5	of	of	IN
cord-315453-mbv8vb2r	21	1	COVID-19	covid-19	JJ
cord-315453-mbv8vb2r	21	2	patients	patient	NNS
cord-315453-mbv8vb2r	21	3	required	require	VBD
cord-315453-mbv8vb2r	21	4	the	the	DT
cord-315453-mbv8vb2r	21	5	hospitalization	hospitalization	NN
cord-315453-mbv8vb2r	21	6	at	at	IN
cord-315453-mbv8vb2r	21	7	intensive	intensive	JJ
cord-315453-mbv8vb2r	21	8	care	care	NN
cord-315453-mbv8vb2r	21	9	units	unit	NNS
cord-315453-mbv8vb2r	21	10	,	,	,
cord-315453-mbv8vb2r	21	11	32.8	32.8	CD
cord-315453-mbv8vb2r	21	12	%	%	NN
cord-315453-mbv8vb2r	21	13	presented	present	VBN
cord-315453-mbv8vb2r	21	14	with	with	IN
cord-315453-mbv8vb2r	21	15	acute	acute	JJ
cord-315453-mbv8vb2r	21	16	respiratory	respiratory	JJ
cord-315453-mbv8vb2r	21	17	distress	distress	NN
cord-315453-mbv8vb2r	21	18	syndrome	syndrome	NN
cord-315453-mbv8vb2r	21	19	(	(	-LRB-
cord-315453-mbv8vb2r	21	20	ARDS	ARDS	NNP
cord-315453-mbv8vb2r	21	21	)	)	-RRB-
cord-315453-mbv8vb2r	21	22	,	,	,
cord-315453-mbv8vb2r	21	23	6.2	6.2	CD
cord-315453-mbv8vb2r	21	24	%	%	NN
cord-315453-mbv8vb2r	21	25	had	have	VBD
cord-315453-mbv8vb2r	21	26	shock	shock	NN
cord-315453-mbv8vb2r	21	27	,	,	,
cord-315453-mbv8vb2r	21	28	and	and	CC
cord-315453-mbv8vb2r	21	29	13.9	13.9	CD
cord-315453-mbv8vb2r	21	30	%	%	NN
cord-315453-mbv8vb2r	21	31	of	of	IN
cord-315453-mbv8vb2r	21	32	hospitalized	hospitalize	VBN
cord-315453-mbv8vb2r	21	33	patients	patient	NNS
cord-315453-mbv8vb2r	21	34	had	have	VBD
cord-315453-mbv8vb2r	21	35	fatal	fatal	JJ
cord-315453-mbv8vb2r	21	36	outcomes	outcome	NNS
cord-315453-mbv8vb2r	21	37	.	.	.
cord-315453-mbv8vb2r	22	1	The	the	DT
cord-315453-mbv8vb2r	22	2	pandemic	pandemic	NN
cord-315453-mbv8vb2r	22	3	caused	cause	VBN
cord-315453-mbv8vb2r	22	4	by	by	IN
cord-315453-mbv8vb2r	22	5	COVID-19	COVID-19	NNP
cord-315453-mbv8vb2r	22	6	has	have	VBZ
cord-315453-mbv8vb2r	22	7	brought	bring	VBN
cord-315453-mbv8vb2r	22	8	a	a	DT
cord-315453-mbv8vb2r	22	9	huge	huge	JJ
cord-315453-mbv8vb2r	22	10	burden	burden	NN
cord-315453-mbv8vb2r	22	11	to	to	IN
cord-315453-mbv8vb2r	22	12	healthcare	healthcare	NN
cord-315453-mbv8vb2r	22	13	facilities	facility	NNS
cord-315453-mbv8vb2r	22	14	for	for	IN
cord-315453-mbv8vb2r	22	15	many	many	JJ
cord-315453-mbv8vb2r	22	16	countries	country	NNS
cord-315453-mbv8vb2r	22	17	,	,	,
cord-315453-mbv8vb2r	22	18	especially	especially	RB
cord-315453-mbv8vb2r	22	19	in	in	IN
cord-315453-mbv8vb2r	22	20	patients	patient	NNS
cord-315453-mbv8vb2r	22	21	with	with	IN
cord-315453-mbv8vb2r	22	22	comorbidities	comorbiditie	NNS
cord-315453-mbv8vb2r	22	23	[	[	-LRB-
cord-315453-mbv8vb2r	22	24	4	4	CD
cord-315453-mbv8vb2r	22	25	]	]	-RRB-
cord-315453-mbv8vb2r	22	26	.	.	.
cord-315453-mbv8vb2r	23	1	Unfortunately	unfortunately	RB
cord-315453-mbv8vb2r	23	2	,	,	,
cord-315453-mbv8vb2r	23	3	standard	standard	JJ
cord-315453-mbv8vb2r	23	4	treatment	treatment	NN
cord-315453-mbv8vb2r	23	5	against	against	IN
cord-315453-mbv8vb2r	23	6	COVID-19	COVID-19	NNP
cord-315453-mbv8vb2r	23	7	is	be	VBZ
cord-315453-mbv8vb2r	23	8	currently	currently	RB
cord-315453-mbv8vb2r	23	9	lacking	lack	VBG
cord-315453-mbv8vb2r	23	10	.	.	.
cord-315453-mbv8vb2r	24	1	In	in	IN
cord-315453-mbv8vb2r	24	2	addition	addition	NN
cord-315453-mbv8vb2r	24	3	to	to	IN
cord-315453-mbv8vb2r	24	4	developing	develop	VBG
cord-315453-mbv8vb2r	24	5	new	new	JJ
cord-315453-mbv8vb2r	24	6	treatment	treatment	NN
cord-315453-mbv8vb2r	24	7	options	option	NNS
cord-315453-mbv8vb2r	24	8	(	(	-LRB-
cord-315453-mbv8vb2r	24	9	such	such	JJ
cord-315453-mbv8vb2r	24	10	as	as	IN
cord-315453-mbv8vb2r	24	11	immunotherapies	immunotherapy	NNS
cord-315453-mbv8vb2r	24	12	and	and	CC
cord-315453-mbv8vb2r	24	13	host	host	NN
cord-315453-mbv8vb2r	24	14	-	-	HYPH
cord-315453-mbv8vb2r	24	15	directed	direct	VBN
cord-315453-mbv8vb2r	24	16	therapies	therapy	NNS
cord-315453-mbv8vb2r	24	17	)	)	-RRB-
cord-315453-mbv8vb2r	24	18	,	,	,
cord-315453-mbv8vb2r	24	19	scientists	scientist	NNS
cord-315453-mbv8vb2r	24	20	worldwide	worldwide	RB
cord-315453-mbv8vb2r	24	21	continue	continue	VBP
cord-315453-mbv8vb2r	24	22	to	to	TO
cord-315453-mbv8vb2r	24	23	simultaneously	simultaneously	RB
cord-315453-mbv8vb2r	24	24	explore	explore	VB
cord-315453-mbv8vb2r	24	25	the	the	DT
cord-315453-mbv8vb2r	24	26	efficacy	efficacy	NN
cord-315453-mbv8vb2r	24	27	of	of	IN
cord-315453-mbv8vb2r	24	28	existing	exist	VBG
cord-315453-mbv8vb2r	24	29	drugs	drug	NNS
cord-315453-mbv8vb2r	24	30	against	against	IN
cord-315453-mbv8vb2r	24	31	SARS	SARS	NNP
cord-315453-mbv8vb2r	24	32	-	-	HYPH
cord-315453-mbv8vb2r	24	33	CoV-2	CoV-2	NNP
cord-315453-mbv8vb2r	24	34	.	.	.
cord-315453-mbv8vb2r	25	1	This	this	DT
cord-315453-mbv8vb2r	25	2	article	article	NN
cord-315453-mbv8vb2r	25	3	summarizes	summarize	VBZ
cord-315453-mbv8vb2r	25	4	old	old	JJ
cord-315453-mbv8vb2r	25	5	drugs	drug	NNS
cord-315453-mbv8vb2r	26	1	that	that	DT
cord-315453-mbv8vb2r	26	2	could	could	MD
cord-315453-mbv8vb2r	26	3	be	be	VB
cord-315453-mbv8vb2r	26	4	potentially	potentially	RB
cord-315453-mbv8vb2r	26	5	re	re	VB
cord-315453-mbv8vb2r	26	6	-	-	JJ
cord-315453-mbv8vb2r	26	7	purposed	purpose	VBN
cord-315453-mbv8vb2r	26	8	for	for	IN
cord-315453-mbv8vb2r	26	9	COVID-19	covid-19	JJ
cord-315453-mbv8vb2r	26	10	treatment	treatment	NN
cord-315453-mbv8vb2r	26	11	.	.	.
cord-315453-mbv8vb2r	27	1	Remdesivir	Remdesivir	NNP
cord-315453-mbv8vb2r	27	2	,	,	,
cord-315453-mbv8vb2r	27	3	which	which	WDT
cord-315453-mbv8vb2r	27	4	targets	target	VBZ
cord-315453-mbv8vb2r	27	5	the	the	DT
cord-315453-mbv8vb2r	27	6	viral	viral	JJ
cord-315453-mbv8vb2r	27	7	RNA	rna	NN
cord-315453-mbv8vb2r	27	8	-	-	HYPH
cord-315453-mbv8vb2r	27	9	dependent	dependent	JJ
cord-315453-mbv8vb2r	27	10	RNA	RNA	NNP
cord-315453-mbv8vb2r	27	11	polymerase	polymerase	NN
cord-315453-mbv8vb2r	27	12	(	(	-LRB-
cord-315453-mbv8vb2r	27	13	RdRp	RdRp	NNP
cord-315453-mbv8vb2r	27	14	)	)	-RRB-
cord-315453-mbv8vb2r	27	15	and	and	CC
cord-315453-mbv8vb2r	27	16	induces	induce	VBZ
cord-315453-mbv8vb2r	27	17	premature	premature	JJ
cord-315453-mbv8vb2r	27	18	termination	termination	NN
cord-315453-mbv8vb2r	27	19	of	of	IN
cord-315453-mbv8vb2r	27	20	viral	viral	JJ
cord-315453-mbv8vb2r	27	21	RNA	RNA	NNP
cord-315453-mbv8vb2r	27	22	transcription	transcription	NN
cord-315453-mbv8vb2r	27	23	[	[	-LRB-
cord-315453-mbv8vb2r	27	24	6	6	CD
cord-315453-mbv8vb2r	27	25	]	]	-RRB-
cord-315453-mbv8vb2r	27	26	,	,	,
cord-315453-mbv8vb2r	27	27	is	be	VBZ
cord-315453-mbv8vb2r	27	28	considered	consider	VBN
cord-315453-mbv8vb2r	27	29	as	as	IN
cord-315453-mbv8vb2r	27	30	the	the	DT
cord-315453-mbv8vb2r	27	31	most	most	RBS
cord-315453-mbv8vb2r	27	32	promising	promising	JJ
cord-315453-mbv8vb2r	27	33	drug	drug	NN
cord-315453-mbv8vb2r	27	34	against	against	IN
cord-315453-mbv8vb2r	27	35	SARS	SARS	NNP
cord-315453-mbv8vb2r	27	36	-	-	HYPH
cord-315453-mbv8vb2r	27	37	CoV-2	CoV-2	NNP
cord-315453-mbv8vb2r	27	38	[	[	-LRB-
cord-315453-mbv8vb2r	27	39	7	7	CD
cord-315453-mbv8vb2r	27	40	,	,	,
cord-315453-mbv8vb2r	27	41	8	8	CD
cord-315453-mbv8vb2r	27	42	]	]	-RRB-
cord-315453-mbv8vb2r	27	43	.	.	.
cord-315453-mbv8vb2r	28	1	Initially	initially	RB
cord-315453-mbv8vb2r	28	2	,	,	,
cord-315453-mbv8vb2r	28	3	uncertainties	uncertainty	NNS
cord-315453-mbv8vb2r	28	4	regarding	regard	VBG
cord-315453-mbv8vb2r	28	5	the	the	DT
cord-315453-mbv8vb2r	28	6	adverse	adverse	JJ
cord-315453-mbv8vb2r	28	7	effects	effect	NNS
cord-315453-mbv8vb2r	28	8	(	(	-LRB-
cord-315453-mbv8vb2r	28	9	such	such	JJ
cord-315453-mbv8vb2r	28	10	as	as	IN
cord-315453-mbv8vb2r	28	11	nausea	nausea	NN
cord-315453-mbv8vb2r	28	12	,	,	,
cord-315453-mbv8vb2r	28	13	vomiting	vomiting	NN
cord-315453-mbv8vb2r	28	14	,	,	,
cord-315453-mbv8vb2r	28	15	rectal	rectal	JJ
cord-315453-mbv8vb2r	28	16	hemorrhage	hemorrhage	NN
cord-315453-mbv8vb2r	28	17	,	,	,
cord-315453-mbv8vb2r	28	18	and	and	CC
cord-315453-mbv8vb2r	28	19	hepatic	hepatic	JJ
cord-315453-mbv8vb2r	28	20	toxicity	toxicity	NN
cord-315453-mbv8vb2r	28	21	)	)	-RRB-
cord-315453-mbv8vb2r	28	22	and	and	CC
cord-315453-mbv8vb2r	28	23	clinical	clinical	JJ
cord-315453-mbv8vb2r	28	24	efficacy	efficacy	NN
cord-315453-mbv8vb2r	28	25	of	of	IN
cord-315453-mbv8vb2r	28	26	remdesivir	remdesivir	NNP
cord-315453-mbv8vb2r	28	27	were	be	VBD
cord-315453-mbv8vb2r	28	28	reported	report	VBN
cord-315453-mbv8vb2r	28	29	in	in	IN
cord-315453-mbv8vb2r	28	30	the	the	DT
cord-315453-mbv8vb2r	28	31	clinical	clinical	JJ
cord-315453-mbv8vb2r	28	32	treatment	treatment	NN
cord-315453-mbv8vb2r	28	33	of	of	IN
cord-315453-mbv8vb2r	28	34	COVID-19	COVID-19	NNP
cord-315453-mbv8vb2r	28	35	[	[	-LRB-
cord-315453-mbv8vb2r	28	36	8	8	CD
cord-315453-mbv8vb2r	28	37	]	]	-RRB-
cord-315453-mbv8vb2r	28	38	.	.	.
cord-315453-mbv8vb2r	29	1	An	an	DT
cord-315453-mbv8vb2r	29	2	important	important	JJ
cord-315453-mbv8vb2r	29	3	study	study	NN
cord-315453-mbv8vb2r	29	4	reported	report	VBD
cord-315453-mbv8vb2r	29	5	the	the	DT
cord-315453-mbv8vb2r	29	6	outcomes	outcome	NNS
cord-315453-mbv8vb2r	29	7	of	of	IN
cord-315453-mbv8vb2r	29	8	the	the	DT
cord-315453-mbv8vb2r	29	9	53	53	CD
cord-315453-mbv8vb2r	29	10	hospitalized	hospitalize	VBN
cord-315453-mbv8vb2r	29	11	patients	patient	NNS
cord-315453-mbv8vb2r	29	12	(	(	-LRB-
cord-315453-mbv8vb2r	29	13	22	22	CD
cord-315453-mbv8vb2r	29	14	in	in	IN
cord-315453-mbv8vb2r	29	15	the	the	DT
cord-315453-mbv8vb2r	29	16	US	US	NNP
cord-315453-mbv8vb2r	29	17	,	,	,
cord-315453-mbv8vb2r	29	18	22	22	CD
cord-315453-mbv8vb2r	29	19	in	in	IN
cord-315453-mbv8vb2r	29	20	Europe	Europe	NNP
cord-315453-mbv8vb2r	29	21	or	or	CC
cord-315453-mbv8vb2r	29	22	Canada	Canada	NNP
cord-315453-mbv8vb2r	29	23	,	,	,
cord-315453-mbv8vb2r	29	24	and	and	CC
cord-315453-mbv8vb2r	29	25	9	9	CD
cord-315453-mbv8vb2r	29	26	in	in	IN
cord-315453-mbv8vb2r	29	27	Japan	Japan	NNP
cord-315453-mbv8vb2r	29	28	)	)	-RRB-
cord-315453-mbv8vb2r	29	29	who	who	WP
cord-315453-mbv8vb2r	29	30	were	be	VBD
cord-315453-mbv8vb2r	29	31	treated	treat	VBN
cord-315453-mbv8vb2r	29	32	with	with	IN
cord-315453-mbv8vb2r	29	33	compassionate	compassionate	JJ
cord-315453-mbv8vb2r	29	34	-	-	HYPH
cord-315453-mbv8vb2r	29	35	use	use	NN
cord-315453-mbv8vb2r	29	36	remdesivir	remdesivir	NN
cord-315453-mbv8vb2r	29	37	for	for	IN
cord-315453-mbv8vb2r	29	38	severe	severe	JJ
cord-315453-mbv8vb2r	29	39	COVID-19	COVID-19	NNP
cord-315453-mbv8vb2r	29	40	recently	recently	RB
cord-315453-mbv8vb2r	29	41	[	[	-LRB-
cord-315453-mbv8vb2r	29	42	9	9	CD
cord-315453-mbv8vb2r	29	43	]	]	-RRB-
cord-315453-mbv8vb2r	29	44	.	.	.
cord-315453-mbv8vb2r	30	1	Among	among	IN
cord-315453-mbv8vb2r	30	2	these	these	DT
cord-315453-mbv8vb2r	30	3	patients	patient	NNS
cord-315453-mbv8vb2r	30	4	,	,	,
cord-315453-mbv8vb2r	30	5	30	30	CD
cord-315453-mbv8vb2r	30	6	patients	patient	NNS
cord-315453-mbv8vb2r	30	7	(	(	-LRB-
cord-315453-mbv8vb2r	30	8	56.7	56.7	CD
cord-315453-mbv8vb2r	30	9	%	%	NN
cord-315453-mbv8vb2r	30	10	)	)	-RRB-
cord-315453-mbv8vb2r	30	11	received	receive	VBD
cord-315453-mbv8vb2r	30	12	mechanical	mechanical	JJ
cord-315453-mbv8vb2r	30	13	ventilation	ventilation	NN
cord-315453-mbv8vb2r	30	14	and	and	CC
cord-315453-mbv8vb2r	30	15	4	4	CD
cord-315453-mbv8vb2r	30	16	(	(	-LRB-
cord-315453-mbv8vb2r	30	17	7.5	7.5	CD
cord-315453-mbv8vb2r	30	18	%	%	NN
cord-315453-mbv8vb2r	30	19	)	)	-RRB-
cord-315453-mbv8vb2r	30	20	underwent	undergo	VBD
cord-315453-mbv8vb2r	30	21	extracorporeal	extracorporeal	JJ
cord-315453-mbv8vb2r	30	22	membrane	membrane	NN
cord-315453-mbv8vb2r	30	23	oxygenation	oxygenation	NN
cord-315453-mbv8vb2r	30	24	prior	prior	RB
cord-315453-mbv8vb2r	30	25	to	to	IN
cord-315453-mbv8vb2r	30	26	initiation	initiation	NN
cord-315453-mbv8vb2r	30	27	of	of	IN
cord-315453-mbv8vb2r	30	28	remdesivir	remdesivir	NNP
cord-315453-mbv8vb2r	30	29	treatment	treatment	NN
cord-315453-mbv8vb2r	30	30	.	.	.
cord-315453-mbv8vb2r	31	1	All	all	PDT
cord-315453-mbv8vb2r	31	2	these	these	DT
cord-315453-mbv8vb2r	31	3	patients	patient	NNS
cord-315453-mbv8vb2r	31	4	received	receive	VBD
cord-315453-mbv8vb2r	31	5	a	a	DT
cord-315453-mbv8vb2r	31	6	10-day	10-day	CD
cord-315453-mbv8vb2r	31	7	course	course	NN
cord-315453-mbv8vb2r	31	8	of	of	IN
cord-315453-mbv8vb2r	31	9	remdesivir	remdesivir	NNP
cord-315453-mbv8vb2r	31	10	administered	administer	VBN
cord-315453-mbv8vb2r	31	11	intravenously	intravenously	RB
cord-315453-mbv8vb2r	31	12	,	,	,
cord-315453-mbv8vb2r	31	13	consisting	consist	VBG
cord-315453-mbv8vb2r	31	14	of	of	IN
cord-315453-mbv8vb2r	31	15	200	200	CD
cord-315453-mbv8vb2r	31	16	mg	mg	NN
cord-315453-mbv8vb2r	31	17	on	on	IN
cord-315453-mbv8vb2r	31	18	day	day	NN
cord-315453-mbv8vb2r	31	19	1	1	CD
cord-315453-mbv8vb2r	31	20	and	and	CC
cord-315453-mbv8vb2r	31	21	followed	follow	VBN
cord-315453-mbv8vb2r	31	22	by	by	IN
cord-315453-mbv8vb2r	31	23	100	100	CD
cord-315453-mbv8vb2r	31	24	mg	mg	NNP
cord-315453-mbv8vb2r	31	25	daily	daily	RB
cord-315453-mbv8vb2r	31	26	for	for	IN
cord-315453-mbv8vb2r	31	27	the	the	DT
cord-315453-mbv8vb2r	31	28	remaining	remain	VBG
cord-315453-mbv8vb2r	31	29	9	9	CD
cord-315453-mbv8vb2r	31	30	days	day	NNS
cord-315453-mbv8vb2r	31	31	of	of	IN
cord-315453-mbv8vb2r	31	32	treatment	treatment	NN
cord-315453-mbv8vb2r	31	33	.	.	.
cord-315453-mbv8vb2r	32	1	The	the	DT
cord-315453-mbv8vb2r	32	2	overall	overall	JJ
cord-315453-mbv8vb2r	32	3	mortality	mortality	NN
cord-315453-mbv8vb2r	32	4	was	be	VBD
cord-315453-mbv8vb2r	32	5	13.2	13.2	CD
cord-315453-mbv8vb2r	32	6	%	%	NN
cord-315453-mbv8vb2r	32	7	.	.	.
cord-315453-mbv8vb2r	33	1	Of	of	IN
cord-315453-mbv8vb2r	33	2	note	note	VB
cord-315453-mbv8vb2r	33	3	,	,	,
cord-315453-mbv8vb2r	33	4	clinical	clinical	JJ
cord-315453-mbv8vb2r	33	5	improvement	improvement	NN
cord-315453-mbv8vb2r	33	6	was	be	VBD
cord-315453-mbv8vb2r	33	7	observed	observe	VBN
cord-315453-mbv8vb2r	33	8	in	in	IN
cord-315453-mbv8vb2r	33	9	36	36	CD
cord-315453-mbv8vb2r	33	10	(	(	-LRB-
cord-315453-mbv8vb2r	33	11	68	68	CD
cord-315453-mbv8vb2r	33	12	%	%	NN
cord-315453-mbv8vb2r	33	13	)	)	-RRB-
cord-315453-mbv8vb2r	33	14	patients	patient	NNS
cord-315453-mbv8vb2r	33	15	,	,	,
cord-315453-mbv8vb2r	33	16	and	and	CC
cord-315453-mbv8vb2r	33	17	the	the	DT
cord-315453-mbv8vb2r	33	18	abnormality	abnormality	NN
cord-315453-mbv8vb2r	33	19	of	of	IN
cord-315453-mbv8vb2r	33	20	hepatic	hepatic	JJ
cord-315453-mbv8vb2r	33	21	function	function	NN
cord-315453-mbv8vb2r	33	22	was	be	VBD
cord-315453-mbv8vb2r	33	23	the	the	DT
cord-315453-mbv8vb2r	33	24	most	most	RBS
cord-315453-mbv8vb2r	33	25	frequent	frequent	JJ
cord-315453-mbv8vb2r	33	26	adverse	adverse	JJ
cord-315453-mbv8vb2r	33	27	effect	effect	NN
cord-315453-mbv8vb2r	33	28	(	(	-LRB-
cord-315453-mbv8vb2r	33	29	23	23	CD
cord-315453-mbv8vb2r	33	30	%	%	NN
cord-315453-mbv8vb2r	33	31	)	)	-RRB-
cord-315453-mbv8vb2r	33	32	,	,	,
cord-315453-mbv8vb2r	33	33	followed	follow	VBN
cord-315453-mbv8vb2r	33	34	by	by	IN
cord-315453-mbv8vb2r	33	35	diarrhea	diarrhea	NN
cord-315453-mbv8vb2r	33	36	(	(	-LRB-
cord-315453-mbv8vb2r	33	37	9	9	CD
cord-315453-mbv8vb2r	33	38	%	%	NN
cord-315453-mbv8vb2r	33	39	)	)	-RRB-
cord-315453-mbv8vb2r	33	40	,	,	,
cord-315453-mbv8vb2r	33	41	skin	skin	NN
cord-315453-mbv8vb2r	33	42	rash	rash	NN
cord-315453-mbv8vb2r	33	43	(	(	-LRB-
cord-315453-mbv8vb2r	33	44	8	8	CD
cord-315453-mbv8vb2r	33	45	%	%	NN
cord-315453-mbv8vb2r	33	46	)	)	-RRB-
cord-315453-mbv8vb2r	33	47	,	,	,
cord-315453-mbv8vb2r	33	48	acute	acute	JJ
cord-315453-mbv8vb2r	33	49	kidney	kidney	NN
cord-315453-mbv8vb2r	33	50	injury	injury	NN
cord-315453-mbv8vb2r	33	51	(	(	-LRB-
cord-315453-mbv8vb2r	33	52	8	8	CD
cord-315453-mbv8vb2r	33	53	%	%	NN
cord-315453-mbv8vb2r	33	54	)	)	-RRB-
cord-315453-mbv8vb2r	33	55	,	,	,
cord-315453-mbv8vb2r	33	56	etc	etc	FW
cord-315453-mbv8vb2r	33	57	.	.	.
cord-315453-mbv8vb2r	34	1	Limitations	limitation	NNS
cord-315453-mbv8vb2r	34	2	of	of	IN
cord-315453-mbv8vb2r	34	3	this	this	DT
cord-315453-mbv8vb2r	34	4	study	study	NN
cord-315453-mbv8vb2r	34	5	included	include	VBD
cord-315453-mbv8vb2r	34	6	the	the	DT
cord-315453-mbv8vb2r	34	7	small	small	JJ
cord-315453-mbv8vb2r	34	8	size	size	NN
cord-315453-mbv8vb2r	34	9	of	of	IN
cord-315453-mbv8vb2r	34	10	the	the	DT
cord-315453-mbv8vb2r	34	11	cohort	cohort	NN
cord-315453-mbv8vb2r	34	12	,	,	,
cord-315453-mbv8vb2r	34	13	no	no	DT
cord-315453-mbv8vb2r	34	14	viral	viral	JJ
cord-315453-mbv8vb2r	34	15	load	load	NN
cord-315453-mbv8vb2r	34	16	data	data	NN
cord-315453-mbv8vb2r	34	17	collections	collection	NNS
cord-315453-mbv8vb2r	34	18	at	at	IN
cord-315453-mbv8vb2r	34	19	baseline	baseline	NN
cord-315453-mbv8vb2r	34	20	and	and	CC
cord-315453-mbv8vb2r	34	21	follow	follow	NN
cord-315453-mbv8vb2r	34	22	-	-	HYPH
cord-315453-mbv8vb2r	34	23	up	up	NN
cord-315453-mbv8vb2r	34	24	periods	period	NNS
cord-315453-mbv8vb2r	34	25	,	,	,
cord-315453-mbv8vb2r	34	26	and	and	CC
cord-315453-mbv8vb2r	34	27	the	the	DT
cord-315453-mbv8vb2r	34	28	lack	lack	NN
cord-315453-mbv8vb2r	34	29	of	of	IN
cord-315453-mbv8vb2r	34	30	a	a	DT
cord-315453-mbv8vb2r	34	31	randomized	randomized	JJ
cord-315453-mbv8vb2r	34	32	control	control	NN
cord-315453-mbv8vb2r	34	33	group	group	NN
cord-315453-mbv8vb2r	34	34	[	[	-LRB-
cord-315453-mbv8vb2r	34	35	9	9	CD
cord-315453-mbv8vb2r	34	36	]	]	-RRB-
cord-315453-mbv8vb2r	34	37	.	.	.
cord-315453-mbv8vb2r	35	1	Ongoing	ongoing	JJ
cord-315453-mbv8vb2r	35	2	randomized	randomized	JJ
cord-315453-mbv8vb2r	35	3	controlled	control	VBN
cord-315453-mbv8vb2r	35	4	trials	trial	NNS
cord-315453-mbv8vb2r	35	5	for	for	IN
cord-315453-mbv8vb2r	35	6	evaluating	evaluate	VBG
cord-315453-mbv8vb2r	35	7	the	the	DT
cord-315453-mbv8vb2r	35	8	clinical	clinical	JJ
cord-315453-mbv8vb2r	35	9	efficacy	efficacy	NN
cord-315453-mbv8vb2r	35	10	of	of	IN
cord-315453-mbv8vb2r	35	11	remdesivir	remdesivir	NNP
cord-315453-mbv8vb2r	35	12	is	be	VBZ
cord-315453-mbv8vb2r	35	13	absolutely	absolutely	RB
cord-315453-mbv8vb2r	35	14	needed	need	VBN
cord-315453-mbv8vb2r	35	15	.	.	.
cord-315453-mbv8vb2r	36	1	The	the	DT
cord-315453-mbv8vb2r	36	2	other	other	JJ
cord-315453-mbv8vb2r	36	3	RdRp	RdRp	NNP
cord-315453-mbv8vb2r	36	4	inhibitor	inhibitor	NN
cord-315453-mbv8vb2r	36	5	favipiravir	favipiravir	NNP
cord-315453-mbv8vb2r	36	6	is	be	VBZ
cord-315453-mbv8vb2r	36	7	known	know	VBN
cord-315453-mbv8vb2r	36	8	to	to	TO
cord-315453-mbv8vb2r	36	9	be	be	VB
cord-315453-mbv8vb2r	36	10	active	active	JJ
cord-315453-mbv8vb2r	36	11	in	in	IN
cord-315453-mbv8vb2r	36	12	vitro	vitro	FW
cord-315453-mbv8vb2r	36	13	against	against	IN
cord-315453-mbv8vb2r	36	14	oseltamivir	oseltamivir	NN
cord-315453-mbv8vb2r	36	15	-	-	HYPH
cord-315453-mbv8vb2r	36	16	resistant	resistant	JJ
cord-315453-mbv8vb2r	36	17	influenza	influenza	NN
cord-315453-mbv8vb2r	36	18	A	a	NN
cord-315453-mbv8vb2r	36	19	,	,	,
cord-315453-mbv8vb2r	36	20	B	b	NN
cord-315453-mbv8vb2r	36	21	,	,	,
cord-315453-mbv8vb2r	36	22	and	and	CC
cord-315453-mbv8vb2r	36	23	C	c	NN
cord-315453-mbv8vb2r	36	24	viruses	virus	NNS
cord-315453-mbv8vb2r	36	25	[	[	-LRB-
cord-315453-mbv8vb2r	36	26	10	10	CD
cord-315453-mbv8vb2r	36	27	]	]	-RRB-
cord-315453-mbv8vb2r	36	28	.	.	.
cord-315453-mbv8vb2r	37	1	Although	although	IN
cord-315453-mbv8vb2r	37	2	favipiravir	favipiravir	NNP
cord-315453-mbv8vb2r	37	3	has	have	VBZ
cord-315453-mbv8vb2r	37	4	been	be	VBN
cord-315453-mbv8vb2r	37	5	reported	report	VBN
cord-315453-mbv8vb2r	37	6	to	to	TO
cord-315453-mbv8vb2r	37	7	significantly	significantly	RB
cord-315453-mbv8vb2r	37	8	shorten	shorten	VB
cord-315453-mbv8vb2r	37	9	the	the	DT
cord-315453-mbv8vb2r	37	10	duration	duration	NN
cord-315453-mbv8vb2r	37	11	of	of	IN
cord-315453-mbv8vb2r	37	12	clinical	clinical	JJ
cord-315453-mbv8vb2r	37	13	recovery	recovery	NN
cord-315453-mbv8vb2r	37	14	for	for	IN
cord-315453-mbv8vb2r	37	15	COVID-19	covid-19	JJ
cord-315453-mbv8vb2r	37	16	patients	patient	NNS
cord-315453-mbv8vb2r	37	17	by	by	IN
cord-315453-mbv8vb2r	37	18	Cai	Cai	NNP
cord-315453-mbv8vb2r	37	19	et	et	FW
cord-315453-mbv8vb2r	37	20	al	al	NNP
cord-315453-mbv8vb2r	37	21	.	.	NNP
cord-315453-mbv8vb2r	37	22	,	,	,
cord-315453-mbv8vb2r	37	23	who	who	WP
cord-315453-mbv8vb2r	37	24	published	publish	VBD
cord-315453-mbv8vb2r	37	25	their	-PRON-	PRP$
cord-315453-mbv8vb2r	37	26	investigational	investigational	JJ
cord-315453-mbv8vb2r	37	27	results	result	NNS
cord-315453-mbv8vb2r	37	28	in	in	IN
cord-315453-mbv8vb2r	37	29	Engineering	Engineering	NNP
cord-315453-mbv8vb2r	37	30	,	,	,
cord-315453-mbv8vb2r	37	31	this	this	DT
cord-315453-mbv8vb2r	37	32	article	article	NN
cord-315453-mbv8vb2r	37	33	has	have	VBZ
cord-315453-mbv8vb2r	37	34	been	be	VBN
cord-315453-mbv8vb2r	37	35	temporarily	temporarily	RB
cord-315453-mbv8vb2r	37	36	withdrawn	withdraw	VBN
cord-315453-mbv8vb2r	37	37	.	.	.
cord-315453-mbv8vb2r	38	1	In	in	IN
cord-315453-mbv8vb2r	38	2	spite	spite	NN
cord-315453-mbv8vb2r	38	3	of	of	IN
cord-315453-mbv8vb2r	38	4	unfavorable	unfavorable	JJ
cord-315453-mbv8vb2r	38	5	pharmacokinetic	pharmacokinetic	JJ
cord-315453-mbv8vb2r	38	6	(	(	-LRB-
cord-315453-mbv8vb2r	38	7	PK	PK	NNP
cord-315453-mbv8vb2r	38	8	)	)	-RRB-
cord-315453-mbv8vb2r	38	9	profile	profile	NN
cord-315453-mbv8vb2r	38	10	and	and	CC
cord-315453-mbv8vb2r	38	11	no	no	DT
cord-315453-mbv8vb2r	38	12	conclusive	conclusive	JJ
cord-315453-mbv8vb2r	38	13	data	datum	NNS
cord-315453-mbv8vb2r	38	14	regarding	regard	VBG
cord-315453-mbv8vb2r	38	15	its	-PRON-	PRP$
cord-315453-mbv8vb2r	38	16	efficacy	efficacy	NN
cord-315453-mbv8vb2r	38	17	in	in	IN
cord-315453-mbv8vb2r	38	18	the	the	DT
cord-315453-mbv8vb2r	38	19	treatment	treatment	NN
cord-315453-mbv8vb2r	38	20	of	of	IN
cord-315453-mbv8vb2r	38	21	COVID-19	COVID-19	NNP
cord-315453-mbv8vb2r	38	22	,	,	,
cord-315453-mbv8vb2r	38	23	favipiravir	favipiravir	NNP
cord-315453-mbv8vb2r	38	24	was	be	VBD
cord-315453-mbv8vb2r	38	25	approved	approve	VBN
cord-315453-mbv8vb2r	38	26	for	for	IN
cord-315453-mbv8vb2r	38	27	marketing	marketing	NN
cord-315453-mbv8vb2r	38	28	in	in	IN
cord-315453-mbv8vb2r	38	29	the	the	DT
cord-315453-mbv8vb2r	38	30	treatment	treatment	NN
cord-315453-mbv8vb2r	38	31	of	of	IN
cord-315453-mbv8vb2r	38	32	COVID-19	covid-19	JJ
cord-315453-mbv8vb2r	38	33	patients	patient	NNS
cord-315453-mbv8vb2r	38	34	in	in	IN
cord-315453-mbv8vb2r	38	35	China	China	NNP
cord-315453-mbv8vb2r	38	36	in	in	IN
cord-315453-mbv8vb2r	38	37	March	March	NNP
cord-315453-mbv8vb2r	38	38	2020	2020	CD
cord-315453-mbv8vb2r	38	39	.	.	.
cord-315453-mbv8vb2r	39	1	Ribavirin	ribavirin	RB
cord-315453-mbv8vb2r	39	2	,	,	,
cord-315453-mbv8vb2r	39	3	a	a	DT
cord-315453-mbv8vb2r	39	4	guanosine	guanosine	NN
cord-315453-mbv8vb2r	39	5	analogue	analogue	NN
cord-315453-mbv8vb2r	39	6	,	,	,
cord-315453-mbv8vb2r	39	7	is	be	VBZ
cord-315453-mbv8vb2r	39	8	an	an	DT
cord-315453-mbv8vb2r	39	9	antiviral	antiviral	JJ
cord-315453-mbv8vb2r	39	10	drug	drug	NN
cord-315453-mbv8vb2r	39	11	that	that	WDT
cord-315453-mbv8vb2r	39	12	has	have	VBZ
cord-315453-mbv8vb2r	39	13	been	be	VBN
cord-315453-mbv8vb2r	39	14	used	use	VBN
cord-315453-mbv8vb2r	39	15	to	to	TO
cord-315453-mbv8vb2r	39	16	treat	treat	VB
cord-315453-mbv8vb2r	39	17	several	several	JJ
cord-315453-mbv8vb2r	39	18	viral	viral	JJ
cord-315453-mbv8vb2r	39	19	infections	infection	NNS
cord-315453-mbv8vb2r	39	20	,	,	,
cord-315453-mbv8vb2r	39	21	including	include	VBG
cord-315453-mbv8vb2r	39	22	hepatitis	hepatitis	NN
cord-315453-mbv8vb2r	39	23	C	C	NNP
cord-315453-mbv8vb2r	39	24	virus	virus	NN
cord-315453-mbv8vb2r	39	25	and	and	CC
cord-315453-mbv8vb2r	39	26	respiratory	respiratory	JJ
cord-315453-mbv8vb2r	39	27	syncytial	syncytial	JJ
cord-315453-mbv8vb2r	39	28	virus	virus	NN
cord-315453-mbv8vb2r	39	29	(	(	-LRB-
cord-315453-mbv8vb2r	39	30	RSV	RSV	NNP
cord-315453-mbv8vb2r	39	31	)	)	-RRB-
cord-315453-mbv8vb2r	39	32	.	.	.
cord-315453-mbv8vb2r	40	1	It	-PRON-	PRP
cord-315453-mbv8vb2r	40	2	was	be	VBD
cord-315453-mbv8vb2r	40	3	recommended	recommend	VBN
cord-315453-mbv8vb2r	40	4	for	for	IN
cord-315453-mbv8vb2r	40	5	COVID-19	covid-19	JJ
cord-315453-mbv8vb2r	40	6	treatment	treatment	NN
cord-315453-mbv8vb2r	40	7	by	by	IN
cord-315453-mbv8vb2r	40	8	the	the	DT
cord-315453-mbv8vb2r	40	9	National	National	NNP
cord-315453-mbv8vb2r	40	10	Health	Health	NNP
cord-315453-mbv8vb2r	40	11	Commission	Commission	NNP
cord-315453-mbv8vb2r	40	12	and	and	CC
cord-315453-mbv8vb2r	40	13	State	State	NNP
cord-315453-mbv8vb2r	40	14	Administration	Administration	NNP
cord-315453-mbv8vb2r	40	15	of	of	IN
cord-315453-mbv8vb2r	40	16	Traditional	Traditional	NNP
cord-315453-mbv8vb2r	40	17	Chinese	Chinese	NNP
cord-315453-mbv8vb2r	40	18	Medicine	Medicine	NNP
cord-315453-mbv8vb2r	40	19	in	in	IN
cord-315453-mbv8vb2r	40	20	the	the	DT
cord-315453-mbv8vb2r	40	21	7th	7th	JJ
cord-315453-mbv8vb2r	40	22	edition	edition	NN
cord-315453-mbv8vb2r	40	23	of	of	IN
cord-315453-mbv8vb2r	40	24	their	-PRON-	PRP$
cord-315453-mbv8vb2r	40	25	report	report	NN
cord-315453-mbv8vb2r	40	26	,	,	,
cord-315453-mbv8vb2r	40	27	'	'	''
cord-315453-mbv8vb2r	40	28	Novel	Novel	NNP
cord-315453-mbv8vb2r	40	29	Coronavirus	Coronavirus	NNP
cord-315453-mbv8vb2r	40	30	Pneumonia	Pneumonia	NNP
cord-315453-mbv8vb2r	40	31	Diagnosis	Diagnosis	NNP
cord-315453-mbv8vb2r	40	32	and	and	CC
cord-315453-mbv8vb2r	40	33	Treatment	Treatment	NNP
cord-315453-mbv8vb2r	40	34	Plan	Plan	NNP
cord-315453-mbv8vb2r	40	35	'	'	''
cord-315453-mbv8vb2r	40	36	[	[	-LRB-
cord-315453-mbv8vb2r	40	37	11	11	CD
cord-315453-mbv8vb2r	40	38	]	]	-RRB-
cord-315453-mbv8vb2r	40	39	.	.	.
cord-315453-mbv8vb2r	41	1	The	the	DT
cord-315453-mbv8vb2r	41	2	in	in	IN
cord-315453-mbv8vb2r	41	3	vitro	vitro	FW
cord-315453-mbv8vb2r	41	4	antiviral	antiviral	JJ
cord-315453-mbv8vb2r	41	5	activity	activity	NN
cord-315453-mbv8vb2r	41	6	of	of	IN
cord-315453-mbv8vb2r	41	7	ribavirin	ribavirin	NN
cord-315453-mbv8vb2r	41	8	against	against	IN
cord-315453-mbv8vb2r	41	9	SARS	SARS	NNP
cord-315453-mbv8vb2r	41	10	-	-	HYPH
cord-315453-mbv8vb2r	41	11	CoV	CoV	NNP
cord-315453-mbv8vb2r	41	12	,	,	,
cord-315453-mbv8vb2r	41	13	however	however	RB
cord-315453-mbv8vb2r	41	14	,	,	,
cord-315453-mbv8vb2r	41	15	was	be	VBD
cord-315453-mbv8vb2r	41	16	estimated	estimate	VBN
cord-315453-mbv8vb2r	41	17	at	at	IN
cord-315453-mbv8vb2r	41	18	concentrations	concentration	NNS
cord-315453-mbv8vb2r	42	1	up	up	IN
cord-315453-mbv8vb2r	42	2	to	to	TO
cord-315453-mbv8vb2r	42	3	50	50	CD
cord-315453-mbv8vb2r	42	4	μg	μg	NNS
cord-315453-mbv8vb2r	42	5	/	/	SYM
cord-315453-mbv8vb2r	42	6	mL	mL	NNP
cord-315453-mbv8vb2r	42	7	[	[	-LRB-
cord-315453-mbv8vb2r	42	8	12	12	CD
cord-315453-mbv8vb2r	42	9	]	]	-RRB-
cord-315453-mbv8vb2r	42	10	.	.	.
cord-315453-mbv8vb2r	43	1	The	the	DT
cord-315453-mbv8vb2r	43	2	regimen	regimen	NN
cord-315453-mbv8vb2r	43	3	of	of	IN
cord-315453-mbv8vb2r	43	4	lopinavir	lopinavir	NNP
cord-315453-mbv8vb2r	43	5	/	/	SYM
cord-315453-mbv8vb2r	43	6	ritonavir	ritonavir	NNP
cord-315453-mbv8vb2r	43	7	(	(	-LRB-
cord-315453-mbv8vb2r	43	8	see	see	VB
cord-315453-mbv8vb2r	43	9	as	as	IN
cord-315453-mbv8vb2r	43	10	follows	follow	VBZ
cord-315453-mbv8vb2r	43	11	)	)	-RRB-
cord-315453-mbv8vb2r	43	12	plus	plus	CC
cord-315453-mbv8vb2r	43	13	ribavirin	ribavirin	NNP
cord-315453-mbv8vb2r	43	14	was	be	VBD
cord-315453-mbv8vb2r	43	15	also	also	RB
cord-315453-mbv8vb2r	43	16	shown	show	VBN
cord-315453-mbv8vb2r	43	17	to	to	TO
cord-315453-mbv8vb2r	43	18	be	be	VB
cord-315453-mbv8vb2r	43	19	effective	effective	JJ
cord-315453-mbv8vb2r	43	20	against	against	IN
cord-315453-mbv8vb2r	43	21	SARS	SARS	NNP
cord-315453-mbv8vb2r	43	22	-	-	HYPH
cord-315453-mbv8vb2r	43	23	CoV	CoV	NNP
cord-315453-mbv8vb2r	43	24	in	in	IN
cord-315453-mbv8vb2r	43	25	patients	patient	NNS
cord-315453-mbv8vb2r	43	26	and	and	CC
cord-315453-mbv8vb2r	43	27	in	in	IN
cord-315453-mbv8vb2r	43	28	tissue	tissue	NN
cord-315453-mbv8vb2r	43	29	culture	culture	NN
cord-315453-mbv8vb2r	43	30	[	[	-LRB-
cord-315453-mbv8vb2r	43	31	13	13	CD
cord-315453-mbv8vb2r	43	32	]	]	-RRB-
cord-315453-mbv8vb2r	43	33	;	;	:
cord-315453-mbv8vb2r	43	34	however	however	RB
cord-315453-mbv8vb2r	43	35	,	,	,
cord-315453-mbv8vb2r	43	36	its	-PRON-	PRP$
cord-315453-mbv8vb2r	43	37	clinical	clinical	JJ
cord-315453-mbv8vb2r	43	38	efficacy	efficacy	NN
cord-315453-mbv8vb2r	43	39	is	be	VBZ
cord-315453-mbv8vb2r	43	40	currently	currently	RB
cord-315453-mbv8vb2r	43	41	unproven	unproven	JJ
cord-315453-mbv8vb2r	43	42	.	.	.
cord-315453-mbv8vb2r	44	1	For	for	IN
cord-315453-mbv8vb2r	44	2	the	the	DT
cord-315453-mbv8vb2r	44	3	Orthocoronavirinae	Orthocoronavirinae	NNP
cord-315453-mbv8vb2r	44	4	family	family	NN
cord-315453-mbv8vb2r	44	5	,	,	,
cord-315453-mbv8vb2r	44	6	protease	protease	NN
cord-315453-mbv8vb2r	44	7	inhibitors	inhibitor	NNS
cord-315453-mbv8vb2r	44	8	(	(	-LRB-
cord-315453-mbv8vb2r	44	9	PI	PI	NNP
cord-315453-mbv8vb2r	44	10	)	)	-RRB-
cord-315453-mbv8vb2r	44	11	are	be	VBP
cord-315453-mbv8vb2r	44	12	used	use	VBN
cord-315453-mbv8vb2r	44	13	to	to	TO
cord-315453-mbv8vb2r	44	14	target	target	VB
cord-315453-mbv8vb2r	44	15	papain	papain	NN
cord-315453-mbv8vb2r	44	16	-	-	HYPH
cord-315453-mbv8vb2r	44	17	like	like	JJ
cord-315453-mbv8vb2r	44	18	protease	protease	NN
cord-315453-mbv8vb2r	44	19	and	and	CC
cord-315453-mbv8vb2r	44	20	3	3	CD
cord-315453-mbv8vb2r	44	21	C	c	NN
cord-315453-mbv8vb2r	44	22	-	-	HYPH
cord-315453-mbv8vb2r	44	23	like	like	JJ
cord-315453-mbv8vb2r	44	24	protease	protease	NN
cord-315453-mbv8vb2r	44	25	[	[	-LRB-
cord-315453-mbv8vb2r	44	26	6	6	CD
cord-315453-mbv8vb2r	44	27	]	]	-RRB-
cord-315453-mbv8vb2r	44	28	.	.	.
cord-315453-mbv8vb2r	45	1	Among	among	IN
cord-315453-mbv8vb2r	45	2	the	the	DT
cord-315453-mbv8vb2r	45	3	PIs	pi	NNS
cord-315453-mbv8vb2r	45	4	that	that	WDT
cord-315453-mbv8vb2r	45	5	inhibit	inhibit	VBP
cord-315453-mbv8vb2r	45	6	the	the	DT
cord-315453-mbv8vb2r	45	7	coronavirus	coronavirus	NN
cord-315453-mbv8vb2r	45	8	,	,	,
cord-315453-mbv8vb2r	45	9	the	the	DT
cord-315453-mbv8vb2r	45	10	antiviral	antiviral	JJ
cord-315453-mbv8vb2r	45	11	activity	activity	NN
cord-315453-mbv8vb2r	45	12	of	of	IN
cord-315453-mbv8vb2r	45	13	LPV	LPV	NNP
cord-315453-mbv8vb2r	45	14	against	against	IN
cord-315453-mbv8vb2r	45	15	MERS	MERS	NNP
cord-315453-mbv8vb2r	45	16	-	-	HYPH
cord-315453-mbv8vb2r	45	17	CoV	CoV	NNP
cord-315453-mbv8vb2r	45	18	is	be	VBZ
cord-315453-mbv8vb2r	45	19	controversial	controversial	JJ
cord-315453-mbv8vb2r	45	20	in	in	IN
cord-315453-mbv8vb2r	45	21	the	the	DT
cord-315453-mbv8vb2r	45	22	tissue	tissue	NN
cord-315453-mbv8vb2r	45	23	culture	culture	NN
cord-315453-mbv8vb2r	45	24	model	model	NN
cord-315453-mbv8vb2r	45	25	[	[	-LRB-
cord-315453-mbv8vb2r	45	26	12	12	CD
cord-315453-mbv8vb2r	45	27	]	]	-RRB-
cord-315453-mbv8vb2r	45	28	.	.	.
cord-315453-mbv8vb2r	46	1	Notably	notably	RB
cord-315453-mbv8vb2r	46	2	,	,	,
cord-315453-mbv8vb2r	46	3	treatment	treatment	NN
cord-315453-mbv8vb2r	46	4	with	with	IN
cord-315453-mbv8vb2r	46	5	LPV	LPV	NNP
cord-315453-mbv8vb2r	46	6	/	/	SYM
cord-315453-mbv8vb2r	46	7	RTV	RTV	NNP
cord-315453-mbv8vb2r	46	8	alone	alone	RB
cord-315453-mbv8vb2r	47	1	(	(	-LRB-
cord-315453-mbv8vb2r	47	2	400/100	400/100	CD
cord-315453-mbv8vb2r	47	3	mg	mg	PRP
cord-315453-mbv8vb2r	47	4	administered	administer	VBD
cord-315453-mbv8vb2r	47	5	orally	orally	RB
cord-315453-mbv8vb2r	47	6	twice	twice	RB
cord-315453-mbv8vb2r	47	7	daily	daily	RB
cord-315453-mbv8vb2r	47	8	for	for	IN
cord-315453-mbv8vb2r	47	9	14	14	CD
cord-315453-mbv8vb2r	47	10	days	day	NNS
cord-315453-mbv8vb2r	47	11	;	;	:
cord-315453-mbv8vb2r	47	12	Chinese	Chinese	NNP
cord-315453-mbv8vb2r	47	13	Clinical	Clinical	NNP
cord-315453-mbv8vb2r	47	14	Trial	Trial	NNP
cord-315453-mbv8vb2r	47	15	Register	Register	NNP
cord-315453-mbv8vb2r	47	16	number	number	NN
cord-315453-mbv8vb2r	47	17	,	,	,
cord-315453-mbv8vb2r	47	18	ChiCTR2000029308	ChiCTR2000029308	NNS
cord-315453-mbv8vb2r	47	19	)	)	-RRB-
cord-315453-mbv8vb2r	47	20	failed	fail	VBD
cord-315453-mbv8vb2r	47	21	to	to	TO
cord-315453-mbv8vb2r	47	22	demonstrate	demonstrate	VB
cord-315453-mbv8vb2r	47	23	clinical	clinical	JJ
cord-315453-mbv8vb2r	47	24	improvement	improvement	NN
cord-315453-mbv8vb2r	47	25	and	and	CC
cord-315453-mbv8vb2r	47	26	reduction	reduction	NN
cord-315453-mbv8vb2r	47	27	of	of	IN
cord-315453-mbv8vb2r	47	28	viral	viral	JJ
cord-315453-mbv8vb2r	47	29	RNA	RNA	NNP
cord-315453-mbv8vb2r	47	30	load	load	NN
cord-315453-mbv8vb2r	47	31	compared	compare	VBN
cord-315453-mbv8vb2r	47	32	to	to	IN
cord-315453-mbv8vb2r	47	33	standard	standard	JJ
cord-315453-mbv8vb2r	47	34	care	care	NN
cord-315453-mbv8vb2r	47	35	alone	alone	JJ
cord-315453-mbv8vb2r	47	36	in	in	IN
cord-315453-mbv8vb2r	47	37	patients	patient	NNS
cord-315453-mbv8vb2r	47	38	with	with	IN
cord-315453-mbv8vb2r	47	39	severe	severe	JJ
cord-315453-mbv8vb2r	47	40	SARS	SARS	NNP
cord-315453-mbv8vb2r	47	41	-	-	HYPH
cord-315453-mbv8vb2r	47	42	CoV-2	CoV-2	NNP
cord-315453-mbv8vb2r	47	43	[	[	-LRB-
cord-315453-mbv8vb2r	47	44	14	14	CD
cord-315453-mbv8vb2r	47	45	]	]	-RRB-
cord-315453-mbv8vb2r	47	46	.	.	.
cord-315453-mbv8vb2r	48	1	The	the	DT
cord-315453-mbv8vb2r	48	2	other	other	JJ
cord-315453-mbv8vb2r	48	3	PI	PI	NNP
cord-315453-mbv8vb2r	48	4	darunavir	darunavir	NNS
cord-315453-mbv8vb2r	48	5	,	,	,
cord-315453-mbv8vb2r	48	6	which	which	WDT
cord-315453-mbv8vb2r	48	7	has	have	VBZ
cord-315453-mbv8vb2r	48	8	been	be	VBN
cord-315453-mbv8vb2r	48	9	extensively	extensively	RB
cord-315453-mbv8vb2r	48	10	used	use	VBN
cord-315453-mbv8vb2r	48	11	for	for	IN
cord-315453-mbv8vb2r	48	12	the	the	DT
cord-315453-mbv8vb2r	48	13	treatment	treatment	NN
cord-315453-mbv8vb2r	48	14	of	of	IN
cord-315453-mbv8vb2r	48	15	HIV	HIV	NNP
cord-315453-mbv8vb2r	48	16	infection	infection	NN
cord-315453-mbv8vb2r	48	17	in	in	IN
cord-315453-mbv8vb2r	48	18	both	both	CC
cord-315453-mbv8vb2r	48	19	naïve	naïve	JJ
cord-315453-mbv8vb2r	48	20	and	and	CC
cord-315453-mbv8vb2r	48	21	experienced	experienced	JJ
cord-315453-mbv8vb2r	48	22	subjects	subject	NNS
cord-315453-mbv8vb2r	48	23	,	,	,
cord-315453-mbv8vb2r	48	24	has	have	VBZ
cord-315453-mbv8vb2r	48	25	been	be	VBN
cord-315453-mbv8vb2r	48	26	shown	show	VBN
cord-315453-mbv8vb2r	48	27	to	to	TO
cord-315453-mbv8vb2r	48	28	have	have	VB
cord-315453-mbv8vb2r	48	29	promising	promising	JJ
cord-315453-mbv8vb2r	48	30	potential	potential	NN
cord-315453-mbv8vb2r	48	31	against	against	IN
cord-315453-mbv8vb2r	48	32	SARS	SARS	NNP
cord-315453-mbv8vb2r	48	33	-	-	HYPH
cord-315453-mbv8vb2r	48	34	CoV-2	CoV-2	NNP
cord-315453-mbv8vb2r	48	35	in	in	IN
cord-315453-mbv8vb2r	48	36	vitro	vitro	FW
cord-315453-mbv8vb2r	48	37	;	;	:
cord-315453-mbv8vb2r	48	38	nevertheless	nevertheless	RB
cord-315453-mbv8vb2r	48	39	,	,	,
cord-315453-mbv8vb2r	48	40	this	this	DT
cord-315453-mbv8vb2r	48	41	drug	drug	NN
cord-315453-mbv8vb2r	48	42	needs	need	VBZ
cord-315453-mbv8vb2r	48	43	to	to	TO
cord-315453-mbv8vb2r	48	44	be	be	VB
cord-315453-mbv8vb2r	48	45	further	further	RB
cord-315453-mbv8vb2r	48	46	investigated	investigate	VBN
cord-315453-mbv8vb2r	48	47	(	(	-LRB-
cord-315453-mbv8vb2r	48	48	http://www.sd	http://www.sd	NNP
cord-315453-mbv8vb2r	48	49	.	.	.
cord-315453-mbv8vb2r	48	50	chinanews.com/2/2020/0205/70145.html	chinanews.com/2/2020/0205/70145.html	NN
cord-315453-mbv8vb2r	48	51	)	)	-RRB-
cord-315453-mbv8vb2r	48	52	.	.	.
cord-315453-mbv8vb2r	49	1	Because	because	IN
cord-315453-mbv8vb2r	49	2	of	of	IN
cord-315453-mbv8vb2r	49	3	their	-PRON-	PRP$
cord-315453-mbv8vb2r	49	4	unfavorable	unfavorable	JJ
cord-315453-mbv8vb2r	49	5	PK	PK	NNP
cord-315453-mbv8vb2r	49	6	profiles	profile	NNS
cord-315453-mbv8vb2r	49	7	and	and	CC
cord-315453-mbv8vb2r	49	8	negative	negative	JJ
cord-315453-mbv8vb2r	49	9	clinical	clinical	JJ
cord-315453-mbv8vb2r	49	10	trial	trial	NN
cord-315453-mbv8vb2r	49	11	data	datum	NNS
cord-315453-mbv8vb2r	49	12	,	,	,
cord-315453-mbv8vb2r	49	13	however	however	RB
cord-315453-mbv8vb2r	49	14	,	,	,
cord-315453-mbv8vb2r	49	15	the	the	DT
cord-315453-mbv8vb2r	49	16	US	US	NNP
cord-315453-mbv8vb2r	49	17	National	National	NNP
cord-315453-mbv8vb2r	49	18	Institute	Institute	NNP
cord-315453-mbv8vb2r	49	19	of	of	IN
cord-315453-mbv8vb2r	49	20	Health	Health	NNP
cord-315453-mbv8vb2r	49	21	(	(	-LRB-
cord-315453-mbv8vb2r	49	22	NIH	NIH	NNP
cord-315453-mbv8vb2r	49	23	)	)	-RRB-
cord-315453-mbv8vb2r	49	24	Consensus	Consensus	NNP
cord-315453-mbv8vb2r	49	25	Treatment	Treatment	NNP
cord-315453-mbv8vb2r	49	26	Guidelines	Guidelines	NNPS
cord-315453-mbv8vb2r	49	27	Panel	Panel	NNP
cord-315453-mbv8vb2r	49	28	recommended	recommend	VBD
cord-315453-mbv8vb2r	49	29	against	against	IN
cord-315453-mbv8vb2r	49	30	the	the	DT
cord-315453-mbv8vb2r	49	31	use	use	NN
cord-315453-mbv8vb2r	49	32	of	of	IN
cord-315453-mbv8vb2r	49	33	LPV	LPV	NNP
cord-315453-mbv8vb2r	49	34	/	/	SYM
cord-315453-mbv8vb2r	49	35	RTV	RTV	NNP
cord-315453-mbv8vb2r	49	36	and	and	CC
cord-315453-mbv8vb2r	49	37	other	other	JJ
cord-315453-mbv8vb2r	49	38	human	human	JJ
cord-315453-mbv8vb2r	49	39	immunodeficiency	immunodeficiency	NN
cord-315453-mbv8vb2r	49	40	virus	virus	NN
cord-315453-mbv8vb2r	49	41	(	(	-LRB-
cord-315453-mbv8vb2r	49	42	HIV	HIV	NNP
cord-315453-mbv8vb2r	49	43	)	)	-RRB-
cord-315453-mbv8vb2r	49	44	PIs	pi	NNS
cord-315453-mbv8vb2r	49	45	alone	alone	RB
cord-315453-mbv8vb2r	49	46	in	in	IN
cord-315453-mbv8vb2r	49	47	treatment	treatment	NN
cord-315453-mbv8vb2r	49	48	of	of	IN
cord-315453-mbv8vb2r	49	49	COVID-19	COVID-19	NNP
cord-315453-mbv8vb2r	49	50	in	in	IN
cord-315453-mbv8vb2r	49	51	April	April	NNP
cord-315453-mbv8vb2r	49	52	,	,	,
cord-315453-mbv8vb2r	49	53	2020	2020	CD
cord-315453-mbv8vb2r	49	54	[	[	-LRB-
cord-315453-mbv8vb2r	49	55	15	15	CD
cord-315453-mbv8vb2r	49	56	]	]	-RRB-
cord-315453-mbv8vb2r	49	57	.	.	.
cord-315453-mbv8vb2r	50	1	Chloroquine	Chloroquine	NNP
cord-315453-mbv8vb2r	50	2	is	be	VBZ
cord-315453-mbv8vb2r	50	3	an	an	DT
cord-315453-mbv8vb2r	50	4	important	important	JJ
cord-315453-mbv8vb2r	50	5	drug	drug	NN
cord-315453-mbv8vb2r	50	6	in	in	IN
cord-315453-mbv8vb2r	50	7	the	the	DT
cord-315453-mbv8vb2r	50	8	treatment	treatment	NN
cord-315453-mbv8vb2r	50	9	of	of	IN
cord-315453-mbv8vb2r	50	10	malaria	malaria	NN
cord-315453-mbv8vb2r	50	11	and	and	CC
cord-315453-mbv8vb2r	50	12	autoimmune	autoimmune	JJ
cord-315453-mbv8vb2r	50	13	diseases	disease	NNS
cord-315453-mbv8vb2r	50	14	(	(	-LRB-
cord-315453-mbv8vb2r	50	15	such	such	JJ
cord-315453-mbv8vb2r	50	16	as	as	IN
cord-315453-mbv8vb2r	50	17	rheumatoid	rheumatoid	NN
cord-315453-mbv8vb2r	50	18	arthritis	arthritis	NN
cord-315453-mbv8vb2r	50	19	[	[	-LRB-
cord-315453-mbv8vb2r	50	20	RA	RA	NNP
cord-315453-mbv8vb2r	50	21	]	]	-RRB-
cord-315453-mbv8vb2r	50	22	and	and	CC
cord-315453-mbv8vb2r	50	23	lupus	lupus	NN
cord-315453-mbv8vb2r	50	24	erythematosus	erythematosus	NN
cord-315453-mbv8vb2r	50	25	)	)	-RRB-
cord-315453-mbv8vb2r	50	26	.	.	.
cord-315453-mbv8vb2r	51	1	Additionally	additionally	RB
cord-315453-mbv8vb2r	51	2	,	,	,
cord-315453-mbv8vb2r	51	3	chloroquine	chloroquine	NN
cord-315453-mbv8vb2r	51	4	was	be	VBD
cord-315453-mbv8vb2r	51	5	shown	show	VBN
cord-315453-mbv8vb2r	51	6	to	to	TO
cord-315453-mbv8vb2r	51	7	increase	increase	VB
cord-315453-mbv8vb2r	51	8	endosomal	endosomal	NNP
cord-315453-mbv8vb2r	51	9	pH	pH	NNP
cord-315453-mbv8vb2r	51	10	,	,	,
cord-315453-mbv8vb2r	51	11	which	which	WDT
cord-315453-mbv8vb2r	51	12	eliminates	eliminate	VBZ
cord-315453-mbv8vb2r	51	13	an	an	DT
cord-315453-mbv8vb2r	51	14	important	important	JJ
cord-315453-mbv8vb2r	51	15	prerequisite	prerequisite	NN
cord-315453-mbv8vb2r	51	16	for	for	IN
cord-315453-mbv8vb2r	51	17	virus	virus	NN
cord-315453-mbv8vb2r	51	18	/	/	SYM
cord-315453-mbv8vb2r	51	19	cell	cell	NN
cord-315453-mbv8vb2r	51	20	fusion	fusion	NN
cord-315453-mbv8vb2r	51	21	and	and	CC
cord-315453-mbv8vb2r	51	22	interferes	interfere	VBZ
cord-315453-mbv8vb2r	51	23	with	with	IN
cord-315453-mbv8vb2r	51	24	the	the	DT
cord-315453-mbv8vb2r	51	25	glycosylation	glycosylation	NN
cord-315453-mbv8vb2r	51	26	of	of	IN
cord-315453-mbv8vb2r	51	27	the	the	DT
cord-315453-mbv8vb2r	51	28	cellular	cellular	JJ
cord-315453-mbv8vb2r	51	29	receptors	receptor	NNS
cord-315453-mbv8vb2r	51	30	of	of	IN
cord-315453-mbv8vb2r	51	31	SARS	SARS	NNP
cord-315453-mbv8vb2r	51	32	-	-	HYPH
cord-315453-mbv8vb2r	51	33	CoV	CoV	NNP
cord-315453-mbv8vb2r	51	34	[	[	-LRB-
cord-315453-mbv8vb2r	51	35	16	16	CD
cord-315453-mbv8vb2r	51	36	]	]	-RRB-
cord-315453-mbv8vb2r	51	37	.	.	.
cord-315453-mbv8vb2r	52	1	Notably	notably	RB
cord-315453-mbv8vb2r	52	2	,	,	,
cord-315453-mbv8vb2r	52	3	hydroxychloroquine	hydroxychloroquine	NNP
cord-315453-mbv8vb2r	52	4	has	have	VBZ
cord-315453-mbv8vb2r	52	5	been	be	VBN
cord-315453-mbv8vb2r	52	6	shown	show	VBN
cord-315453-mbv8vb2r	52	7	to	to	TO
cord-315453-mbv8vb2r	52	8	be	be	VB
cord-315453-mbv8vb2r	52	9	significantly	significantly	RB
cord-315453-mbv8vb2r	52	10	more	more	RBR
cord-315453-mbv8vb2r	52	11	potent	potent	JJ
cord-315453-mbv8vb2r	52	12	than	than	IN
cord-315453-mbv8vb2r	52	13	chloroquine	chloroquine	NN
cord-315453-mbv8vb2r	52	14	in	in	IN
cord-315453-mbv8vb2r	52	15	vitro	vitro	FW
cord-315453-mbv8vb2r	53	1	(	(	-LRB-
cord-315453-mbv8vb2r	53	2	EC	EC	NNP
cord-315453-mbv8vb2r	53	3	50	50	CD
cord-315453-mbv8vb2r	53	4	values	value	NNS
cord-315453-mbv8vb2r	53	5	,	,	,
cord-315453-mbv8vb2r	53	6	0.72	0.72	CD
cord-315453-mbv8vb2r	53	7	and	and	CC
cord-315453-mbv8vb2r	53	8	5.47	5.47	CD
cord-315453-mbv8vb2r	53	9	μM	μm	NN
cord-315453-mbv8vb2r	53	10	,	,	,
cord-315453-mbv8vb2r	53	11	respectively	respectively	RB
cord-315453-mbv8vb2r	53	12	)	)	-RRB-
cord-315453-mbv8vb2r	53	13	;	;	:
cord-315453-mbv8vb2r	53	14	additionally	additionally	RB
cord-315453-mbv8vb2r	53	15	,	,	,
cord-315453-mbv8vb2r	53	16	there	there	EX
cord-315453-mbv8vb2r	53	17	are	be	VBP
cord-315453-mbv8vb2r	53	18	fewer	few	JJR
cord-315453-mbv8vb2r	53	19	concerns	concern	NNS
cord-315453-mbv8vb2r	53	20	regarding	regard	VBG
cord-315453-mbv8vb2r	53	21	drug	drug	NN
cord-315453-mbv8vb2r	53	22	-	-	HYPH
cord-315453-mbv8vb2r	53	23	drug	drug	NN
cord-315453-mbv8vb2r	53	24	interactions	interaction	NNS
cord-315453-mbv8vb2r	53	25	for	for	IN
cord-315453-mbv8vb2r	53	26	hydroxychloroquine	hydroxychloroquine	NN
cord-315453-mbv8vb2r	53	27	than	than	IN
cord-315453-mbv8vb2r	53	28	for	for	IN
cord-315453-mbv8vb2r	53	29	chloroquine	chloroquine	NN
cord-315453-mbv8vb2r	53	30	.	.	.
cord-315453-mbv8vb2r	54	1	Consequently	consequently	RB
cord-315453-mbv8vb2r	54	2	,	,	,
cord-315453-mbv8vb2r	54	3	despite	despite	IN
cord-315453-mbv8vb2r	54	4	conflicting	conflict	VBG
cord-315453-mbv8vb2r	54	5	opinions	opinion	NNS
cord-315453-mbv8vb2r	54	6	[	[	-LRB-
cord-315453-mbv8vb2r	54	7	17	17	CD
cord-315453-mbv8vb2r	54	8	]	]	-RRB-
cord-315453-mbv8vb2r	54	9	,	,	,
cord-315453-mbv8vb2r	54	10	hydroxychloroquine	hydroxychloroquine	NNP
cord-315453-mbv8vb2r	54	11	has	have	VBZ
cord-315453-mbv8vb2r	54	12	been	be	VBN
cord-315453-mbv8vb2r	54	13	recently	recently	RB
cord-315453-mbv8vb2r	54	14	proposed	propose	VBN
cord-315453-mbv8vb2r	54	15	as	as	IN
cord-315453-mbv8vb2r	54	16	having	have	VBG
cord-315453-mbv8vb2r	54	17	the	the	DT
cord-315453-mbv8vb2r	54	18	ability	ability	NN
cord-315453-mbv8vb2r	54	19	to	to	TO
cord-315453-mbv8vb2r	54	20	control	control	VB
cord-315453-mbv8vb2r	54	21	cytokine	cytokine	NN
cord-315453-mbv8vb2r	54	22	storms	storm	NNS
cord-315453-mbv8vb2r	54	23	and	and	CC
cord-315453-mbv8vb2r	54	24	shorten	shorten	VB
cord-315453-mbv8vb2r	54	25	the	the	DT
cord-315453-mbv8vb2r	54	26	clinical	clinical	JJ
cord-315453-mbv8vb2r	54	27	recovery	recovery	NN
cord-315453-mbv8vb2r	54	28	time	time	NN
cord-315453-mbv8vb2r	54	29	among	among	IN
cord-315453-mbv8vb2r	54	30	critically	critically	RB
cord-315453-mbv8vb2r	54	31	ill	ill	JJ
cord-315453-mbv8vb2r	54	32	SARS	SARS	NNP
cord-315453-mbv8vb2r	54	33	-	-	HYPH
cord-315453-mbv8vb2r	54	34	CoV-2-infected	cov-2-infecte	VBN
cord-315453-mbv8vb2r	54	35	patients	patient	NNS
cord-315453-mbv8vb2r	54	36	[	[	-LRB-
cord-315453-mbv8vb2r	54	37	18	18	CD
cord-315453-mbv8vb2r	54	38	,	,	,
cord-315453-mbv8vb2r	54	39	19	19	CD
cord-315453-mbv8vb2r	54	40	]	]	-RRB-
cord-315453-mbv8vb2r	54	41	.	.	.
cord-315453-mbv8vb2r	55	1	Recently	recently	RB
cord-315453-mbv8vb2r	55	2	,	,	,
cord-315453-mbv8vb2r	55	3	hydroxychloroquine	hydroxychloroquine	NN
cord-315453-mbv8vb2r	55	4	sulfate	sulfate	NN
cord-315453-mbv8vb2r	55	5	was	be	VBD
cord-315453-mbv8vb2r	55	6	approved	approve	VBN
cord-315453-mbv8vb2r	55	7	by	by	IN
cord-315453-mbv8vb2r	55	8	the	the	DT
cord-315453-mbv8vb2r	55	9	US	US	NNP
cord-315453-mbv8vb2r	55	10	Centers	Centers	NNPS
cord-315453-mbv8vb2r	55	11	for	for	IN
cord-315453-mbv8vb2r	55	12	Disease	Disease	NNP
cord-315453-mbv8vb2r	55	13	Control	Control	NNP
cord-315453-mbv8vb2r	55	14	and	and	CC
cord-315453-mbv8vb2r	55	15	Prevention	Prevention	NNP
cord-315453-mbv8vb2r	55	16	for	for	IN
cord-315453-mbv8vb2r	55	17	emergent	emergent	JJ
cord-315453-mbv8vb2r	55	18	use	use	NN
cord-315453-mbv8vb2r	55	19	in	in	IN
cord-315453-mbv8vb2r	55	20	treating	treat	VBG
cord-315453-mbv8vb2r	55	21	adolescent	adolescent	JJ
cord-315453-mbv8vb2r	55	22	or	or	CC
cord-315453-mbv8vb2r	55	23	adult	adult	NN
cord-315453-mbv8vb2r	55	24	patients	patient	NNS
cord-315453-mbv8vb2r	55	25	(	(	-LRB-
cord-315453-mbv8vb2r	55	26	body	body	NN
cord-315453-mbv8vb2r	55	27	weight	weight	NN
cord-315453-mbv8vb2r	55	28	≥50	≥50	NNP
cord-315453-mbv8vb2r	55	29	kg	kg	NN
cord-315453-mbv8vb2r	55	30	)	)	-RRB-
cord-315453-mbv8vb2r	55	31	with	with	IN
cord-315453-mbv8vb2r	55	32	severe	severe	JJ
cord-315453-mbv8vb2r	55	33	COVID-19	covid-19	NN
cord-315453-mbv8vb2r	55	34	on	on	IN
cord-315453-mbv8vb2r	55	35	28	28	CD
cord-315453-mbv8vb2r	55	36	March	March	NNP
cord-315453-mbv8vb2r	55	37	2020	2020	CD
cord-315453-mbv8vb2r	55	38	.	.	.
cord-315453-mbv8vb2r	56	1	According	accord	VBG
cord-315453-mbv8vb2r	56	2	to	to	IN
cord-315453-mbv8vb2r	56	3	data	datum	NNS
cord-315453-mbv8vb2r	56	4	from	from	IN
cord-315453-mbv8vb2r	56	5	physiologically	physiologically	RB
cord-315453-mbv8vb2r	56	6	based	base	VBN
cord-315453-mbv8vb2r	56	7	pharmacokinetic	pharmacokinetic	JJ
cord-315453-mbv8vb2r	56	8	models	model	NNS
cord-315453-mbv8vb2r	56	9	,	,	,
cord-315453-mbv8vb2r	56	10	a	a	DT
cord-315453-mbv8vb2r	56	11	loading	loading	NN
cord-315453-mbv8vb2r	56	12	dose	dose	NN
cord-315453-mbv8vb2r	56	13	of	of	IN
cord-315453-mbv8vb2r	56	14	400	400	CD
cord-315453-mbv8vb2r	56	15	mg	mg	NNS
cord-315453-mbv8vb2r	56	16	twice	twice	RB
cord-315453-mbv8vb2r	56	17	daily	daily	RB
cord-315453-mbv8vb2r	56	18	of	of	IN
cord-315453-mbv8vb2r	56	19	hydroxychloroquine	hydroxychloroquine	NNP
cord-315453-mbv8vb2r	56	20	sulfate	sulfate	NNP
cord-315453-mbv8vb2r	56	21	,	,	,
cord-315453-mbv8vb2r	56	22	which	which	WDT
cord-315453-mbv8vb2r	56	23	is	be	VBZ
cord-315453-mbv8vb2r	56	24	followed	follow	VBN
cord-315453-mbv8vb2r	56	25	by	by	IN
cord-315453-mbv8vb2r	56	26	a	a	DT
cord-315453-mbv8vb2r	56	27	maintenance	maintenance	NN
cord-315453-mbv8vb2r	56	28	dose	dose	NN
cord-315453-mbv8vb2r	56	29	of	of	IN
cord-315453-mbv8vb2r	56	30	200	200	CD
cord-315453-mbv8vb2r	56	31	mg	mg	NNS
cord-315453-mbv8vb2r	56	32	twice	twice	RB
cord-315453-mbv8vb2r	56	33	daily	daily	RB
cord-315453-mbv8vb2r	56	34	for	for	IN
cord-315453-mbv8vb2r	56	35	4	4	CD
cord-315453-mbv8vb2r	56	36	days	day	NNS
cord-315453-mbv8vb2r	56	37	,	,	,
cord-315453-mbv8vb2r	56	38	has	have	VBZ
cord-315453-mbv8vb2r	56	39	demonstrated	demonstrate	VBN
cord-315453-mbv8vb2r	56	40	significant	significant	JJ
cord-315453-mbv8vb2r	56	41	superiority	superiority	NN
cord-315453-mbv8vb2r	56	42	(	(	-LRB-
cord-315453-mbv8vb2r	56	43	5	5	CD
cord-315453-mbv8vb2r	56	44	days	day	NNS
cord-315453-mbv8vb2r	56	45	in	in	IN
cord-315453-mbv8vb2r	56	46	advance	advance	NN
cord-315453-mbv8vb2r	56	47	)	)	-RRB-
cord-315453-mbv8vb2r	56	48	to	to	IN
cord-315453-mbv8vb2r	56	49	chloroquine	chloroquine	NN
cord-315453-mbv8vb2r	56	50	phosphate	phosphate	NN
cord-315453-mbv8vb2r	56	51	(	(	-LRB-
cord-315453-mbv8vb2r	56	52	500	500	CD
cord-315453-mbv8vb2r	56	53	mg	mg	NNS
cord-315453-mbv8vb2r	56	54	twice	twice	RB
cord-315453-mbv8vb2r	56	55	daily	daily	RB
cord-315453-mbv8vb2r	56	56	,	,	,
cord-315453-mbv8vb2r	56	57	4-fold	4-fold	CD
cord-315453-mbv8vb2r	56	58	higher	high	JJR
cord-315453-mbv8vb2r	56	59	than	than	IN
cord-315453-mbv8vb2r	56	60	that	that	DT
cord-315453-mbv8vb2r	56	61	used	use	VBN
cord-315453-mbv8vb2r	56	62	in	in	IN
cord-315453-mbv8vb2r	56	63	malaria	malaria	NN
cord-315453-mbv8vb2r	56	64	treatment	treatment	NN
cord-315453-mbv8vb2r	56	65	)	)	-RRB-
cord-315453-mbv8vb2r	56	66	in	in	IN
cord-315453-mbv8vb2r	56	67	inhibiting	inhibit	VBG
cord-315453-mbv8vb2r	56	68	SARS	SARS	NNP
cord-315453-mbv8vb2r	56	69	-	-	HYPH
cord-315453-mbv8vb2r	56	70	CoV-2	CoV-2	NNP
cord-315453-mbv8vb2r	56	71	in	in	IN
cord-315453-mbv8vb2r	56	72	vitro	vitro	FW
cord-315453-mbv8vb2r	56	73	[	[	-LRB-
cord-315453-mbv8vb2r	56	74	18	18	CD
cord-315453-mbv8vb2r	56	75	]	]	-RRB-
cord-315453-mbv8vb2r	56	76	.	.	.
cord-315453-mbv8vb2r	57	1	Additionally	additionally	RB
cord-315453-mbv8vb2r	57	2	,	,	,
cord-315453-mbv8vb2r	57	3	the	the	DT
cord-315453-mbv8vb2r	57	4	cardiac	cardiac	JJ
cord-315453-mbv8vb2r	57	5	toxicity	toxicity	NN
cord-315453-mbv8vb2r	57	6	might	may	MD
cord-315453-mbv8vb2r	57	7	temper	temper	VB
cord-315453-mbv8vb2r	57	8	the	the	DT
cord-315453-mbv8vb2r	57	9	enthusiasm	enthusiasm	NN
cord-315453-mbv8vb2r	57	10	for	for	IN
cord-315453-mbv8vb2r	57	11	the	the	DT
cord-315453-mbv8vb2r	57	12	widespread	widespread	JJ
cord-315453-mbv8vb2r	57	13	use	use	NN
cord-315453-mbv8vb2r	57	14	of	of	IN
cord-315453-mbv8vb2r	57	15	chloroquine	chloroquine	NN
cord-315453-mbv8vb2r	57	16	in	in	IN
cord-315453-mbv8vb2r	57	17	the	the	DT
cord-315453-mbv8vb2r	57	18	treatment	treatment	NN
cord-315453-mbv8vb2r	57	19	of	of	IN
cord-315453-mbv8vb2r	57	20	COVID-19	COVID-19	NNP
cord-315453-mbv8vb2r	57	21	.	.	.
cord-315453-mbv8vb2r	58	1	It	-PRON-	PRP
cord-315453-mbv8vb2r	58	2	is	be	VBZ
cord-315453-mbv8vb2r	58	3	noteworthy	noteworthy	JJ
cord-315453-mbv8vb2r	58	4	that	that	IN
cord-315453-mbv8vb2r	58	5	one	one	CD
cord-315453-mbv8vb2r	58	6	randomized	randomize	VBN
cord-315453-mbv8vb2r	58	7	controlled	control	VBN
cord-315453-mbv8vb2r	58	8	trial	trial	NN
cord-315453-mbv8vb2r	58	9	in	in	IN
cord-315453-mbv8vb2r	58	10	Wuhan	Wuhan	NNP
cord-315453-mbv8vb2r	58	11	,	,	,
cord-315453-mbv8vb2r	58	12	China	China	NNP
cord-315453-mbv8vb2r	58	13	validates	validate	VBZ
cord-315453-mbv8vb2r	58	14	the	the	DT
cord-315453-mbv8vb2r	58	15	clinical	clinical	JJ
cord-315453-mbv8vb2r	58	16	superiority	superiority	NN
cord-315453-mbv8vb2r	58	17	of	of	IN
cord-315453-mbv8vb2r	58	18	hydroxychloroquine	hydroxychloroquine	NNP
cord-315453-mbv8vb2r	58	19	(	(	-LRB-
cord-315453-mbv8vb2r	58	20	200	200	CD
cord-315453-mbv8vb2r	58	21	mg	mg	NN
cord-315453-mbv8vb2r	58	22	twice	twice	RB
cord-315453-mbv8vb2r	58	23	daily	daily	RB
cord-315453-mbv8vb2r	58	24	for	for	IN
cord-315453-mbv8vb2r	58	25	5	5	CD
cord-315453-mbv8vb2r	58	26	days	day	NNS
cord-315453-mbv8vb2r	58	27	)	)	-RRB-
cord-315453-mbv8vb2r	58	28	over	over	IN
cord-315453-mbv8vb2r	58	29	the	the	DT
cord-315453-mbv8vb2r	58	30	control	control	NN
cord-315453-mbv8vb2r	58	31	group	group	NN
cord-315453-mbv8vb2r	58	32	in	in	IN
cord-315453-mbv8vb2r	58	33	significantly	significantly	RB
cord-315453-mbv8vb2r	58	34	shortening	shorten	VBG
cord-315453-mbv8vb2r	58	35	recovery	recovery	NN
cord-315453-mbv8vb2r	58	36	time	time	NN
cord-315453-mbv8vb2r	58	37	[	[	-LRB-
cord-315453-mbv8vb2r	58	38	20	20	CD
cord-315453-mbv8vb2r	58	39	]	]	-RRB-
cord-315453-mbv8vb2r	58	40	.	.	.
cord-315453-mbv8vb2r	59	1	According	accord	VBG
cord-315453-mbv8vb2r	59	2	to	to	IN
cord-315453-mbv8vb2r	59	3	one	one	CD
cord-315453-mbv8vb2r	59	4	notable	notable	JJ
cord-315453-mbv8vb2r	59	5	study	study	NN
cord-315453-mbv8vb2r	59	6	,	,	,
cord-315453-mbv8vb2r	59	7	azithromycin	azithromycin	NNP
cord-315453-mbv8vb2r	59	8	(	(	-LRB-
cord-315453-mbv8vb2r	59	9	500	500	CD
cord-315453-mbv8vb2r	59	10	mg	mg	NN
cord-315453-mbv8vb2r	59	11	on	on	IN
cord-315453-mbv8vb2r	59	12	day	day	NN
cord-315453-mbv8vb2r	59	13	1	1	CD
cord-315453-mbv8vb2r	59	14	,	,	,
cord-315453-mbv8vb2r	59	15	followed	follow	VBN
cord-315453-mbv8vb2r	59	16	by	by	IN
cord-315453-mbv8vb2r	59	17	250	250	CD
cord-315453-mbv8vb2r	59	18	mg	mg	NN
cord-315453-mbv8vb2r	59	19	per	per	IN
cord-315453-mbv8vb2r	59	20	day	day	NN
cord-315453-mbv8vb2r	59	21	on	on	IN
cord-315453-mbv8vb2r	59	22	days	day	NNS
cord-315453-mbv8vb2r	59	23	2	2	CD
cord-315453-mbv8vb2r	59	24	-	-	SYM
cord-315453-mbv8vb2r	59	25	5	5	CD
cord-315453-mbv8vb2r	59	26	)	)	-RRB-
cord-315453-mbv8vb2r	59	27	was	be	VBD
cord-315453-mbv8vb2r	59	28	shown	show	VBN
cord-315453-mbv8vb2r	59	29	to	to	TO
cord-315453-mbv8vb2r	59	30	significantly	significantly	RB
cord-315453-mbv8vb2r	59	31	reinforce	reinforce	VB
cord-315453-mbv8vb2r	59	32	the	the	DT
cord-315453-mbv8vb2r	59	33	efficacy	efficacy	NN
cord-315453-mbv8vb2r	59	34	of	of	IN
cord-315453-mbv8vb2r	59	35	hydroxychloroquine	hydroxychloroquine	NNP
cord-315453-mbv8vb2r	59	36	(	(	-LRB-
cord-315453-mbv8vb2r	59	37	200	200	CD
cord-315453-mbv8vb2r	59	38	mg	mg	NNP
cord-315453-mbv8vb2r	59	39	thrice	thrice	RB
cord-315453-mbv8vb2r	59	40	daily	daily	RB
cord-315453-mbv8vb2r	59	41	for	for	IN
cord-315453-mbv8vb2r	59	42	10	10	CD
cord-315453-mbv8vb2r	59	43	days	day	NNS
cord-315453-mbv8vb2r	59	44	)	)	-RRB-
cord-315453-mbv8vb2r	59	45	in	in	IN
cord-315453-mbv8vb2r	59	46	the	the	DT
cord-315453-mbv8vb2r	59	47	treatment	treatment	NN
cord-315453-mbv8vb2r	59	48	of	of	IN
cord-315453-mbv8vb2r	59	49	20	20	CD
cord-315453-mbv8vb2r	59	50	patients	patient	NNS
cord-315453-mbv8vb2r	59	51	with	with	IN
cord-315453-mbv8vb2r	59	52	severe	severe	JJ
cord-315453-mbv8vb2r	59	53	COVID-19	covid-19	NN
cord-315453-mbv8vb2r	59	54	.	.	.
cord-315453-mbv8vb2r	60	1	The	the	DT
cord-315453-mbv8vb2r	60	2	positive	positive	JJ
cord-315453-mbv8vb2r	60	3	clinical	clinical	JJ
cord-315453-mbv8vb2r	60	4	outcome	outcome	NN
cord-315453-mbv8vb2r	60	5	in	in	IN
cord-315453-mbv8vb2r	60	6	these	these	DT
cord-315453-mbv8vb2r	60	7	COVID-19	COVID-19	NNP
cord-315453-mbv8vb2r	60	8	patients	patient	NNS
cord-315453-mbv8vb2r	60	9	is	be	VBZ
cord-315453-mbv8vb2r	60	10	attributed	attribute	VBN
cord-315453-mbv8vb2r	60	11	to	to	IN
cord-315453-mbv8vb2r	60	12	the	the	DT
cord-315453-mbv8vb2r	60	13	excellent	excellent	JJ
cord-315453-mbv8vb2r	60	14	efficiency	efficiency	NN
cord-315453-mbv8vb2r	60	15	of	of	IN
cord-315453-mbv8vb2r	60	16	virus	virus	NN
cord-315453-mbv8vb2r	60	17	elimination	elimination	NN
cord-315453-mbv8vb2r	60	18	after	after	IN
cord-315453-mbv8vb2r	60	19	administration	administration	NN
cord-315453-mbv8vb2r	60	20	of	of	IN
cord-315453-mbv8vb2r	60	21	this	this	DT
cord-315453-mbv8vb2r	60	22	combination	combination	NN
cord-315453-mbv8vb2r	60	23	regimen	regimen	NN
cord-315453-mbv8vb2r	60	24	[	[	-LRB-
cord-315453-mbv8vb2r	60	25	21	21	CD
cord-315453-mbv8vb2r	60	26	]	]	-RRB-
cord-315453-mbv8vb2r	60	27	.	.	.
cord-315453-mbv8vb2r	61	1	Consequently	consequently	RB
cord-315453-mbv8vb2r	61	2	,	,	,
cord-315453-mbv8vb2r	61	3	hydroxychloroquine	hydroxychloroquine	NN
cord-315453-mbv8vb2r	61	4	in	in	IN
cord-315453-mbv8vb2r	61	5	combination	combination	NN
cord-315453-mbv8vb2r	61	6	with	with	IN
cord-315453-mbv8vb2r	61	7	azithromycin	azithromycin	NNP
cord-315453-mbv8vb2r	61	8	might	may	MD
cord-315453-mbv8vb2r	61	9	be	be	VB
cord-315453-mbv8vb2r	61	10	deemed	deem	VBN
cord-315453-mbv8vb2r	61	11	a	a	DT
cord-315453-mbv8vb2r	61	12	promising	promising	JJ
cord-315453-mbv8vb2r	61	13	alternative	alternative	NN
cord-315453-mbv8vb2r	61	14	to	to	IN
cord-315453-mbv8vb2r	61	15	remdesivir	remdesivir	NNP
cord-315453-mbv8vb2r	61	16	in	in	IN
cord-315453-mbv8vb2r	61	17	the	the	DT
cord-315453-mbv8vb2r	61	18	treatment	treatment	NN
cord-315453-mbv8vb2r	61	19	of	of	IN
cord-315453-mbv8vb2r	61	20	patients	patient	NNS
cord-315453-mbv8vb2r	61	21	with	with	IN
cord-315453-mbv8vb2r	61	22	SARS	SARS	NNP
cord-315453-mbv8vb2r	61	23	-	-	HYPH
cord-315453-mbv8vb2r	61	24	CoV-2	CoV-2	NNP
cord-315453-mbv8vb2r	61	25	infection	infection	NN
cord-315453-mbv8vb2r	61	26	.	.	.
cord-315453-mbv8vb2r	62	1	Nevertheless	nevertheless	RB
cord-315453-mbv8vb2r	62	2	,	,	,
cord-315453-mbv8vb2r	62	3	the	the	DT
cord-315453-mbv8vb2r	62	4	warning	warning	NN
cord-315453-mbv8vb2r	62	5	on	on	IN
cord-315453-mbv8vb2r	62	6	QTc	qtc	NN
cord-315453-mbv8vb2r	62	7	prolongation	prolongation	NN
cord-315453-mbv8vb2r	62	8	caused	cause	VBN
cord-315453-mbv8vb2r	62	9	by	by	IN
cord-315453-mbv8vb2r	62	10	this	this	DT
cord-315453-mbv8vb2r	62	11	combination	combination	NN
cord-315453-mbv8vb2r	62	12	regimen	regimen	NN
cord-315453-mbv8vb2r	62	13	should	should	MD
cord-315453-mbv8vb2r	62	14	be	be	VB
cord-315453-mbv8vb2r	62	15	cautiously	cautiously	RB
cord-315453-mbv8vb2r	62	16	considered	consider	VBN
cord-315453-mbv8vb2r	62	17	.	.	.
cord-315453-mbv8vb2r	63	1	Despite	despite	IN
cord-315453-mbv8vb2r	63	2	excellent	excellent	JJ
cord-315453-mbv8vb2r	63	3	efficacy	efficacy	NN
cord-315453-mbv8vb2r	63	4	on	on	IN
cord-315453-mbv8vb2r	63	5	a	a	DT
cord-315453-mbv8vb2r	63	6	small	small	JJ
cord-315453-mbv8vb2r	63	7	group	group	NN
cord-315453-mbv8vb2r	63	8	of	of	IN
cord-315453-mbv8vb2r	63	9	patients	patient	NNS
cord-315453-mbv8vb2r	63	10	with	with	IN
cord-315453-mbv8vb2r	63	11	COVID-19	COVID-19	NNP
cord-315453-mbv8vb2r	63	12	,	,	,
cord-315453-mbv8vb2r	63	13	the	the	DT
cord-315453-mbv8vb2r	63	14	US	US	NNP
cord-315453-mbv8vb2r	63	15	NIH	NIH	NNP
cord-315453-mbv8vb2r	63	16	Consensus	Consensus	NNP
cord-315453-mbv8vb2r	63	17	Treatment	Treatment	NNP
cord-315453-mbv8vb2r	63	18	Guidelines	Guidelines	NNPS
cord-315453-mbv8vb2r	63	19	Panel	Panel	NNP
cord-315453-mbv8vb2r	63	20	recommended	recommend	VBD
cord-315453-mbv8vb2r	63	21	against	against	IN
cord-315453-mbv8vb2r	63	22	the	the	DT
cord-315453-mbv8vb2r	63	23	use	use	NN
cord-315453-mbv8vb2r	63	24	of	of	IN
cord-315453-mbv8vb2r	63	25	this	this	DT
cord-315453-mbv8vb2r	63	26	combination	combination	NN
cord-315453-mbv8vb2r	63	27	regimen	regimen	NN
cord-315453-mbv8vb2r	63	28	in	in	IN
cord-315453-mbv8vb2r	63	29	the	the	DT
cord-315453-mbv8vb2r	63	30	treatment	treatment	NN
cord-315453-mbv8vb2r	63	31	of	of	IN
cord-315453-mbv8vb2r	63	32	COVID-19	COVID-19	NNP
cord-315453-mbv8vb2r	63	33	due	due	IN
cord-315453-mbv8vb2r	63	34	to	to	IN
cord-315453-mbv8vb2r	63	35	its	-PRON-	PRP$
cord-315453-mbv8vb2r	63	36	cardiac	cardiac	JJ
cord-315453-mbv8vb2r	63	37	toxicity	toxicity	NN
cord-315453-mbv8vb2r	63	38	[	[	-LRB-
cord-315453-mbv8vb2r	63	39	15	15	CD
cord-315453-mbv8vb2r	63	40	]	]	-RRB-
cord-315453-mbv8vb2r	63	41	.	.	.
cord-315453-mbv8vb2r	64	1	Tocilizumab	Tocilizumab	NNP
cord-315453-mbv8vb2r	64	2	is	be	VBZ
cord-315453-mbv8vb2r	64	3	a	a	DT
cord-315453-mbv8vb2r	64	4	monoclonal	monoclonal	JJ
cord-315453-mbv8vb2r	64	5	antibody	antibody	NN
cord-315453-mbv8vb2r	64	6	employed	employ	VBN
cord-315453-mbv8vb2r	64	7	in	in	IN
cord-315453-mbv8vb2r	64	8	treatment	treatment	NN
cord-315453-mbv8vb2r	64	9	of	of	IN
cord-315453-mbv8vb2r	64	10	RA	RA	NNP
cord-315453-mbv8vb2r	64	11	exacerbation	exacerbation	NN
cord-315453-mbv8vb2r	64	12	.	.	.
cord-315453-mbv8vb2r	65	1	It	-PRON-	PRP
cord-315453-mbv8vb2r	65	2	was	be	VBD
cord-315453-mbv8vb2r	65	3	originally	originally	RB
cord-315453-mbv8vb2r	65	4	designed	design	VBN
cord-315453-mbv8vb2r	65	5	to	to	TO
cord-315453-mbv8vb2r	65	6	inhibit	inhibit	VB
cord-315453-mbv8vb2r	65	7	the	the	DT
cord-315453-mbv8vb2r	65	8	binding	binding	NN
cord-315453-mbv8vb2r	65	9	of	of	IN
cord-315453-mbv8vb2r	65	10	IL-6	IL-6	NNP
cord-315453-mbv8vb2r	65	11	to	to	IN
cord-315453-mbv8vb2r	65	12	its	-PRON-	PRP$
cord-315453-mbv8vb2r	65	13	receptors	receptor	NNS
cord-315453-mbv8vb2r	65	14	for	for	IN
cord-315453-mbv8vb2r	65	15	alleviating	alleviate	VBG
cord-315453-mbv8vb2r	65	16	cytokine	cytokine	NN
cord-315453-mbv8vb2r	65	17	release	release	NN
cord-315453-mbv8vb2r	65	18	syndrome	syndrome	NN
cord-315453-mbv8vb2r	65	19	.	.	.
cord-315453-mbv8vb2r	66	1	Tocilizumab	Tocilizumab	NNP
cord-315453-mbv8vb2r	66	2	is	be	VBZ
cord-315453-mbv8vb2r	66	3	currently	currently	RB
cord-315453-mbv8vb2r	66	4	being	be	VBG
cord-315453-mbv8vb2r	66	5	investigated	investigate	VBN
cord-315453-mbv8vb2r	66	6	in	in	IN
cord-315453-mbv8vb2r	66	7	a	a	DT
cord-315453-mbv8vb2r	66	8	randomized	randomized	JJ
cord-315453-mbv8vb2r	66	9	,	,	,
cord-315453-mbv8vb2r	66	10	double	double	JJ
cord-315453-mbv8vb2r	66	11	-	-	HYPH
cord-315453-mbv8vb2r	66	12	blind	blind	JJ
cord-315453-mbv8vb2r	66	13	phase	phase	NN
cord-315453-mbv8vb2r	66	14	3	3	CD
cord-315453-mbv8vb2r	66	15	trial	trial	NN
cord-315453-mbv8vb2r	66	16	for	for	IN
cord-315453-mbv8vb2r	66	17	its	-PRON-	PRP$
cord-315453-mbv8vb2r	66	18	clinical	clinical	JJ
cord-315453-mbv8vb2r	66	19	efficacy	efficacy	NN
cord-315453-mbv8vb2r	66	20	and	and	CC
cord-315453-mbv8vb2r	66	21	safety	safety	NN
cord-315453-mbv8vb2r	66	22	in	in	IN
cord-315453-mbv8vb2r	66	23	patients	patient	NNS
cord-315453-mbv8vb2r	66	24	with	with	IN
cord-315453-mbv8vb2r	66	25	COVID-19	covid-19	NN
cord-315453-mbv8vb2r	66	26	compared	compare	VBN
cord-315453-mbv8vb2r	66	27	to	to	IN
cord-315453-mbv8vb2r	66	28	placebo	placebo	NN
cord-315453-mbv8vb2r	66	29	plus	plus	CC
cord-315453-mbv8vb2r	66	30	standard	standard	JJ
cord-315453-mbv8vb2r	66	31	care	care	NN
cord-315453-mbv8vb2r	66	32	in	in	IN
cord-315453-mbv8vb2r	66	33	the	the	DT
cord-315453-mbv8vb2r	66	34	US	US	NNP
cord-315453-mbv8vb2r	66	35	[	[	-LRB-
cord-315453-mbv8vb2r	66	36	22	22	CD
cord-315453-mbv8vb2r	66	37	]	]	-RRB-
cord-315453-mbv8vb2r	66	38	.	.	.
cord-315453-mbv8vb2r	67	1	Recently	recently	RB
cord-315453-mbv8vb2r	67	2	,	,	,
cord-315453-mbv8vb2r	67	3	in	in	IN
cord-315453-mbv8vb2r	67	4	China	China	NNP
cord-315453-mbv8vb2r	67	5	,	,	,
cord-315453-mbv8vb2r	67	6	an	an	DT
cord-315453-mbv8vb2r	67	7	open	open	JJ
cord-315453-mbv8vb2r	67	8	label	label	NN
cord-315453-mbv8vb2r	67	9	,	,	,
cord-315453-mbv8vb2r	67	10	non	non	JJ
cord-315453-mbv8vb2r	67	11	-	-	JJ
cord-315453-mbv8vb2r	67	12	controlled	controlled	JJ
cord-315453-mbv8vb2r	67	13	study	study	NN
cord-315453-mbv8vb2r	67	14	(	(	-LRB-
cord-315453-mbv8vb2r	67	15	ClinicalTrials.gov	ClinicalTrials.gov	NNP
cord-315453-mbv8vb2r	67	16	Identifier	Identifier	NNP
cord-315453-mbv8vb2r	67	17	:	:	:
cord-315453-mbv8vb2r	67	18	NCT04322773	NCT04322773	NNP
cord-315453-mbv8vb2r	67	19	)	)	-RRB-
cord-315453-mbv8vb2r	67	20	investigated	investigate	VBD
cord-315453-mbv8vb2r	67	21	the	the	DT
cord-315453-mbv8vb2r	67	22	efficacy	efficacy	NN
cord-315453-mbv8vb2r	67	23	of	of	IN
cord-315453-mbv8vb2r	67	24	tocilizumab	tocilizumab	NNP
cord-315453-mbv8vb2r	67	25	for	for	IN
cord-315453-mbv8vb2r	67	26	reducing	reduce	VBG
cord-315453-mbv8vb2r	67	27	oxygen	oxygen	NN
cord-315453-mbv8vb2r	67	28	requirement	requirement	NN
cord-315453-mbv8vb2r	67	29	.	.	.
cord-315453-mbv8vb2r	68	1	Although	although	IN
cord-315453-mbv8vb2r	68	2	no	no	DT
cord-315453-mbv8vb2r	68	3	control	control	NN
cord-315453-mbv8vb2r	68	4	group	group	NN
cord-315453-mbv8vb2r	68	5	was	be	VBD
cord-315453-mbv8vb2r	68	6	included	include	VBN
cord-315453-mbv8vb2r	68	7	in	in	IN
cord-315453-mbv8vb2r	68	8	that	that	DT
cord-315453-mbv8vb2r	68	9	study	study	NN
cord-315453-mbv8vb2r	68	10	,	,	,
cord-315453-mbv8vb2r	68	11	the	the	DT
cord-315453-mbv8vb2r	68	12	preliminary	preliminary	JJ
cord-315453-mbv8vb2r	68	13	report	report	NN
cord-315453-mbv8vb2r	68	14	shows	show	VBZ
cord-315453-mbv8vb2r	68	15	a	a	DT
cord-315453-mbv8vb2r	68	16	promising	promising	JJ
cord-315453-mbv8vb2r	68	17	potential	potential	NN
cord-315453-mbv8vb2r	68	18	for	for	IN
cord-315453-mbv8vb2r	68	19	tocilizumab	tocilizumab	NNP
cord-315453-mbv8vb2r	68	20	on	on	IN
cord-315453-mbv8vb2r	68	21	the	the	DT
cord-315453-mbv8vb2r	68	22	basis	basis	NN
cord-315453-mbv8vb2r	68	23	of	of	IN
cord-315453-mbv8vb2r	68	24	the	the	DT
cord-315453-mbv8vb2r	68	25	outcome	outcome	NN
cord-315453-mbv8vb2r	68	26	in	in	IN
cord-315453-mbv8vb2r	68	27	the	the	DT
cord-315453-mbv8vb2r	68	28	COVID-19	COVID-19	NNP
cord-315453-mbv8vb2r	68	29	patients	patient	NNS
cord-315453-mbv8vb2r	68	30	,	,	,
cord-315453-mbv8vb2r	68	31	who	who	WP
cord-315453-mbv8vb2r	68	32	had	have	VBD
cord-315453-mbv8vb2r	68	33	mild	mild	JJ
cord-315453-mbv8vb2r	68	34	-	-	HYPH
cord-315453-mbv8vb2r	68	35	to	to	IN
cord-315453-mbv8vb2r	68	36	-	-	HYPH
cord-315453-mbv8vb2r	68	37	moderate	moderate	JJ
cord-315453-mbv8vb2r	68	38	ARDS	ARDS	NNP
cord-315453-mbv8vb2r	68	39	and	and	CC
cord-315453-mbv8vb2r	68	40	received	receive	VBD
cord-315453-mbv8vb2r	68	41	a	a	DT
cord-315453-mbv8vb2r	68	42	single	single	JJ
cord-315453-mbv8vb2r	68	43	intravenous	intravenous	JJ
cord-315453-mbv8vb2r	68	44	dose	dose	NN
cord-315453-mbv8vb2r	68	45	of	of	IN
cord-315453-mbv8vb2r	68	46	400	400	CD
cord-315453-mbv8vb2r	68	47	mg	mg	NN
cord-315453-mbv8vb2r	68	48	tocilizumab	tocilizumab	NN
cord-315453-mbv8vb2r	68	49	[	[	-LRB-
cord-315453-mbv8vb2r	68	50	23	23	CD
cord-315453-mbv8vb2r	68	51	]	]	-RRB-
cord-315453-mbv8vb2r	68	52	.	.	.
cord-315453-mbv8vb2r	69	1	The	the	DT
cord-315453-mbv8vb2r	69	2	efficacy	efficacy	NN
cord-315453-mbv8vb2r	69	3	of	of	IN
cord-315453-mbv8vb2r	69	4	a	a	DT
cord-315453-mbv8vb2r	69	5	Janus	Janus	NNP
cord-315453-mbv8vb2r	69	6	kinase	kinase	NN
cord-315453-mbv8vb2r	69	7	inhibitor	inhibitor	NN
cord-315453-mbv8vb2r	69	8	ruxolitinib	ruxolitinib	NN
cord-315453-mbv8vb2r	69	9	,	,	,
cord-315453-mbv8vb2r	69	10	which	which	WDT
cord-315453-mbv8vb2r	69	11	was	be	VBD
cord-315453-mbv8vb2r	69	12	originally	originally	RB
cord-315453-mbv8vb2r	69	13	used	use	VBN
cord-315453-mbv8vb2r	69	14	in	in	IN
cord-315453-mbv8vb2r	69	15	the	the	DT
cord-315453-mbv8vb2r	69	16	treatment	treatment	NN
cord-315453-mbv8vb2r	69	17	of	of	IN
cord-315453-mbv8vb2r	69	18	intermediate	intermediate	JJ
cord-315453-mbv8vb2r	69	19	-	-	HYPH
cord-315453-mbv8vb2r	69	20	or	or	CC
cord-315453-mbv8vb2r	69	21	high	high	JJ
cord-315453-mbv8vb2r	69	22	-	-	HYPH
cord-315453-mbv8vb2r	69	23	risk	risk	NN
cord-315453-mbv8vb2r	69	24	myelofibrosis	myelofibrosis	NN
cord-315453-mbv8vb2r	69	25	,	,	,
cord-315453-mbv8vb2r	69	26	is	be	VBZ
cord-315453-mbv8vb2r	69	27	currently	currently	RB
cord-315453-mbv8vb2r	69	28	being	be	VBG
cord-315453-mbv8vb2r	69	29	evaluated	evaluate	VBN
cord-315453-mbv8vb2r	69	30	in	in	IN
cord-315453-mbv8vb2r	69	31	a	a	DT
cord-315453-mbv8vb2r	69	32	phase	phase	NN
cord-315453-mbv8vb2r	69	33	3	3	CD
cord-315453-mbv8vb2r	69	34	trial	trial	NN
cord-315453-mbv8vb2r	69	35	for	for	IN
cord-315453-mbv8vb2r	69	36	the	the	DT
cord-315453-mbv8vb2r	69	37	treatment	treatment	NN
cord-315453-mbv8vb2r	69	38	of	of	IN
cord-315453-mbv8vb2r	69	39	patients	patient	NNS
cord-315453-mbv8vb2r	69	40	with	with	IN
cord-315453-mbv8vb2r	69	41	COVID-19-associated	covid-19-associated	JJ
cord-315453-mbv8vb2r	69	42	cytokine	cytokine	NN
cord-315453-mbv8vb2r	69	43	storm	storm	NN
cord-315453-mbv8vb2r	69	44	[	[	-LRB-
cord-315453-mbv8vb2r	69	45	23	23	CD
cord-315453-mbv8vb2r	69	46	,	,	,
cord-315453-mbv8vb2r	69	47	24	24	CD
cord-315453-mbv8vb2r	69	48	]	]	-RRB-
cord-315453-mbv8vb2r	69	49	.	.	.
cord-315453-mbv8vb2r	70	1	Despite	despite	IN
cord-315453-mbv8vb2r	70	2	a	a	DT
cord-315453-mbv8vb2r	70	3	theoretically	theoretically	RB
cord-315453-mbv8vb2r	70	4	promising	promising	JJ
cord-315453-mbv8vb2r	70	5	role	role	NN
cord-315453-mbv8vb2r	70	6	in	in	IN
cord-315453-mbv8vb2r	70	7	alleviating	alleviate	VBG
cord-315453-mbv8vb2r	70	8	cytokine	cytokine	NN
cord-315453-mbv8vb2r	70	9	release	release	NN
cord-315453-mbv8vb2r	70	10	storm	storm	NN
cord-315453-mbv8vb2r	70	11	,	,	,
cord-315453-mbv8vb2r	70	12	the	the	DT
cord-315453-mbv8vb2r	70	13	US	US	NNP
cord-315453-mbv8vb2r	70	14	NIH	NIH	NNP
cord-315453-mbv8vb2r	70	15	Consensus	Consensus	NNP
cord-315453-mbv8vb2r	70	16	Treatment	Treatment	NNP
cord-315453-mbv8vb2r	70	17	Guidelines	Guidelines	NNPS
cord-315453-mbv8vb2r	70	18	Panel	Panel	NNP
cord-315453-mbv8vb2r	70	19	recommended	recommend	VBD
cord-315453-mbv8vb2r	70	20	against	against	IN
cord-315453-mbv8vb2r	70	21	use	use	NN
cord-315453-mbv8vb2r	70	22	of	of	IN
cord-315453-mbv8vb2r	70	23	the	the	DT
cord-315453-mbv8vb2r	70	24	Janus	Janus	NNP
cord-315453-mbv8vb2r	70	25	kinase	kinase	NN
cord-315453-mbv8vb2r	70	26	inhibitors	inhibitor	NNS
cord-315453-mbv8vb2r	70	27	in	in	IN
cord-315453-mbv8vb2r	70	28	the	the	DT
cord-315453-mbv8vb2r	70	29	treatment	treatment	NN
cord-315453-mbv8vb2r	70	30	of	of	IN
cord-315453-mbv8vb2r	70	31	COVID-19	COVID-19	NNP
cord-315453-mbv8vb2r	70	32	presently	presently	RB
cord-315453-mbv8vb2r	70	33	due	due	IN
cord-315453-mbv8vb2r	70	34	to	to	IN
cord-315453-mbv8vb2r	70	35	their	-PRON-	PRP$
cord-315453-mbv8vb2r	70	36	broad	broad	JJ
cord-315453-mbv8vb2r	70	37	immunosuppressive	immunosuppressive	JJ
cord-315453-mbv8vb2r	70	38	effects	effect	NNS
cord-315453-mbv8vb2r	70	39	[	[	-LRB-
cord-315453-mbv8vb2r	70	40	15	15	CD
cord-315453-mbv8vb2r	70	41	]	]	-RRB-
cord-315453-mbv8vb2r	70	42	.	.	.
cord-315453-mbv8vb2r	71	1	Teicoplanin	Teicoplanin	NNP
cord-315453-mbv8vb2r	71	2	was	be	VBD
cord-315453-mbv8vb2r	71	3	demonstrated	demonstrate	VBN
cord-315453-mbv8vb2r	71	4	to	to	TO
cord-315453-mbv8vb2r	71	5	potently	potently	RB
cord-315453-mbv8vb2r	71	6	prevent	prevent	VB
cord-315453-mbv8vb2r	71	7	the	the	DT
cord-315453-mbv8vb2r	71	8	entry	entry	NN
cord-315453-mbv8vb2r	71	9	of	of	IN
cord-315453-mbv8vb2r	71	10	Ebola	Ebola	NNP
cord-315453-mbv8vb2r	71	11	,	,	,
cord-315453-mbv8vb2r	71	12	MERS	MERS	NNP
cord-315453-mbv8vb2r	71	13	,	,	,
cord-315453-mbv8vb2r	71	14	and	and	CC
cord-315453-mbv8vb2r	71	15	SARS	SARS	NNP
cord-315453-mbv8vb2r	71	16	envelope	envelope	NN
cord-315453-mbv8vb2r	71	17	pseudotyped	pseudotyped	NNP
cord-315453-mbv8vb2r	71	18	viruses	virus	NNS
cord-315453-mbv8vb2r	71	19	into	into	IN
cord-315453-mbv8vb2r	71	20	the	the	DT
cord-315453-mbv8vb2r	71	21	cytoplasm	cytoplasm	NN
cord-315453-mbv8vb2r	71	22	,	,	,
cord-315453-mbv8vb2r	71	23	as	as	RB
cord-315453-mbv8vb2r	71	24	well	well	RB
cord-315453-mbv8vb2r	71	25	as	as	IN
cord-315453-mbv8vb2r	71	26	exhibit	exhibit	VB
cord-315453-mbv8vb2r	71	27	an	an	DT
cord-315453-mbv8vb2r	71	28	inhibitory	inhibitory	JJ
cord-315453-mbv8vb2r	71	29	effect	effect	NN
cord-315453-mbv8vb2r	71	30	on	on	IN
cord-315453-mbv8vb2r	71	31	transcription	transcription	NN
cord-315453-mbv8vb2r	71	32	-	-	HYPH
cord-315453-mbv8vb2r	71	33	and	and	CC
cord-315453-mbv8vb2r	71	34	replication	replication	NN
cord-315453-mbv8vb2r	71	35	-	-	HYPH
cord-315453-mbv8vb2r	71	36	competent	competent	JJ
cord-315453-mbv8vb2r	71	37	virus	virus	NN
cord-315453-mbv8vb2r	71	38	-	-	HYPH
cord-315453-mbv8vb2r	71	39	like	like	JJ
cord-315453-mbv8vb2r	71	40	particles	particle	NNS
cord-315453-mbv8vb2r	71	41	in	in	IN
cord-315453-mbv8vb2r	71	42	the	the	DT
cord-315453-mbv8vb2r	71	43	low	low	JJ
cord-315453-mbv8vb2r	71	44	micromolar	micromolar	JJ
cord-315453-mbv8vb2r	71	45	range	range	NN
cord-315453-mbv8vb2r	71	46	(	(	-LRB-
cord-315453-mbv8vb2r	71	47	IC	IC	NNP
cord-315453-mbv8vb2r	71	48	50	50	CD
cord-315453-mbv8vb2r	71	49	,	,	,
cord-315453-mbv8vb2r	71	50	330	330	CD
cord-315453-mbv8vb2r	71	51	nM	nm	CD
cord-315453-mbv8vb2r	71	52	)	)	-RRB-
cord-315453-mbv8vb2r	71	53	[	[	-LRB-
cord-315453-mbv8vb2r	71	54	25	25	CD
cord-315453-mbv8vb2r	71	55	]	]	-RRB-
cord-315453-mbv8vb2r	71	56	.	.	.
cord-315453-mbv8vb2r	72	1	Mechanistic	mechanistic	JJ
cord-315453-mbv8vb2r	72	2	investigations	investigation	NNS
cord-315453-mbv8vb2r	72	3	showed	show	VBD
cord-315453-mbv8vb2r	72	4	that	that	IN
cord-315453-mbv8vb2r	72	5	teicoplanin	teicoplanin	NNS
cord-315453-mbv8vb2r	72	6	specifically	specifically	RB
cord-315453-mbv8vb2r	72	7	inhibits	inhibit	VBZ
cord-315453-mbv8vb2r	72	8	the	the	DT
cord-315453-mbv8vb2r	72	9	activities	activity	NNS
cord-315453-mbv8vb2r	72	10	of	of	IN
cord-315453-mbv8vb2r	72	11	the	the	DT
cord-315453-mbv8vb2r	72	12	host	host	NN
cord-315453-mbv8vb2r	72	13	cell	cell	NN
cord-315453-mbv8vb2r	72	14	's	's	POS
cord-315453-mbv8vb2r	72	15	cathepsin	cathepsin	NN
cord-315453-mbv8vb2r	72	16	L	l	NN
cord-315453-mbv8vb2r	72	17	and	and	CC
cord-315453-mbv8vb2r	72	18	cathepsin	cathepsin	NN
cord-315453-mbv8vb2r	72	19	B	b	NN
cord-315453-mbv8vb2r	72	20	,	,	,
cord-315453-mbv8vb2r	72	21	responsible	responsible	JJ
cord-315453-mbv8vb2r	72	22	for	for	IN
cord-315453-mbv8vb2r	72	23	cleaving	cleave	VBG
cord-315453-mbv8vb2r	72	24	the	the	DT
cord-315453-mbv8vb2r	72	25	viral	viral	JJ
cord-315453-mbv8vb2r	72	26	glycoprotein	glycoprotein	NN
cord-315453-mbv8vb2r	72	27	and	and	CC
cord-315453-mbv8vb2r	72	28	allowing	allow	VBG
cord-315453-mbv8vb2r	72	29	the	the	DT
cord-315453-mbv8vb2r	72	30	exposure	exposure	NN
cord-315453-mbv8vb2r	72	31	of	of	IN
cord-315453-mbv8vb2r	72	32	the	the	DT
cord-315453-mbv8vb2r	72	33	receptor	receptor	NN
cord-315453-mbv8vb2r	72	34	-	-	HYPH
cord-315453-mbv8vb2r	72	35	binding	bind	VBG
cord-315453-mbv8vb2r	72	36	domain	domain	NN
cord-315453-mbv8vb2r	72	37	of	of	IN
cord-315453-mbv8vb2r	72	38	its	-PRON-	PRP$
cord-315453-mbv8vb2r	72	39	core	core	NN
cord-315453-mbv8vb2r	72	40	genome	genome	NN
cord-315453-mbv8vb2r	72	41	and	and	CC
cord-315453-mbv8vb2r	72	42	its	-PRON-	PRP$
cord-315453-mbv8vb2r	72	43	subsequent	subsequent	JJ
cord-315453-mbv8vb2r	72	44	release	release	NN
cord-315453-mbv8vb2r	72	45	into	into	IN
cord-315453-mbv8vb2r	72	46	the	the	DT
cord-315453-mbv8vb2r	72	47	cytoplasm	cytoplasm	NN
cord-315453-mbv8vb2r	72	48	of	of	IN
cord-315453-mbv8vb2r	72	49	the	the	DT
cord-315453-mbv8vb2r	72	50	host	host	NN
cord-315453-mbv8vb2r	72	51	cells	cell	NNS
cord-315453-mbv8vb2r	72	52	(	(	-LRB-
cord-315453-mbv8vb2r	72	53	i.e.	i.e.	FW
cord-315453-mbv8vb2r	72	54	,	,	,
cord-315453-mbv8vb2r	72	55	the	the	DT
cord-315453-mbv8vb2r	72	56	late	late	JJ
cord-315453-mbv8vb2r	72	57	endosomal	endosomal	NNP
cord-315453-mbv8vb2r	72	58	pathway	pathway	NN
cord-315453-mbv8vb2r	72	59	)	)	-RRB-
cord-315453-mbv8vb2r	73	1	[	[	-LRB-
cord-315453-mbv8vb2r	73	2	26	26	CD
cord-315453-mbv8vb2r	73	3	,	,	,
cord-315453-mbv8vb2r	73	4	27	27	CD
cord-315453-mbv8vb2r	73	5	]	]	-RRB-
cord-315453-mbv8vb2r	73	6	.	.	.
cord-315453-mbv8vb2r	74	1	Although	although	IN
cord-315453-mbv8vb2r	74	2	the	the	DT
cord-315453-mbv8vb2r	74	3	clinical	clinical	JJ
cord-315453-mbv8vb2r	74	4	efficacy	efficacy	NN
cord-315453-mbv8vb2r	74	5	of	of	IN
cord-315453-mbv8vb2r	74	6	teicoplanin	teicoplanin	NNP
cord-315453-mbv8vb2r	74	7	against	against	IN
cord-315453-mbv8vb2r	74	8	SARS	SARS	NNP
cord-315453-mbv8vb2r	74	9	-	-	HYPH
cord-315453-mbv8vb2r	74	10	CoV-2	CoV-2	NNP
cord-315453-mbv8vb2r	74	11	is	be	VBZ
cord-315453-mbv8vb2r	74	12	not	not	RB
cord-315453-mbv8vb2r	74	13	proven	prove	VBN
cord-315453-mbv8vb2r	74	14	presently	presently	RB
cord-315453-mbv8vb2r	74	15	,	,	,
cord-315453-mbv8vb2r	74	16	these	these	DT
cord-315453-mbv8vb2r	74	17	studies	study	NNS
cord-315453-mbv8vb2r	74	18	indicate	indicate	VBP
cord-315453-mbv8vb2r	74	19	the	the	DT
cord-315453-mbv8vb2r	74	20	potential	potential	JJ
cord-315453-mbv8vb2r	74	21	role	role	NN
cord-315453-mbv8vb2r	74	22	of	of	IN
cord-315453-mbv8vb2r	74	23	teicoplanin	teicoplanin	NNS
cord-315453-mbv8vb2r	74	24	as	as	IN
cord-315453-mbv8vb2r	74	25	a	a	DT
cord-315453-mbv8vb2r	74	26	novel	novel	JJ
cord-315453-mbv8vb2r	74	27	inhibitor	inhibitor	NN
cord-315453-mbv8vb2r	74	28	against	against	IN
cord-315453-mbv8vb2r	74	29	cathepsin	cathepsin	NN
cord-315453-mbv8vb2r	74	30	L	l	NN
cord-315453-mbv8vb2r	74	31	-	-	HYPH
cord-315453-mbv8vb2r	74	32	dependent	dependent	JJ
cord-315453-mbv8vb2r	74	33	viruses	virus	NNS
cord-315453-mbv8vb2r	74	34	.	.	.
cord-315453-mbv8vb2r	75	1	Apart	apart	RB
cord-315453-mbv8vb2r	75	2	from	from	IN
cord-315453-mbv8vb2r	75	3	teicoplanin	teicoplanin	NNP
cord-315453-mbv8vb2r	75	4	,	,	,
cord-315453-mbv8vb2r	75	5	lipoglycopeptides	lipoglycopeptides	NNP
cord-315453-mbv8vb2r	75	6	(	(	-LRB-
cord-315453-mbv8vb2r	75	7	dalbavancin	dalbavancin	NNP
cord-315453-mbv8vb2r	75	8	,	,	,
cord-315453-mbv8vb2r	75	9	oritavancin	oritavancin	NNP
cord-315453-mbv8vb2r	75	10	,	,	,
cord-315453-mbv8vb2r	75	11	and	and	CC
cord-315453-mbv8vb2r	75	12	telavancin	telavancin	NNS
cord-315453-mbv8vb2r	75	13	)	)	-RRB-
cord-315453-mbv8vb2r	75	14	are	be	VBP
cord-315453-mbv8vb2r	75	15	also	also	RB
cord-315453-mbv8vb2r	75	16	considered	consider	VBN
cord-315453-mbv8vb2r	75	17	as	as	RB
cord-315453-mbv8vb2r	75	18	potentially	potentially	RB
cord-315453-mbv8vb2r	75	19	repurposable	repurposable	JJ
cord-315453-mbv8vb2r	75	20	drugs	drug	NNS
cord-315453-mbv8vb2r	75	21	for	for	IN
cord-315453-mbv8vb2r	75	22	COVID-19	covid-19	JJ
cord-315453-mbv8vb2r	75	23	treatment	treatment	NN
cord-315453-mbv8vb2r	75	24	[	[	-LRB-
cord-315453-mbv8vb2r	75	25	26	26	CD
cord-315453-mbv8vb2r	75	26	]	]	-RRB-
cord-315453-mbv8vb2r	75	27	.	.	.
cord-315453-mbv8vb2r	76	1	Ivermectin	Ivermectin	NNP
cord-315453-mbv8vb2r	76	2	is	be	VBZ
cord-315453-mbv8vb2r	76	3	an	an	DT
cord-315453-mbv8vb2r	76	4	FDA	FDA	NNP
cord-315453-mbv8vb2r	76	5	-	-	HYPH
cord-315453-mbv8vb2r	76	6	approved	approve	VBN
cord-315453-mbv8vb2r	76	7	broad	broad	JJ
cord-315453-mbv8vb2r	76	8	-	-	HYPH
cord-315453-mbv8vb2r	76	9	spectrum	spectrum	NN
cord-315453-mbv8vb2r	76	10	anti	anti	JJ
cord-315453-mbv8vb2r	76	11	-	-	JJ
cord-315453-mbv8vb2r	76	12	parasitic	parasitic	JJ
cord-315453-mbv8vb2r	76	13	(	(	-LRB-
cord-315453-mbv8vb2r	76	14	helminths	helminth	NNS
cord-315453-mbv8vb2r	76	15	,	,	,
cord-315453-mbv8vb2r	76	16	scabies	scabie	NNS
cord-315453-mbv8vb2r	76	17	,	,	,
cord-315453-mbv8vb2r	76	18	etc	etc	FW
cord-315453-mbv8vb2r	76	19	)	)	-RRB-
cord-315453-mbv8vb2r	76	20	agent	agent	NN
cord-315453-mbv8vb2r	76	21	.	.	.
cord-315453-mbv8vb2r	77	1	It	-PRON-	PRP
cord-315453-mbv8vb2r	77	2	is	be	VBZ
cord-315453-mbv8vb2r	77	3	usually	usually	RB
cord-315453-mbv8vb2r	77	4	administered	administer	VBN
cord-315453-mbv8vb2r	77	5	with	with	IN
cord-315453-mbv8vb2r	77	6	a	a	DT
cord-315453-mbv8vb2r	77	7	single	single	JJ
cord-315453-mbv8vb2r	77	8	dose	dose	NN
cord-315453-mbv8vb2r	77	9	of	of	IN
cord-315453-mbv8vb2r	77	10	150	150	CD
cord-315453-mbv8vb2r	77	11	μg	μg	NN
cord-315453-mbv8vb2r	77	12	/	/	SYM
cord-315453-mbv8vb2r	77	13	kg	kg	CC
cord-315453-mbv8vb2r	77	14	orally	orally	RB
cord-315453-mbv8vb2r	77	15	[	[	-LRB-
cord-315453-mbv8vb2r	77	16	28	28	CD
cord-315453-mbv8vb2r	77	17	]	]	-RRB-
cord-315453-mbv8vb2r	77	18	.	.	.
cord-315453-mbv8vb2r	78	1	Of	of	IN
cord-315453-mbv8vb2r	78	2	note	note	NN
cord-315453-mbv8vb2r	78	3	,	,	,
cord-315453-mbv8vb2r	78	4	it	-PRON-	PRP
cord-315453-mbv8vb2r	78	5	has	have	VBZ
cord-315453-mbv8vb2r	78	6	been	be	VBN
cord-315453-mbv8vb2r	78	7	shown	show	VBN
cord-315453-mbv8vb2r	78	8	to	to	TO
cord-315453-mbv8vb2r	78	9	boost	boost	VB
cord-315453-mbv8vb2r	78	10	human	human	JJ
cord-315453-mbv8vb2r	78	11	immunity	immunity	NN
cord-315453-mbv8vb2r	78	12	(	(	-LRB-
cord-315453-mbv8vb2r	78	13	including	include	VBG
cord-315453-mbv8vb2r	78	14	enhancement	enhancement	NN
cord-315453-mbv8vb2r	78	15	of	of	IN
cord-315453-mbv8vb2r	78	16	production	production	NN
cord-315453-mbv8vb2r	78	17	of	of	IN
cord-315453-mbv8vb2r	78	18	IL-1	IL-1	NNP
cord-315453-mbv8vb2r	78	19	and	and	CC
cord-315453-mbv8vb2r	78	20	other	other	JJ
cord-315453-mbv8vb2r	78	21	cytokines	cytokine	NNS
cord-315453-mbv8vb2r	78	22	,	,	,
cord-315453-mbv8vb2r	78	23	activation	activation	NN
cord-315453-mbv8vb2r	78	24	of	of	IN
cord-315453-mbv8vb2r	78	25	superoxide	superoxide	NN
cord-315453-mbv8vb2r	78	26	anion	anion	NN
cord-315453-mbv8vb2r	78	27	production	production	NN
cord-315453-mbv8vb2r	78	28	,	,	,
cord-315453-mbv8vb2r	78	29	and	and	CC
cord-315453-mbv8vb2r	78	30	augmentation	augmentation	NN
cord-315453-mbv8vb2r	78	31	of	of	IN
cord-315453-mbv8vb2r	78	32	lymphocyte	lymphocyte	NN
cord-315453-mbv8vb2r	78	33	response	response	NN
cord-315453-mbv8vb2r	78	34	to	to	IN
cord-315453-mbv8vb2r	78	35	mitogens	mitogens	NNP
cord-315453-mbv8vb2r	78	36	)	)	-RRB-
cord-315453-mbv8vb2r	78	37	[	[	-LRB-
cord-315453-mbv8vb2r	78	38	29	29	CD
cord-315453-mbv8vb2r	78	39	]	]	-RRB-
cord-315453-mbv8vb2r	78	40	.	.	.
cord-315453-mbv8vb2r	79	1	Originally	originally	RB
cord-315453-mbv8vb2r	79	2	,	,	,
cord-315453-mbv8vb2r	79	3	ivermectin	ivermectin	NNP
cord-315453-mbv8vb2r	79	4	was	be	VBD
cord-315453-mbv8vb2r	79	5	identified	identify	VBN
cord-315453-mbv8vb2r	79	6	as	as	IN
cord-315453-mbv8vb2r	79	7	an	an	DT
cord-315453-mbv8vb2r	79	8	inhibitor	inhibitor	NN
cord-315453-mbv8vb2r	79	9	of	of	IN
cord-315453-mbv8vb2r	79	10	the	the	DT
cord-315453-mbv8vb2r	79	11	interaction	interaction	NN
cord-315453-mbv8vb2r	79	12	between	between	IN
cord-315453-mbv8vb2r	79	13	the	the	DT
cord-315453-mbv8vb2r	79	14	HIV-1	HIV-1	NNP
cord-315453-mbv8vb2r	79	15	integrase	integrase	NN
cord-315453-mbv8vb2r	79	16	protein	protein	NN
cord-315453-mbv8vb2r	79	17	(	(	-LRB-
cord-315453-mbv8vb2r	79	18	IN	in	IN
cord-315453-mbv8vb2r	79	19	)	)	-RRB-
cord-315453-mbv8vb2r	79	20	and	and	CC
cord-315453-mbv8vb2r	79	21	α	α	NNP
cord-315453-mbv8vb2r	79	22	/	/	SYM
cord-315453-mbv8vb2r	79	23	β1	β1	NNP
cord-315453-mbv8vb2r	79	24	heterodimer	heterodimer	NN
cord-315453-mbv8vb2r	79	25	of	of	IN
cord-315453-mbv8vb2r	79	26	the	the	DT
cord-315453-mbv8vb2r	79	27	importin	importin	NN
cord-315453-mbv8vb2r	79	28	,	,	,
cord-315453-mbv8vb2r	79	29	which	which	WDT
cord-315453-mbv8vb2r	79	30	is	be	VBZ
cord-315453-mbv8vb2r	79	31	responsible	responsible	JJ
cord-315453-mbv8vb2r	79	32	for	for	IN
cord-315453-mbv8vb2r	79	33	IN	in	IN
cord-315453-mbv8vb2r	79	34	nuclear	nuclear	JJ
cord-315453-mbv8vb2r	79	35	import	import	NN
cord-315453-mbv8vb2r	79	36	[	[	-LRB-
cord-315453-mbv8vb2r	79	37	30	30	CD
cord-315453-mbv8vb2r	79	38	]	]	-RRB-
cord-315453-mbv8vb2r	79	39	,	,	,
cord-315453-mbv8vb2r	79	40	thus	thus	RB
cord-315453-mbv8vb2r	79	41	inhibiting	inhibit	VBG
cord-315453-mbv8vb2r	79	42	HIV	HIV	NNP
cord-315453-mbv8vb2r	79	43	replication	replication	NN
cord-315453-mbv8vb2r	79	44	.	.	.
cord-315453-mbv8vb2r	80	1	Additionally	additionally	RB
cord-315453-mbv8vb2r	80	2	,	,	,
cord-315453-mbv8vb2r	80	3	ivermectin	ivermectin	NNP
cord-315453-mbv8vb2r	80	4	has	have	VBZ
cord-315453-mbv8vb2r	80	5	also	also	RB
cord-315453-mbv8vb2r	80	6	been	be	VBN
cord-315453-mbv8vb2r	80	7	demonstrated	demonstrate	VBN
cord-315453-mbv8vb2r	80	8	to	to	TO
cord-315453-mbv8vb2r	80	9	effectively	effectively	RB
cord-315453-mbv8vb2r	80	10	control	control	VB
cord-315453-mbv8vb2r	80	11	infections	infection	NNS
cord-315453-mbv8vb2r	80	12	caused	cause	VBN
cord-315453-mbv8vb2r	80	13	by	by	IN
cord-315453-mbv8vb2r	80	14	several	several	JJ
cord-315453-mbv8vb2r	80	15	other	other	JJ
cord-315453-mbv8vb2r	80	16	RNA	RNA	NNP
cord-315453-mbv8vb2r	80	17	viruses	virus	NNS
cord-315453-mbv8vb2r	80	18	(	(	-LRB-
cord-315453-mbv8vb2r	80	19	such	such	JJ
cord-315453-mbv8vb2r	80	20	as	as	IN
cord-315453-mbv8vb2r	80	21	dengue	dengue	NN
cord-315453-mbv8vb2r	80	22	,	,	,
cord-315453-mbv8vb2r	80	23	influenza	influenza	NN
cord-315453-mbv8vb2r	80	24	,	,	,
cord-315453-mbv8vb2r	80	25	RSV	RSV	NNP
cord-315453-mbv8vb2r	80	26	,	,	,
cord-315453-mbv8vb2r	80	27	and	and	CC
cord-315453-mbv8vb2r	80	28	rabies	rabies	NN
cord-315453-mbv8vb2r	80	29	)	)	-RRB-
cord-315453-mbv8vb2r	81	1	[	[	-LRB-
cord-315453-mbv8vb2r	81	2	31	31	CD
cord-315453-mbv8vb2r	81	3	]	]	-RRB-
cord-315453-mbv8vb2r	81	4	.	.	.
cord-315453-mbv8vb2r	82	1	Its	-PRON-	PRP$
cord-315453-mbv8vb2r	82	2	broad	broad	JJ
cord-315453-mbv8vb2r	82	3	-	-	HYPH
cord-315453-mbv8vb2r	82	4	spectrum	spectrum	NN
cord-315453-mbv8vb2r	82	5	antiviral	antiviral	JJ
cord-315453-mbv8vb2r	82	6	activity	activity	NN
cord-315453-mbv8vb2r	82	7	was	be	VBD
cord-315453-mbv8vb2r	82	8	considered	consider	VBN
cord-315453-mbv8vb2r	82	9	to	to	TO
cord-315453-mbv8vb2r	82	10	be	be	VB
cord-315453-mbv8vb2r	82	11	related	relate	VBN
cord-315453-mbv8vb2r	82	12	to	to	IN
cord-315453-mbv8vb2r	82	13	the	the	DT
cord-315453-mbv8vb2r	82	14	reliance	reliance	NN
cord-315453-mbv8vb2r	82	15	of	of	IN
cord-315453-mbv8vb2r	82	16	multiple	multiple	JJ
cord-315453-mbv8vb2r	82	17	RNA	RNA	NNP
cord-315453-mbv8vb2r	82	18	viruses	virus	NNS
cord-315453-mbv8vb2r	82	19	on	on	IN
cord-315453-mbv8vb2r	82	20	IMPα	IMPα	NNS
cord-315453-mbv8vb2r	82	21	/	/	SYM
cord-315453-mbv8vb2r	82	22	β1	β1	NNP
cord-315453-mbv8vb2r	82	23	during	during	IN
cord-315453-mbv8vb2r	82	24	infection	infection	NN
cord-315453-mbv8vb2r	82	25	[	[	-LRB-
cord-315453-mbv8vb2r	82	26	32	32	CD
cord-315453-mbv8vb2r	82	27	]	]	-RRB-
cord-315453-mbv8vb2r	82	28	.	.	.
cord-315453-mbv8vb2r	83	1	Caly	Caly	NNP
cord-315453-mbv8vb2r	83	2	et	et	NNP
cord-315453-mbv8vb2r	83	3	al	al	NNP
cord-315453-mbv8vb2r	83	4	.	.	.
cord-315453-mbv8vb2r	84	1	recently	recently	RB
cord-315453-mbv8vb2r	84	2	demonstrated	demonstrate	VBD
cord-315453-mbv8vb2r	84	3	that	that	IN
cord-315453-mbv8vb2r	84	4	a	a	DT
cord-315453-mbv8vb2r	84	5	single	single	JJ
cord-315453-mbv8vb2r	84	6	-	-	HYPH
cord-315453-mbv8vb2r	84	7	dose	dose	NN
cord-315453-mbv8vb2r	84	8	treatment	treatment	NN
cord-315453-mbv8vb2r	84	9	with	with	IN
cord-315453-mbv8vb2r	84	10	ivermectin	ivermectin	NNP
cord-315453-mbv8vb2r	84	11	induced	induce	VBD
cord-315453-mbv8vb2r	84	12	an	an	DT
cord-315453-mbv8vb2r	84	13	approximately	approximately	RB
cord-315453-mbv8vb2r	84	14	5000-fold	5000-fold	CD
cord-315453-mbv8vb2r	84	15	reduction	reduction	NN
cord-315453-mbv8vb2r	84	16	in	in	IN
cord-315453-mbv8vb2r	84	17	the	the	DT
cord-315453-mbv8vb2r	84	18	viral	viral	JJ
cord-315453-mbv8vb2r	84	19	RNA	RNA	NNP
cord-315453-mbv8vb2r	84	20	of	of	IN
cord-315453-mbv8vb2r	84	21	SARS	SARS	NNP
cord-315453-mbv8vb2r	84	22	-	-	HYPH
cord-315453-mbv8vb2r	84	23	CoV-2	CoV-2	NNP
cord-315453-mbv8vb2r	84	24	at	at	IN
cord-315453-mbv8vb2r	84	25	48	48	CD
cord-315453-mbv8vb2r	84	26	h	h	NN
cord-315453-mbv8vb2r	84	27	in	in	IN
cord-315453-mbv8vb2r	84	28	a	a	DT
cord-315453-mbv8vb2r	84	29	Vero	Vero	NNP
cord-315453-mbv8vb2r	84	30	-	-	HYPH
cord-315453-mbv8vb2r	84	31	hSLAM	hslam	NN
cord-315453-mbv8vb2r	84	32	cell	cell	NN
cord-315453-mbv8vb2r	84	33	culture	culture	NN
cord-315453-mbv8vb2r	84	34	model	model	NN
cord-315453-mbv8vb2r	84	35	[	[	-LRB-
cord-315453-mbv8vb2r	84	36	31	31	CD
cord-315453-mbv8vb2r	84	37	]	]	-RRB-
cord-315453-mbv8vb2r	84	38	.	.	.
cord-315453-mbv8vb2r	85	1	The	the	DT
cord-315453-mbv8vb2r	85	2	therapeutic	therapeutic	JJ
cord-315453-mbv8vb2r	85	3	potential	potential	NN
cord-315453-mbv8vb2r	85	4	of	of	IN
cord-315453-mbv8vb2r	85	5	this	this	DT
cord-315453-mbv8vb2r	85	6	drug	drug	NN
cord-315453-mbv8vb2r	85	7	against	against	IN
cord-315453-mbv8vb2r	85	8	human	human	JJ
cord-315453-mbv8vb2r	85	9	COVID-19	COVID-19	NNP
cord-315453-mbv8vb2r	85	10	is	be	VBZ
cord-315453-mbv8vb2r	85	11	currently	currently	RB
cord-315453-mbv8vb2r	85	12	being	be	VBG
cord-315453-mbv8vb2r	85	13	evaluated	evaluate	VBN
cord-315453-mbv8vb2r	85	14	.	.	.
cord-315453-mbv8vb2r	86	1	Although	although	IN
cord-315453-mbv8vb2r	86	2	severe	severe	JJ
cord-315453-mbv8vb2r	86	3	adverse	adverse	JJ
cord-315453-mbv8vb2r	86	4	effects	effect	NNS
cord-315453-mbv8vb2r	86	5	about	about	IN
cord-315453-mbv8vb2r	86	6	potentiation	potentiation	NN
cord-315453-mbv8vb2r	86	7	of	of	IN
cord-315453-mbv8vb2r	86	8	the	the	DT
cord-315453-mbv8vb2r	86	9	GABAergic	GABAergic	NNP
cord-315453-mbv8vb2r	86	10	synaptic	synaptic	JJ
cord-315453-mbv8vb2r	86	11	transmission	transmission	NN
cord-315453-mbv8vb2r	86	12	(	(	-LRB-
cord-315453-mbv8vb2r	86	13	depression	depression	NN
cord-315453-mbv8vb2r	86	14	,	,	,
cord-315453-mbv8vb2r	86	15	ataxia	ataxia	NN
cord-315453-mbv8vb2r	86	16	)	)	-RRB-
cord-315453-mbv8vb2r	86	17	,	,	,
cord-315453-mbv8vb2r	86	18	and	and	CC
cord-315453-mbv8vb2r	86	19	psychosis	psychosis	NN
cord-315453-mbv8vb2r	86	20	,	,	,
cord-315453-mbv8vb2r	86	21	confusion	confusion	NN
cord-315453-mbv8vb2r	86	22	,	,	,
cord-315453-mbv8vb2r	86	23	seizure	seizure	NN
cord-315453-mbv8vb2r	86	24	were	be	VBD
cord-315453-mbv8vb2r	86	25	occasionally	occasionally	RB
cord-315453-mbv8vb2r	86	26	reported	report	VBN
cord-315453-mbv8vb2r	86	27	in	in	IN
cord-315453-mbv8vb2r	86	28	few	few	JJ
cord-315453-mbv8vb2r	86	29	patients	patient	NNS
cord-315453-mbv8vb2r	86	30	with	with	IN
cord-315453-mbv8vb2r	86	31	diseases	disease	NNS
cord-315453-mbv8vb2r	86	32	other	other	JJ
cord-315453-mbv8vb2r	86	33	than	than	IN
cord-315453-mbv8vb2r	86	34	onchocerciasis	onchocerciasis	NN
cord-315453-mbv8vb2r	86	35	[	[	-LRB-
cord-315453-mbv8vb2r	86	36	33	33	CD
cord-315453-mbv8vb2r	86	37	]	]	-RRB-
cord-315453-mbv8vb2r	86	38	,	,	,
cord-315453-mbv8vb2r	86	39	the	the	DT
cord-315453-mbv8vb2r	86	40	conventional	conventional	JJ
cord-315453-mbv8vb2r	86	41	dose	dose	NN
cord-315453-mbv8vb2r	86	42	(	(	-LRB-
cord-315453-mbv8vb2r	86	43	≤200	≤200	NN
cord-315453-mbv8vb2r	86	44	μg	μg	NNP
cord-315453-mbv8vb2r	86	45	/	/	SYM
cord-315453-mbv8vb2r	86	46	kg	kg	NNP
cord-315453-mbv8vb2r	86	47	)	)	-RRB-
cord-315453-mbv8vb2r	86	48	of	of	IN
cord-315453-mbv8vb2r	86	49	ivermectin	ivermectin	NNP
cord-315453-mbv8vb2r	86	50	is	be	VBZ
cord-315453-mbv8vb2r	86	51	considered	consider	VBN
cord-315453-mbv8vb2r	86	52	to	to	TO
cord-315453-mbv8vb2r	86	53	be	be	VB
cord-315453-mbv8vb2r	86	54	as	as	IN
cord-315453-mbv8vb2r	86	55	a	a	DT
cord-315453-mbv8vb2r	86	56	safe	safe	JJ
cord-315453-mbv8vb2r	86	57	regimen	regimen	NN
cord-315453-mbv8vb2r	86	58	in	in	IN
cord-315453-mbv8vb2r	86	59	human	human	JJ
cord-315453-mbv8vb2r	86	60	therapy	therapy	NN
cord-315453-mbv8vb2r	86	61	[	[	-LRB-
cord-315453-mbv8vb2r	86	62	34	34	CD
cord-315453-mbv8vb2r	86	63	]	]	-RRB-
cord-315453-mbv8vb2r	86	64	.	.	.
cord-315453-mbv8vb2r	87	1	The	the	DT
cord-315453-mbv8vb2r	87	2	neurokinin-1	neurokinin-1	NNP
cord-315453-mbv8vb2r	87	3	(	(	-LRB-
cord-315453-mbv8vb2r	87	4	NK-1	NK-1	NNP
cord-315453-mbv8vb2r	87	5	)	)	-RRB-
cord-315453-mbv8vb2r	87	6	receptor	receptor	NN
cord-315453-mbv8vb2r	87	7	,	,	,
cord-315453-mbv8vb2r	87	8	encoded	encode	VBN
cord-315453-mbv8vb2r	87	9	by	by	IN
cord-315453-mbv8vb2r	87	10	the	the	DT
cord-315453-mbv8vb2r	87	11	TACR1	TACR1	NNP
cord-315453-mbv8vb2r	87	12	gene	gene	NN
cord-315453-mbv8vb2r	87	13	,	,	,
cord-315453-mbv8vb2r	87	14	is	be	VBZ
cord-315453-mbv8vb2r	87	15	the	the	DT
cord-315453-mbv8vb2r	87	16	main	main	JJ
cord-315453-mbv8vb2r	87	17	receptor	receptor	NN
cord-315453-mbv8vb2r	87	18	for	for	IN
cord-315453-mbv8vb2r	87	19	substance	substance	NN
cord-315453-mbv8vb2r	87	20	P.	P.	NNP
cord-315453-mbv8vb2r	87	21	Numerous	numerous	JJ
cord-315453-mbv8vb2r	87	22	insults	insult	NNS
cord-315453-mbv8vb2r	87	23	,	,	,
cord-315453-mbv8vb2r	87	24	including	include	VBG
cord-315453-mbv8vb2r	87	25	multiple	multiple	JJ
cord-315453-mbv8vb2r	87	26	viral	viral	JJ
cord-315453-mbv8vb2r	87	27	infections	infection	NNS
cord-315453-mbv8vb2r	87	28	,	,	,
cord-315453-mbv8vb2r	87	29	likely	likely	RB
cord-315453-mbv8vb2r	87	30	facilitate	facilitate	VB
cord-315453-mbv8vb2r	87	31	the	the	DT
cord-315453-mbv8vb2r	87	32	interaction	interaction	NN
cord-315453-mbv8vb2r	87	33	between	between	IN
cord-315453-mbv8vb2r	87	34	substance	substance	NN
cord-315453-mbv8vb2r	87	35	P	p	NN
cord-315453-mbv8vb2r	87	36	and	and	CC
cord-315453-mbv8vb2r	87	37	NK-1	NK-1	NNP
cord-315453-mbv8vb2r	87	38	receptor	receptor	NN
cord-315453-mbv8vb2r	87	39	,	,	,
cord-315453-mbv8vb2r	87	40	resulting	result	VBG
cord-315453-mbv8vb2r	87	41	in	in	IN
cord-315453-mbv8vb2r	87	42	serious	serious	JJ
cord-315453-mbv8vb2r	87	43	lung	lung	NN
cord-315453-mbv8vb2r	87	44	parenchymal	parenchymal	NN
cord-315453-mbv8vb2r	87	45	injury	injury	NN
cord-315453-mbv8vb2r	87	46	through	through	IN
cord-315453-mbv8vb2r	87	47	neuro	neuro	JJ
cord-315453-mbv8vb2r	87	48	-	-	HYPH
cord-315453-mbv8vb2r	87	49	inflammatory	inflammatory	JJ
cord-315453-mbv8vb2r	87	50	processes	process	NNS
cord-315453-mbv8vb2r	87	51	[	[	-LRB-
cord-315453-mbv8vb2r	87	52	23	23	CD
cord-315453-mbv8vb2r	87	53	]	]	-RRB-
cord-315453-mbv8vb2r	87	54	.	.	.
cord-315453-mbv8vb2r	88	1	Recently	recently	RB
cord-315453-mbv8vb2r	88	2	,	,	,
cord-315453-mbv8vb2r	88	3	US	US	NNP
cord-315453-mbv8vb2r	88	4	Food	Food	NNP
cord-315453-mbv8vb2r	88	5	and	and	CC
cord-315453-mbv8vb2r	88	6	Drug	Drug	NNP
cord-315453-mbv8vb2r	88	7	Administration	Administration	NNP
cord-315453-mbv8vb2r	88	8	(	(	-LRB-
cord-315453-mbv8vb2r	88	9	FDA	FDA	NNP
cord-315453-mbv8vb2r	88	10	)	)	-RRB-
cord-315453-mbv8vb2r	88	11	approved	approve	VBD
cord-315453-mbv8vb2r	88	12	the	the	DT
cord-315453-mbv8vb2r	88	13	phase	phase	NN
cord-315453-mbv8vb2r	88	14	3	3	CD
cord-315453-mbv8vb2r	88	15	,	,	,
cord-315453-mbv8vb2r	88	16	double	double	JJ
cord-315453-mbv8vb2r	88	17	-	-	HYPH
cord-315453-mbv8vb2r	88	18	blind	blind	JJ
cord-315453-mbv8vb2r	88	19	ODYSSEY	odyssey	NN
cord-315453-mbv8vb2r	88	20	study	study	NN
cord-315453-mbv8vb2r	88	21	(	(	-LRB-
cord-315453-mbv8vb2r	88	22	ClinicalTrials.gov	ClinicalTrials.gov	NNP
cord-315453-mbv8vb2r	88	23	Identifier	Identifier	NNP
cord-315453-mbv8vb2r	88	24	:	:	:
cord-315453-mbv8vb2r	88	25	NCT04326426	NCT04326426	NNP
cord-315453-mbv8vb2r	88	26	,	,	,
cord-315453-mbv8vb2r	88	27	initiated	initiate	VBD
cord-315453-mbv8vb2r	88	28	on	on	IN
cord-315453-mbv8vb2r	88	29	12	12	CD
cord-315453-mbv8vb2r	88	30	April	April	NNP
cord-315453-mbv8vb2r	88	31	2020	2020	CD
cord-315453-mbv8vb2r	88	32	)	)	-RRB-
cord-315453-mbv8vb2r	88	33	to	to	TO
cord-315453-mbv8vb2r	88	34	investigate	investigate	VB
cord-315453-mbv8vb2r	88	35	the	the	DT
cord-315453-mbv8vb2r	88	36	efficacy	efficacy	NN
cord-315453-mbv8vb2r	88	37	and	and	CC
cord-315453-mbv8vb2r	88	38	safety	safety	NN
cord-315453-mbv8vb2r	88	39	of	of	IN
cord-315453-mbv8vb2r	88	40	tradipitant	tradipitant	JJ
cord-315453-mbv8vb2r	88	41	at	at	IN
cord-315453-mbv8vb2r	88	42	a	a	DT
cord-315453-mbv8vb2r	88	43	dosage	dosage	NN
cord-315453-mbv8vb2r	88	44	of	of	IN
cord-315453-mbv8vb2r	88	45	85	85	CD
cord-315453-mbv8vb2r	88	46	mg	mg	NNS
cord-315453-mbv8vb2r	88	47	orally	orally	RB
cord-315453-mbv8vb2r	88	48	twice	twice	RB
cord-315453-mbv8vb2r	88	49	daily	daily	RB
cord-315453-mbv8vb2r	88	50	for	for	IN
cord-315453-mbv8vb2r	88	51	the	the	DT
cord-315453-mbv8vb2r	88	52	treatment	treatment	NN
cord-315453-mbv8vb2r	88	53	of	of	IN
cord-315453-mbv8vb2r	88	54	inflammatory	inflammatory	JJ
cord-315453-mbv8vb2r	88	55	lung	lung	NN
cord-315453-mbv8vb2r	88	56	injury	injury	NN
cord-315453-mbv8vb2r	88	57	following	follow	VBG
cord-315453-mbv8vb2r	88	58	critical	critical	JJ
cord-315453-mbv8vb2r	88	59	COVID-19	covid-19	CD
cord-315453-mbv8vb2r	88	60	infection	infection	NN
cord-315453-mbv8vb2r	88	61	[	[	-LRB-
cord-315453-mbv8vb2r	88	62	35	35	CD
cord-315453-mbv8vb2r	88	63	]	]	-RRB-
cord-315453-mbv8vb2r	88	64	.	.	.
cord-315453-mbv8vb2r	89	1	Among	among	IN
cord-315453-mbv8vb2r	89	2	SARS	SARS	NNP
cord-315453-mbv8vb2r	89	3	patients	patient	NNS
cord-315453-mbv8vb2r	89	4	,	,	,
cord-315453-mbv8vb2r	89	5	a	a	DT
cord-315453-mbv8vb2r	89	6	group	group	NN
cord-315453-mbv8vb2r	89	7	treated	treat	VBN
cord-315453-mbv8vb2r	89	8	with	with	IN
cord-315453-mbv8vb2r	89	9	inhaled	inhale	VBN
cord-315453-mbv8vb2r	89	10	nitric	nitric	NN
cord-315453-mbv8vb2r	89	11	oxide	oxide	NN
cord-315453-mbv8vb2r	89	12	experienced	experience	VBD
cord-315453-mbv8vb2r	89	13	a	a	DT
cord-315453-mbv8vb2r	89	14	reversal	reversal	NN
cord-315453-mbv8vb2r	89	15	of	of	IN
cord-315453-mbv8vb2r	89	16	pulmonary	pulmonary	JJ
cord-315453-mbv8vb2r	89	17	hypertension	hypertension	NN
cord-315453-mbv8vb2r	89	18	,	,	,
cord-315453-mbv8vb2r	89	19	thereby	thereby	RB
cord-315453-mbv8vb2r	89	20	exhibiting	exhibit	VBG
cord-315453-mbv8vb2r	89	21	a	a	DT
cord-315453-mbv8vb2r	89	22	significant	significant	JJ
cord-315453-mbv8vb2r	89	23	improvement	improvement	NN
cord-315453-mbv8vb2r	89	24	in	in	IN
cord-315453-mbv8vb2r	89	25	hypoxia	hypoxia	NN
cord-315453-mbv8vb2r	89	26	and	and	CC
cord-315453-mbv8vb2r	89	27	requiring	require	VBG
cord-315453-mbv8vb2r	89	28	a	a	DT
cord-315453-mbv8vb2r	89	29	shorter	short	JJR
cord-315453-mbv8vb2r	89	30	duration	duration	NN
cord-315453-mbv8vb2r	89	31	of	of	IN
cord-315453-mbv8vb2r	89	32	ventilatory	ventilatory	JJ
cord-315453-mbv8vb2r	89	33	support	support	NN
cord-315453-mbv8vb2r	89	34	,	,	,
cord-315453-mbv8vb2r	89	35	compared	compare	VBN
cord-315453-mbv8vb2r	89	36	to	to	IN
cord-315453-mbv8vb2r	89	37	the	the	DT
cord-315453-mbv8vb2r	89	38	matched	match	VBN
cord-315453-mbv8vb2r	89	39	control	control	NN
cord-315453-mbv8vb2r	89	40	group	group	NN
cord-315453-mbv8vb2r	89	41	[	[	-LRB-
cord-315453-mbv8vb2r	89	42	36	36	CD
cord-315453-mbv8vb2r	89	43	]	]	-RRB-
cord-315453-mbv8vb2r	89	44	.	.	.
cord-315453-mbv8vb2r	90	1	Nevertheless	nevertheless	RB
cord-315453-mbv8vb2r	90	2	,	,	,
cord-315453-mbv8vb2r	90	3	the	the	DT
cord-315453-mbv8vb2r	90	4	Society	Society	NNP
cord-315453-mbv8vb2r	90	5	of	of	IN
cord-315453-mbv8vb2r	90	6	Critical	Critical	NNP
cord-315453-mbv8vb2r	90	7	Care	Care	NNP
cord-315453-mbv8vb2r	90	8	Medicine	Medicine	NNP
cord-315453-mbv8vb2r	90	9	recommends	recommend	VBZ
cord-315453-mbv8vb2r	90	10	against	against	IN
cord-315453-mbv8vb2r	90	11	its	-PRON-	PRP$
cord-315453-mbv8vb2r	90	12	routine	routine	JJ
cord-315453-mbv8vb2r	90	13	use	use	NN
cord-315453-mbv8vb2r	90	14	for	for	IN
cord-315453-mbv8vb2r	90	15	patients	patient	NNS
cord-315453-mbv8vb2r	90	16	with	with	IN
cord-315453-mbv8vb2r	90	17	COVID-19	covid-19	JJ
cord-315453-mbv8vb2r	90	18	pneumonia	pneumonia	NN
cord-315453-mbv8vb2r	90	19	unless	unless	IN
cord-315453-mbv8vb2r	90	20	they	-PRON-	PRP
cord-315453-mbv8vb2r	90	21	are	be	VBP
cord-315453-mbv8vb2r	90	22	refractory	refractory	JJ
cord-315453-mbv8vb2r	90	23	to	to	IN
cord-315453-mbv8vb2r	90	24	other	other	JJ
cord-315453-mbv8vb2r	90	25	strategies	strategy	NNS
cord-315453-mbv8vb2r	90	26	[	[	-LRB-
cord-315453-mbv8vb2r	90	27	37	37	CD
cord-315453-mbv8vb2r	90	28	]	]	-RRB-
cord-315453-mbv8vb2r	90	29	.	.	.
cord-315453-mbv8vb2r	91	1	The	the	DT
cord-315453-mbv8vb2r	91	2	ACE2	ACE2	NNP
cord-315453-mbv8vb2r	91	3	within	within	IN
cord-315453-mbv8vb2r	91	4	the	the	DT
cord-315453-mbv8vb2r	91	5	lower	low	JJR
cord-315453-mbv8vb2r	91	6	respiratory	respiratory	JJ
cord-315453-mbv8vb2r	91	7	tract	tract	NN
cord-315453-mbv8vb2r	91	8	is	be	VBZ
cord-315453-mbv8vb2r	91	9	the	the	DT
cord-315453-mbv8vb2r	91	10	primary	primary	JJ
cord-315453-mbv8vb2r	91	11	target	target	NN
cord-315453-mbv8vb2r	91	12	of	of	IN
cord-315453-mbv8vb2r	91	13	the	the	DT
cord-315453-mbv8vb2r	91	14	SARS	SARS	NNP
cord-315453-mbv8vb2r	91	15	-	-	HYPH
cord-315453-mbv8vb2r	91	16	CoV-2	CoV-2	NNP
cord-315453-mbv8vb2r	91	17	infection	infection	NN
cord-315453-mbv8vb2r	91	18	[	[	-LRB-
cord-315453-mbv8vb2r	91	19	2	2	CD
cord-315453-mbv8vb2r	91	20	]	]	-RRB-
cord-315453-mbv8vb2r	91	21	.	.	.
cord-315453-mbv8vb2r	92	1	SARS	SARS	NNP
cord-315453-mbv8vb2r	92	2	-	-	HYPH
cord-315453-mbv8vb2r	92	3	CoV-2	CoV-2	NNP
cord-315453-mbv8vb2r	92	4	and	and	CC
cord-315453-mbv8vb2r	92	5	SARS	SARS	NNP
cord-315453-mbv8vb2r	92	6	-	-	HYPH
cord-315453-mbv8vb2r	92	7	CoV	CoV	NNP
cord-315453-mbv8vb2r	92	8	can	can	MD
cord-315453-mbv8vb2r	92	9	effectively	effectively	RB
cord-315453-mbv8vb2r	92	10	utilize	utilize	VB
cord-315453-mbv8vb2r	92	11	the	the	DT
cord-315453-mbv8vb2r	92	12	ACE2	ACE2	NNP
cord-315453-mbv8vb2r	92	13	receptors	receptor	NNS
cord-315453-mbv8vb2r	92	14	expressed	express	VBN
cord-315453-mbv8vb2r	92	15	on	on	IN
cord-315453-mbv8vb2r	92	16	the	the	DT
cord-315453-mbv8vb2r	92	17	epithelial	epithelial	JJ
cord-315453-mbv8vb2r	92	18	cells	cell	NNS
cord-315453-mbv8vb2r	92	19	of	of	IN
cord-315453-mbv8vb2r	92	20	the	the	DT
cord-315453-mbv8vb2r	92	21	lung	lung	NN
cord-315453-mbv8vb2r	92	22	,	,	,
cord-315453-mbv8vb2r	92	23	intestine	intestine	NN
cord-315453-mbv8vb2r	92	24	and	and	CC
cord-315453-mbv8vb2r	92	25	kidney	kidney	NN
cord-315453-mbv8vb2r	92	26	for	for	IN
cord-315453-mbv8vb2r	92	27	human	human	JJ
cord-315453-mbv8vb2r	92	28	invasion	invasion	NN
cord-315453-mbv8vb2r	92	29	[	[	-LRB-
cord-315453-mbv8vb2r	92	30	8	8	CD
cord-315453-mbv8vb2r	92	31	]	]	-RRB-
cord-315453-mbv8vb2r	92	32	.	.	.
cord-315453-mbv8vb2r	93	1	Therefore	therefore	RB
cord-315453-mbv8vb2r	93	2	,	,	,
cord-315453-mbv8vb2r	93	3	despite	despite	IN
cord-315453-mbv8vb2r	93	4	conflicting	conflict	VBG
cord-315453-mbv8vb2r	93	5	opinions	opinion	NNS
cord-315453-mbv8vb2r	93	6	[	[	-LRB-
cord-315453-mbv8vb2r	93	7	15	15	CD
cord-315453-mbv8vb2r	93	8	]	]	-RRB-
cord-315453-mbv8vb2r	93	9	,	,	,
cord-315453-mbv8vb2r	93	10	a	a	DT
cord-315453-mbv8vb2r	93	11	cautious	cautious	JJ
cord-315453-mbv8vb2r	93	12	administration	administration	NN
cord-315453-mbv8vb2r	93	13	of	of	IN
cord-315453-mbv8vb2r	93	14	ACE	ACE	NNP
cord-315453-mbv8vb2r	93	15	inhibitors	inhibitor	NNS
cord-315453-mbv8vb2r	93	16	or	or	CC
cord-315453-mbv8vb2r	93	17	ARB	ARB	NNP
cord-315453-mbv8vb2r	93	18	might	may	MD
cord-315453-mbv8vb2r	93	19	be	be	VB
cord-315453-mbv8vb2r	93	20	advised	advise	VBN
cord-315453-mbv8vb2r	93	21	for	for	IN
cord-315453-mbv8vb2r	93	22	COVID-19	covid-19	JJ
cord-315453-mbv8vb2r	93	23	patients	patient	NNS
cord-315453-mbv8vb2r	93	24	[	[	-LRB-
cord-315453-mbv8vb2r	93	25	8	8	CD
cord-315453-mbv8vb2r	93	26	]	]	-RRB-
cord-315453-mbv8vb2r	93	27	.	.	.
cord-315453-mbv8vb2r	94	1	Interestingly	interestingly	RB
cord-315453-mbv8vb2r	94	2	,	,	,
cord-315453-mbv8vb2r	94	3	a	a	DT
cord-315453-mbv8vb2r	94	4	high	high	JJ
cord-315453-mbv8vb2r	94	5	ACE2	ACE2	NNP
cord-315453-mbv8vb2r	94	6	activity	activity	NN
cord-315453-mbv8vb2r	94	7	is	be	VBZ
cord-315453-mbv8vb2r	94	8	observed	observe	VBN
cord-315453-mbv8vb2r	94	9	in	in	IN
cord-315453-mbv8vb2r	94	10	association	association	NN
cord-315453-mbv8vb2r	94	11	with	with	IN
cord-315453-mbv8vb2r	94	12	reduced	reduced	JJ
cord-315453-mbv8vb2r	94	13	severity	severity	NN
cord-315453-mbv8vb2r	94	14	of	of	IN
cord-315453-mbv8vb2r	94	15	ARDS	ARDS	NNP
cord-315453-mbv8vb2r	94	16	among	among	IN
cord-315453-mbv8vb2r	94	17	patients	patient	NNS
cord-315453-mbv8vb2r	94	18	with	with	IN
cord-315453-mbv8vb2r	94	19	lower	low	JJR
cord-315453-mbv8vb2r	94	20	respiratory	respiratory	JJ
cord-315453-mbv8vb2r	94	21	tract	tract	NN
cord-315453-mbv8vb2r	94	22	infection	infection	NN
cord-315453-mbv8vb2r	94	23	caused	cause	VBN
cord-315453-mbv8vb2r	94	24	by	by	IN
cord-315453-mbv8vb2r	94	25	RSV	RSV	NNP
cord-315453-mbv8vb2r	94	26	[	[	-LRB-
cord-315453-mbv8vb2r	94	27	38	38	CD
cord-315453-mbv8vb2r	94	28	]	]	-RRB-
cord-315453-mbv8vb2r	94	29	.	.	.
cord-315453-mbv8vb2r	95	1	Fedson	Fedson	NNP
cord-315453-mbv8vb2r	95	2	et	et	NNP
cord-315453-mbv8vb2r	95	3	al	al	NNP
cord-315453-mbv8vb2r	95	4	.	.	.
cord-315453-mbv8vb2r	96	1	observed	observe	VBD
cord-315453-mbv8vb2r	96	2	that	that	IN
cord-315453-mbv8vb2r	96	3	statins	statin	NNS
cord-315453-mbv8vb2r	96	4	target	target	VBP
cord-315453-mbv8vb2r	96	5	the	the	DT
cord-315453-mbv8vb2r	96	6	host	host	NN
cord-315453-mbv8vb2r	96	7	response	response	NN
cord-315453-mbv8vb2r	96	8	to	to	IN
cord-315453-mbv8vb2r	96	9	infection	infection	NN
cord-315453-mbv8vb2r	96	10	(	(	-LRB-
cord-315453-mbv8vb2r	96	11	endothelial	endothelial	JJ
cord-315453-mbv8vb2r	96	12	dysfunction	dysfunction	NN
cord-315453-mbv8vb2r	96	13	)	)	-RRB-
cord-315453-mbv8vb2r	96	14	rather	rather	RB
cord-315453-mbv8vb2r	96	15	than	than	IN
cord-315453-mbv8vb2r	96	16	the	the	DT
cord-315453-mbv8vb2r	96	17	virus	virus	NN
cord-315453-mbv8vb2r	96	18	itself	-PRON-	PRP
cord-315453-mbv8vb2r	96	19	and	and	CC
cord-315453-mbv8vb2r	96	20	suggested	suggest	VBD
cord-315453-mbv8vb2r	96	21	that	that	IN
cord-315453-mbv8vb2r	96	22	combination	combination	NN
cord-315453-mbv8vb2r	96	23	therapy	therapy	NN
cord-315453-mbv8vb2r	96	24	with	with	IN
cord-315453-mbv8vb2r	96	25	ARB	ARB	NNP
cord-315453-mbv8vb2r	96	26	and	and	CC
cord-315453-mbv8vb2r	96	27	statins	statin	NNS
cord-315453-mbv8vb2r	96	28	might	may	MD
cord-315453-mbv8vb2r	96	29	accelerate	accelerate	VB
cord-315453-mbv8vb2r	96	30	a	a	DT
cord-315453-mbv8vb2r	96	31	return	return	NN
cord-315453-mbv8vb2r	96	32	to	to	IN
cord-315453-mbv8vb2r	96	33	homeostasis	homeostasis	NN
cord-315453-mbv8vb2r	96	34	,	,	,
cord-315453-mbv8vb2r	96	35	allowing	allow	VBG
cord-315453-mbv8vb2r	96	36	patients	patient	NNS
cord-315453-mbv8vb2r	96	37	to	to	TO
cord-315453-mbv8vb2r	96	38	recover	recover	VB
cord-315453-mbv8vb2r	96	39	on	on	IN
cord-315453-mbv8vb2r	96	40	their	-PRON-	PRP$
cord-315453-mbv8vb2r	96	41	own	own	JJ
cord-315453-mbv8vb2r	96	42	[	[	-LRB-
cord-315453-mbv8vb2r	96	43	39	39	CD
cord-315453-mbv8vb2r	96	44	]	]	-RRB-
cord-315453-mbv8vb2r	96	45	.	.	.
cord-315453-mbv8vb2r	97	1	Despite	despite	IN
cord-315453-mbv8vb2r	97	2	abovementioned	abovementioned	JJ
cord-315453-mbv8vb2r	97	3	benefits	benefit	NNS
cord-315453-mbv8vb2r	97	4	,	,	,
cord-315453-mbv8vb2r	97	5	the	the	DT
cord-315453-mbv8vb2r	97	6	US	US	NNP
cord-315453-mbv8vb2r	97	7	NIH	NIH	NNP
cord-315453-mbv8vb2r	97	8	Consensus	Consensus	NNP
cord-315453-mbv8vb2r	97	9	Treatment	Treatment	NNP
cord-315453-mbv8vb2r	97	10	Guidelines	Guidelines	NNPS
cord-315453-mbv8vb2r	97	11	Panel	Panel	NNP
cord-315453-mbv8vb2r	97	12	recommended	recommend	VBD
cord-315453-mbv8vb2r	97	13	against	against	IN
cord-315453-mbv8vb2r	97	14	routine	routine	JJ
cord-315453-mbv8vb2r	97	15	addition	addition	NN
cord-315453-mbv8vb2r	97	16	of	of	IN
cord-315453-mbv8vb2r	97	17	this	this	DT
cord-315453-mbv8vb2r	97	18	combination	combination	NN
cord-315453-mbv8vb2r	97	19	regimen	regimen	NN
cord-315453-mbv8vb2r	97	20	in	in	IN
cord-315453-mbv8vb2r	97	21	COVID-19	COVID-19	NNP
cord-315453-mbv8vb2r	97	22	treatment	treatment	NN
cord-315453-mbv8vb2r	97	23	[	[	-LRB-
cord-315453-mbv8vb2r	97	24	15	15	CD
cord-315453-mbv8vb2r	97	25	]	]	-RRB-
cord-315453-mbv8vb2r	97	26	.	.	.
cord-315453-mbv8vb2r	98	1	We	-PRON-	PRP
cord-315453-mbv8vb2r	98	2	are	be	VBP
cord-315453-mbv8vb2r	98	3	fighting	fight	VBG
cord-315453-mbv8vb2r	98	4	an	an	DT
cord-315453-mbv8vb2r	98	5	indefinite	indefinite	JJ
cord-315453-mbv8vb2r	98	6	battle	battle	NN
cord-315453-mbv8vb2r	98	7	against	against	IN
cord-315453-mbv8vb2r	98	8	a	a	DT
cord-315453-mbv8vb2r	98	9	dangerous	dangerous	JJ
cord-315453-mbv8vb2r	98	10	and	and	CC
cord-315453-mbv8vb2r	98	11	highly	highly	RB
cord-315453-mbv8vb2r	98	12	contagious	contagious	JJ
cord-315453-mbv8vb2r	98	13	virus	virus	NN
cord-315453-mbv8vb2r	98	14	with	with	IN
cord-315453-mbv8vb2r	98	15	significantly	significantly	RB
cord-315453-mbv8vb2r	98	16	higher	high	JJR
cord-315453-mbv8vb2r	98	17	spread	spread	NN
cord-315453-mbv8vb2r	98	18	potential	potential	NN
cord-315453-mbv8vb2r	98	19	than	than	IN
cord-315453-mbv8vb2r	98	20	2003	2003	CD
cord-315453-mbv8vb2r	99	1	SARS	SARS	NNP
cord-315453-mbv8vb2r	99	2	-	-	HYPH
cord-315453-mbv8vb2r	99	3	CoV.	CoV.	NNP
cord-315453-mbv8vb2r	100	1	As	as	IN
cord-315453-mbv8vb2r	100	2	stated	state	VBN
cord-315453-mbv8vb2r	100	3	in	in	IN
cord-315453-mbv8vb2r	100	4	the	the	DT
cord-315453-mbv8vb2r	100	5	aforementioned	aforementioned	JJ
cord-315453-mbv8vb2r	100	6	paragraphs	paragraph	NNS
cord-315453-mbv8vb2r	100	7	,	,	,
cord-315453-mbv8vb2r	100	8	most	most	JJS
cord-315453-mbv8vb2r	100	9	drugs	drug	NNS
cord-315453-mbv8vb2r	100	10	that	that	WDT
cord-315453-mbv8vb2r	100	11	are	be	VBP
cord-315453-mbv8vb2r	100	12	being	be	VBG
cord-315453-mbv8vb2r	100	13	considered	consider	VBN
cord-315453-mbv8vb2r	100	14	for	for	IN
cord-315453-mbv8vb2r	100	15	COVID-19	COVID-19	NNP
cord-315453-mbv8vb2r	100	16	therapy	therapy	NN
cord-315453-mbv8vb2r	100	17	are	be	VBP
cord-315453-mbv8vb2r	100	18	under	under	IN
cord-315453-mbv8vb2r	100	19	scrupulous	scrupulous	JJ
cord-315453-mbv8vb2r	100	20	investigations	investigation	NNS
cord-315453-mbv8vb2r	100	21	to	to	TO
cord-315453-mbv8vb2r	100	22	assess	assess	VB
cord-315453-mbv8vb2r	100	23	their	-PRON-	PRP$
cord-315453-mbv8vb2r	100	24	adverse	adverse	JJ
cord-315453-mbv8vb2r	100	25	effects	effect	NNS
cord-315453-mbv8vb2r	100	26	as	as	RB
cord-315453-mbv8vb2r	100	27	well	well	RB
cord-315453-mbv8vb2r	100	28	as	as	IN
cord-315453-mbv8vb2r	100	29	efficacy	efficacy	NN
cord-315453-mbv8vb2r	100	30	against	against	IN
cord-315453-mbv8vb2r	100	31	SARS	SARS	NNP
cord-315453-mbv8vb2r	100	32	-	-	HYPH
cord-315453-mbv8vb2r	100	33	CoV-2	CoV-2	NNP
cord-315453-mbv8vb2r	100	34	.	.	.
cord-315453-mbv8vb2r	101	1	Several	several	JJ
cord-315453-mbv8vb2r	101	2	medicines	medicine	NNS
cord-315453-mbv8vb2r	101	3	have	have	VBP
cord-315453-mbv8vb2r	101	4	been	be	VBN
cord-315453-mbv8vb2r	101	5	withdrawn	withdraw	VBN
cord-315453-mbv8vb2r	101	6	because	because	IN
cord-315453-mbv8vb2r	101	7	of	of	IN
cord-315453-mbv8vb2r	101	8	adverse	adverse	JJ
cord-315453-mbv8vb2r	101	9	reactions	reaction	NNS
cord-315453-mbv8vb2r	101	10	after	after	IN
cord-315453-mbv8vb2r	101	11	showing	show	VBG
cord-315453-mbv8vb2r	101	12	clinical	clinical	JJ
cord-315453-mbv8vb2r	101	13	promise	promise	NN
cord-315453-mbv8vb2r	101	14	[	[	-LRB-
cord-315453-mbv8vb2r	101	15	17	17	CD
cord-315453-mbv8vb2r	101	16	]	]	-RRB-
cord-315453-mbv8vb2r	101	17	.	.	.
cord-315453-mbv8vb2r	102	1	Presently	presently	RB
cord-315453-mbv8vb2r	102	2	,	,	,
cord-315453-mbv8vb2r	102	3	no	no	DT
cord-315453-mbv8vb2r	102	4	drug	drug	NN
cord-315453-mbv8vb2r	102	5	or	or	CC
cord-315453-mbv8vb2r	102	6	specific	specific	JJ
cord-315453-mbv8vb2r	102	7	therapy	therapy	NN
cord-315453-mbv8vb2r	102	8	against	against	IN
cord-315453-mbv8vb2r	102	9	SARS	SARS	NNP
cord-315453-mbv8vb2r	102	10	-	-	HYPH
cord-315453-mbv8vb2r	102	11	CoV-2	CoV-2	NNP
cord-315453-mbv8vb2r	102	12	is	be	VBZ
cord-315453-mbv8vb2r	102	13	formally	formally	RB
cord-315453-mbv8vb2r	102	14	recommended	recommend	VBN
cord-315453-mbv8vb2r	102	15	by	by	IN
cord-315453-mbv8vb2r	102	16	the	the	DT
cord-315453-mbv8vb2r	102	17	US	US	NNP
cord-315453-mbv8vb2r	102	18	FDA	FDA	NNP
cord-315453-mbv8vb2r	102	19	.	.	.
cord-315453-mbv8vb2r	103	1	Till	till	IN
cord-315453-mbv8vb2r	103	2	date	date	NN
cord-315453-mbv8vb2r	103	3	,	,	,
cord-315453-mbv8vb2r	103	4	except	except	IN
cord-315453-mbv8vb2r	103	5	for	for	IN
cord-315453-mbv8vb2r	103	6	supportive	supportive	JJ
cord-315453-mbv8vb2r	103	7	management	management	NN
cord-315453-mbv8vb2r	103	8	,	,	,
cord-315453-mbv8vb2r	103	9	COVID-19	COVID-19	NNP
cord-315453-mbv8vb2r	103	10	is	be	VBZ
cord-315453-mbv8vb2r	103	11	'	'	``
cord-315453-mbv8vb2r	103	12	essentially	essentially	RB
cord-315453-mbv8vb2r	103	13	untreatable	untreatable	JJ
cord-315453-mbv8vb2r	103	14	'	'	''
cord-315453-mbv8vb2r	103	15	[	[	-LRB-
cord-315453-mbv8vb2r	103	16	34	34	CD
cord-315453-mbv8vb2r	103	17	,	,	,
cord-315453-mbv8vb2r	103	18	40	40	CD
cord-315453-mbv8vb2r	103	19	]	]	-RRB-
cord-315453-mbv8vb2r	103	20	.	.	.
cord-315453-mbv8vb2r	104	1	Nevertheless	nevertheless	RB
cord-315453-mbv8vb2r	104	2	,	,	,
cord-315453-mbv8vb2r	104	3	among	among	IN
cord-315453-mbv8vb2r	104	4	the	the	DT
cord-315453-mbv8vb2r	104	5	numerous	numerous	JJ
cord-315453-mbv8vb2r	104	6	drugs	drug	NNS
cord-315453-mbv8vb2r	104	7	with	with	IN
cord-315453-mbv8vb2r	104	8	potentially	potentially	RB
cord-315453-mbv8vb2r	104	9	good	good	JJ
cord-315453-mbv8vb2r	104	10	in	in	IN
cord-315453-mbv8vb2r	104	11	vitro	vitro	FW
cord-315453-mbv8vb2r	104	12	efficacy	efficacy	NN
cord-315453-mbv8vb2r	104	13	against	against	IN
cord-315453-mbv8vb2r	104	14	SARS	SARS	NNP
cord-315453-mbv8vb2r	104	15	-	-	HYPH
cord-315453-mbv8vb2r	104	16	CoV-2	CoV-2	NNP
cord-315453-mbv8vb2r	104	17	,	,	,
cord-315453-mbv8vb2r	104	18	we	-PRON-	PRP
cord-315453-mbv8vb2r	104	19	identified	identify	VBD
cord-315453-mbv8vb2r	104	20	some	some	DT
cord-315453-mbv8vb2r	104	21	that	that	WDT
cord-315453-mbv8vb2r	104	22	have	have	VBP
cord-315453-mbv8vb2r	104	23	been	be	VBN
cord-315453-mbv8vb2r	104	24	validated	validate	VBN
cord-315453-mbv8vb2r	104	25	to	to	TO
cord-315453-mbv8vb2r	104	26	have	have	VB
cord-315453-mbv8vb2r	104	27	acceptable	acceptable	JJ
cord-315453-mbv8vb2r	104	28	safety	safety	NN
cord-315453-mbv8vb2r	104	29	as	as	RB
cord-315453-mbv8vb2r	104	30	well	well	RB
cord-315453-mbv8vb2r	104	31	as	as	IN
cord-315453-mbv8vb2r	104	32	favorable	favorable	JJ
cord-315453-mbv8vb2r	104	33	pharmacokinetic	pharmacokinetic	JJ
cord-315453-mbv8vb2r	104	34	profiles	profile	NNS
cord-315453-mbv8vb2r	104	35	in	in	IN
cord-315453-mbv8vb2r	104	36	human	human	JJ
cord-315453-mbv8vb2r	104	37	therapy	therapy	NN
cord-315453-mbv8vb2r	104	38	.	.	.
cord-315453-mbv8vb2r	105	1	Apart	apart	RB
cord-315453-mbv8vb2r	105	2	from	from	IN
cord-315453-mbv8vb2r	105	3	remdesivir	remdesivir	NNP
cord-315453-mbv8vb2r	105	4	that	that	WDT
cord-315453-mbv8vb2r	105	5	was	be	VBD
cord-315453-mbv8vb2r	105	6	shown	show	VBN
cord-315453-mbv8vb2r	105	7	to	to	TO
cord-315453-mbv8vb2r	105	8	have	have	VB
cord-315453-mbv8vb2r	105	9	acceptable	acceptable	JJ
cord-315453-mbv8vb2r	105	10	clinical	clinical	JJ
cord-315453-mbv8vb2r	105	11	efficacy	efficacy	NN
cord-315453-mbv8vb2r	105	12	against	against	IN
cord-315453-mbv8vb2r	105	13	moderate	moderate	JJ
cord-315453-mbv8vb2r	105	14	-	-	HYPH
cord-315453-mbv8vb2r	105	15	to	to	IN
cord-315453-mbv8vb2r	105	16	-	-	HYPH
cord-315453-mbv8vb2r	105	17	severe	severe	JJ
cord-315453-mbv8vb2r	105	18	COVID-19	covid-19	JJ
cord-315453-mbv8vb2r	105	19	and	and	CC
cord-315453-mbv8vb2r	105	20	acceptable	acceptable	JJ
cord-315453-mbv8vb2r	105	21	side	side	NN
cord-315453-mbv8vb2r	105	22	effects	effect	NNS
cord-315453-mbv8vb2r	105	23	,	,	,
cord-315453-mbv8vb2r	105	24	the	the	DT
cord-315453-mbv8vb2r	105	25	potential	potential	JJ
cord-315453-mbv8vb2r	105	26	antiviral	antiviral	JJ
cord-315453-mbv8vb2r	105	27	drugs	drug	NNS
cord-315453-mbv8vb2r	105	28	that	that	WDT
cord-315453-mbv8vb2r	105	29	are	be	VBP
cord-315453-mbv8vb2r	105	30	likely	likely	RB
cord-315453-mbv8vb2r	105	31	useful	useful	JJ
cord-315453-mbv8vb2r	105	32	in	in	IN
cord-315453-mbv8vb2r	105	33	the	the	DT
cord-315453-mbv8vb2r	105	34	treatment	treatment	NN
cord-315453-mbv8vb2r	105	35	of	of	IN
cord-315453-mbv8vb2r	105	36	patients	patient	NNS
cord-315453-mbv8vb2r	105	37	with	with	IN
cord-315453-mbv8vb2r	105	38	mild	mild	NN
cord-315453-mbv8vb2r	105	39	-	-	HYPH
cord-315453-mbv8vb2r	105	40	to	to	IN
cord-315453-mbv8vb2r	105	41	-	-	HYPH
cord-315453-mbv8vb2r	105	42	moderate	moderate	JJ
cord-315453-mbv8vb2r	105	43	COVID-19	COVID-19	NNP
cord-315453-mbv8vb2r	105	44	included	include	VBD
cord-315453-mbv8vb2r	105	45	hydroxychloroquine	hydroxychloroquine	NN
cord-315453-mbv8vb2r	105	46	,	,	,
cord-315453-mbv8vb2r	105	47	teicoplanin	teicoplanin	NNP
cord-315453-mbv8vb2r	105	48	,	,	,
cord-315453-mbv8vb2r	105	49	and	and	CC
cord-315453-mbv8vb2r	105	50	ivermectin	ivermectin	NNP
cord-315453-mbv8vb2r	105	51	.	.	.
cord-315453-mbv8vb2r	106	1	Moreover	moreover	RB
cord-315453-mbv8vb2r	106	2	,	,	,
cord-315453-mbv8vb2r	106	3	among	among	IN
cord-315453-mbv8vb2r	106	4	the	the	DT
cord-315453-mbv8vb2r	106	5	anti	anti	JJ
cord-315453-mbv8vb2r	106	6	-	-	JJ
cord-315453-mbv8vb2r	106	7	IL-6	il-6	JJ
cord-315453-mbv8vb2r	106	8	receptor	receptor	NN
cord-315453-mbv8vb2r	106	9	monoclonal	monoclonal	JJ
cord-315453-mbv8vb2r	106	10	antibodies	antibody	NNS
cord-315453-mbv8vb2r	106	11	under	under	IN
cord-315453-mbv8vb2r	106	12	evaluation	evaluation	NN
cord-315453-mbv8vb2r	106	13	regarding	regard	VBG
cord-315453-mbv8vb2r	106	14	the	the	DT
cord-315453-mbv8vb2r	106	15	efficacy	efficacy	NN
cord-315453-mbv8vb2r	106	16	of	of	IN
cord-315453-mbv8vb2r	106	17	improvement	improvement	NN
cord-315453-mbv8vb2r	106	18	in	in	IN
cord-315453-mbv8vb2r	106	19	oxygenation	oxygenation	NN
cord-315453-mbv8vb2r	106	20	function	function	NN
cord-315453-mbv8vb2r	106	21	of	of	IN
cord-315453-mbv8vb2r	106	22	lung	lung	NN
cord-315453-mbv8vb2r	106	23	parenchyma	parenchyma	NN
cord-315453-mbv8vb2r	106	24	and	and	CC
cord-315453-mbv8vb2r	106	25	cytokine	cytokine	JJ
cord-315453-mbv8vb2r	106	26	storm	storm	NN
cord-315453-mbv8vb2r	106	27	in	in	IN
cord-315453-mbv8vb2r	106	28	COVID-19	covid-19	JJ
cord-315453-mbv8vb2r	106	29	patients	patient	NNS
cord-315453-mbv8vb2r	106	30	with	with	IN
cord-315453-mbv8vb2r	106	31	moderate	moderate	JJ
cord-315453-mbv8vb2r	106	32	ARDS	ARDS	NNP
cord-315453-mbv8vb2r	106	33	,	,	,
cord-315453-mbv8vb2r	106	34	tocilizumab	tocilizumab	NNP
cord-315453-mbv8vb2r	106	35	probably	probably	RB
cord-315453-mbv8vb2r	106	36	has	have	VBZ
cord-315453-mbv8vb2r	106	37	a	a	DT
cord-315453-mbv8vb2r	106	38	better	well	JJR
cord-315453-mbv8vb2r	106	39	effect	effect	NN
cord-315453-mbv8vb2r	106	40	than	than	IN
cord-315453-mbv8vb2r	106	41	others	other	NNS
cord-315453-mbv8vb2r	106	42	.	.	.
cord-315453-mbv8vb2r	107	1	However	however	RB
cord-315453-mbv8vb2r	107	2	,	,	,
cord-315453-mbv8vb2r	107	3	the	the	DT
cord-315453-mbv8vb2r	107	4	immunosuppression	immunosuppression	NN
cord-315453-mbv8vb2r	107	5	induced	induce	VBN
cord-315453-mbv8vb2r	107	6	by	by	IN
cord-315453-mbv8vb2r	107	7	tocilizumab	tocilizumab	NNP
cord-315453-mbv8vb2r	107	8	is	be	VBZ
cord-315453-mbv8vb2r	107	9	a	a	DT
cord-315453-mbv8vb2r	107	10	cause	cause	NN
cord-315453-mbv8vb2r	107	11	for	for	IN
cord-315453-mbv8vb2r	107	12	concern	concern	NN
cord-315453-mbv8vb2r	107	13	as	as	IN
cord-315453-mbv8vb2r	107	14	many	many	JJ
cord-315453-mbv8vb2r	107	15	patients	patient	NNS
cord-315453-mbv8vb2r	107	16	with	with	IN
cord-315453-mbv8vb2r	107	17	COVID-19	covid-19	DT
cord-315453-mbv8vb2r	107	18	likely	likely	JJ
cord-315453-mbv8vb2r	107	19	have	have	VBP
cord-315453-mbv8vb2r	107	20	leukopenia	leukopenia	NN
cord-315453-mbv8vb2r	107	21	or	or	CC
cord-315453-mbv8vb2r	107	22	lymphopenia	lymphopenia	NNP
cord-315453-mbv8vb2r	107	23	.	.	.
cord-315453-mbv8vb2r	108	1	In	in	IN
cord-315453-mbv8vb2r	108	2	fact	fact	NN
cord-315453-mbv8vb2r	108	3	,	,	,
cord-315453-mbv8vb2r	108	4	despite	despite	IN
cord-315453-mbv8vb2r	108	5	the	the	DT
cord-315453-mbv8vb2r	108	6	current	current	JJ
cord-315453-mbv8vb2r	108	7	unproven	unproven	JJ
cord-315453-mbv8vb2r	108	8	clinical	clinical	JJ
cord-315453-mbv8vb2r	108	9	efficacy	efficacy	NN
cord-315453-mbv8vb2r	108	10	through	through	IN
cord-315453-mbv8vb2r	108	11	stringent	stringent	JJ
cord-315453-mbv8vb2r	108	12	trials	trial	NNS
cord-315453-mbv8vb2r	108	13	,	,	,
cord-315453-mbv8vb2r	108	14	a	a	DT
cord-315453-mbv8vb2r	108	15	combination	combination	NN
cord-315453-mbv8vb2r	108	16	of	of	IN
cord-315453-mbv8vb2r	108	17	the	the	DT
cord-315453-mbv8vb2r	108	18	abovementioned	abovementioned	JJ
cord-315453-mbv8vb2r	108	19	useful	useful	JJ
cord-315453-mbv8vb2r	108	20	drugs	drug	NNS
cord-315453-mbv8vb2r	108	21	ought	ought	MD
cord-315453-mbv8vb2r	108	22	to	to	TO
cord-315453-mbv8vb2r	108	23	be	be	VB
cord-315453-mbv8vb2r	108	24	carefully	carefully	RB
cord-315453-mbv8vb2r	108	25	considered	consider	VBN
cord-315453-mbv8vb2r	108	26	to	to	TO
cord-315453-mbv8vb2r	108	27	combat	combat	VB
cord-315453-mbv8vb2r	108	28	SARS	SARS	NNP
cord-315453-mbv8vb2r	108	29	-	-	HYPH
cord-315453-mbv8vb2r	108	30	CoV-2	CoV-2	NNP
cord-315453-mbv8vb2r	108	31	.	.	.
cord-315453-mbv8vb2r	109	1	In	in	IN
cord-315453-mbv8vb2r	109	2	future	future	NN
cord-315453-mbv8vb2r	109	3	,	,	,
cord-315453-mbv8vb2r	109	4	we	-PRON-	PRP
cord-315453-mbv8vb2r	109	5	sincerely	sincerely	RB
cord-315453-mbv8vb2r	109	6	hope	hope	VBP
cord-315453-mbv8vb2r	109	7	that	that	IN
cord-315453-mbv8vb2r	109	8	effective	effective	JJ
cord-315453-mbv8vb2r	109	9	vaccines	vaccine	NNS
cord-315453-mbv8vb2r	109	10	and	and	CC
cord-315453-mbv8vb2r	109	11	documented	document	VBN
cord-315453-mbv8vb2r	109	12	drug	drug	NN
cord-315453-mbv8vb2r	109	13	regimens	regimen	NNS
cord-315453-mbv8vb2r	109	14	specifically	specifically	RB
cord-315453-mbv8vb2r	109	15	targeting	target	VBG
cord-315453-mbv8vb2r	109	16	SARS	SARS	NNP
cord-315453-mbv8vb2r	109	17	-	-	HYPH
cord-315453-mbv8vb2r	109	18	CoV-2	CoV-2	NNP
cord-315453-mbv8vb2r	109	19	can	can	MD
cord-315453-mbv8vb2r	109	20	be	be	VB
cord-315453-mbv8vb2r	109	21	developed	develop	VBN
cord-315453-mbv8vb2r	109	22	to	to	TO
cord-315453-mbv8vb2r	109	23	authentically	authentically	RB
cord-315453-mbv8vb2r	109	24	prevent	prevent	VB
cord-315453-mbv8vb2r	109	25	COVID-19	covid-19	CD
cord-315453-mbv8vb2r	109	26	and	and	CC
cord-315453-mbv8vb2r	109	27	cure	cure	VB
cord-315453-mbv8vb2r	109	28	critically	critically	RB
cord-315453-mbv8vb2r	109	29	ill	ill	JJ
cord-315453-mbv8vb2r	110	1	COVID-19	covid-19	JJ
cord-315453-mbv8vb2r	110	2	patients	patient	NNS
cord-315453-mbv8vb2r	110	3	as	as	RB
cord-315453-mbv8vb2r	110	4	soon	soon	RB
cord-315453-mbv8vb2r	110	5	as	as	IN
cord-315453-mbv8vb2r	110	6	possible	possible	JJ
cord-315453-mbv8vb2r	110	7	.	.	.
cord-315453-mbv8vb2r	111	1	This	this	DT
cord-315453-mbv8vb2r	111	2	study	study	NN
cord-315453-mbv8vb2r	111	3	was	be	VBD
cord-315453-mbv8vb2r	111	4	not	not	RB
cord-315453-mbv8vb2r	111	5	funded	fund	VBN
cord-315453-mbv8vb2r	111	6	.	.	.
cord-315453-mbv8vb2r	112	1	The	the	DT
cord-315453-mbv8vb2r	112	2	authors	author	NNS
cord-315453-mbv8vb2r	112	3	have	have	VBP
cord-315453-mbv8vb2r	112	4	no	no	DT
cord-315453-mbv8vb2r	112	5	other	other	JJ
cord-315453-mbv8vb2r	112	6	relevant	relevant	JJ
cord-315453-mbv8vb2r	112	7	affiliations	affiliation	NNS
cord-315453-mbv8vb2r	112	8	or	or	CC
cord-315453-mbv8vb2r	112	9	financial	financial	JJ
cord-315453-mbv8vb2r	112	10	involvement	involvement	NN
cord-315453-mbv8vb2r	112	11	with	with	IN
cord-315453-mbv8vb2r	112	12	any	any	DT
cord-315453-mbv8vb2r	112	13	organization	organization	NN
cord-315453-mbv8vb2r	112	14	or	or	CC
cord-315453-mbv8vb2r	112	15	entity	entity	NN
cord-315453-mbv8vb2r	112	16	with	with	IN
cord-315453-mbv8vb2r	112	17	a	a	DT
cord-315453-mbv8vb2r	112	18	financial	financial	JJ
cord-315453-mbv8vb2r	112	19	interest	interest	NN
cord-315453-mbv8vb2r	112	20	in	in	IN
cord-315453-mbv8vb2r	112	21	or	or	CC
cord-315453-mbv8vb2r	112	22	financial	financial	JJ
cord-315453-mbv8vb2r	112	23	conflict	conflict	NN
cord-315453-mbv8vb2r	112	24	with	with	IN
cord-315453-mbv8vb2r	112	25	the	the	DT
cord-315453-mbv8vb2r	112	26	subject	subject	JJ
cord-315453-mbv8vb2r	112	27	matter	matter	NN
cord-315453-mbv8vb2r	112	28	or	or	CC
cord-315453-mbv8vb2r	112	29	materials	material	NNS
cord-315453-mbv8vb2r	112	30	discussed	discuss	VBN
cord-315453-mbv8vb2r	112	31	in	in	IN
cord-315453-mbv8vb2r	112	32	the	the	DT
cord-315453-mbv8vb2r	112	33	manuscript	manuscript	NN
cord-315453-mbv8vb2r	112	34	apart	apart	RB
cord-315453-mbv8vb2r	112	35	from	from	IN
cord-315453-mbv8vb2r	112	36	those	those	DT
cord-315453-mbv8vb2r	112	37	disclosed	disclose	VBN
cord-315453-mbv8vb2r	112	38	.	.	.
cord-315453-mbv8vb2r	113	1	Peer	peer	NN
cord-315453-mbv8vb2r	113	2	reviewers	reviewer	NNS
cord-315453-mbv8vb2r	113	3	on	on	IN
cord-315453-mbv8vb2r	113	4	this	this	DT
cord-315453-mbv8vb2r	113	5	manuscript	manuscript	NN
cord-315453-mbv8vb2r	113	6	have	have	VBP
cord-315453-mbv8vb2r	113	7	no	no	DT
cord-315453-mbv8vb2r	113	8	relevant	relevant	JJ
cord-315453-mbv8vb2r	113	9	financial	financial	JJ
cord-315453-mbv8vb2r	113	10	or	or	CC
cord-315453-mbv8vb2r	113	11	other	other	JJ
cord-315453-mbv8vb2r	113	12	relationships	relationship	NNS
cord-315453-mbv8vb2r	113	13	to	to	TO
cord-315453-mbv8vb2r	113	14	disclose	disclose	VB
cord-315453-mbv8vb2r	113	15	.	.	.
cord-315453-mbv8vb2r	114	1	Characteristics	characteristic	NNS
cord-315453-mbv8vb2r	114	2	of	of	IN
cord-315453-mbv8vb2r	114	3	and	and	CC
cord-315453-mbv8vb2r	114	4	important	important	JJ
cord-315453-mbv8vb2r	114	5	lessons	lesson	NNS
cord-315453-mbv8vb2r	114	6	from	from	IN
cord-315453-mbv8vb2r	114	7	the	the	DT
cord-315453-mbv8vb2r	114	8	coronavirus	coronavirus	NN
cord-315453-mbv8vb2r	114	9	disease	disease	NN
cord-315453-mbv8vb2r	114	10	2019	2019	CD
cord-315453-mbv8vb2r	114	11	(	(	-LRB-
cord-315453-mbv8vb2r	114	12	COVID-19	COVID-19	NNP
cord-315453-mbv8vb2r	114	13	)	)	-RRB-
cord-315453-mbv8vb2r	114	14	outbreak	outbreak	NN
cord-315453-mbv8vb2r	114	15	in	in	IN
cord-315453-mbv8vb2r	114	16	China	China	NNP
cord-315453-mbv8vb2r	114	17	:	:	:
cord-315453-mbv8vb2r	114	18	summary	summary	NN
cord-315453-mbv8vb2r	114	19	of	of	IN
cord-315453-mbv8vb2r	114	20	a	a	DT
cord-315453-mbv8vb2r	114	21	report	report	NN
cord-315453-mbv8vb2r	114	22	of	of	IN
cord-315453-mbv8vb2r	114	23	72314	72314	CD
cord-315453-mbv8vb2r	114	24	cases	case	NNS
cord-315453-mbv8vb2r	114	25	from	from	IN
cord-315453-mbv8vb2r	114	26	the	the	DT
cord-315453-mbv8vb2r	114	27	Chinese	chinese	JJ
cord-315453-mbv8vb2r	114	28	center	center	NN
cord-315453-mbv8vb2r	114	29	for	for	IN
cord-315453-mbv8vb2r	114	30	disease	disease	NNP
cord-315453-mbv8vb2r	114	31	control	control	NN
cord-315453-mbv8vb2r	114	32	and	and	CC
cord-315453-mbv8vb2r	114	33	prevention	prevention	NN
cord-315453-mbv8vb2r	114	34	Are	be	VBP
cord-315453-mbv8vb2r	114	35	children	child	NNS
cord-315453-mbv8vb2r	114	36	less	less	RBR
cord-315453-mbv8vb2r	114	37	susceptible	susceptible	JJ
cord-315453-mbv8vb2r	114	38	to	to	IN
cord-315453-mbv8vb2r	114	39	COVID-19	covid-19	VB
cord-315453-mbv8vb2r	114	40	?	?	.
cord-315453-mbv8vb2r	115	1	Issue	issue	VB
cord-315453-mbv8vb2r	115	2	the	the	DT
cord-315453-mbv8vb2r	115	3	difference	difference	NN
cord-315453-mbv8vb2r	115	4	of	of	IN
cord-315453-mbv8vb2r	115	5	ACE2	ACE2	NNP
cord-315453-mbv8vb2r	115	6	receptor	receptor	NN
cord-315453-mbv8vb2r	115	7	number	number	NN
cord-315453-mbv8vb2r	115	8	between	between	IN
cord-315453-mbv8vb2r	115	9	adults	adult	NNS
cord-315453-mbv8vb2r	115	10	and	and	CC
cord-315453-mbv8vb2r	115	11	children	child	NNS
cord-315453-mbv8vb2r	116	1	Emerging	emerge	VBG
cord-315453-mbv8vb2r	116	2	threats	threat	NNS
cord-315453-mbv8vb2r	116	3	from	from	IN
cord-315453-mbv8vb2r	116	4	zoonotic	zoonotic	JJ
cord-315453-mbv8vb2r	116	5	coronaviruses	coronaviruse	NNS
cord-315453-mbv8vb2r	116	6	-	-	:
cord-315453-mbv8vb2r	116	7	from	from	IN
cord-315453-mbv8vb2r	116	8	SARS	SARS	NNP
cord-315453-mbv8vb2r	116	9	and	and	CC
cord-315453-mbv8vb2r	116	10	MERS	MERS	NNP
cord-315453-mbv8vb2r	116	11	to	to	IN
cord-315453-mbv8vb2r	116	12	2019-nCoV	2019-ncov	CD
cord-315453-mbv8vb2r	116	13	Clinical	clinical	JJ
cord-315453-mbv8vb2r	116	14	,	,	,
cord-315453-mbv8vb2r	116	15	laboratory	laboratory	NN
cord-315453-mbv8vb2r	116	16	and	and	CC
cord-315453-mbv8vb2r	116	17	imaging	imaging	NN
cord-315453-mbv8vb2r	116	18	features	feature	NNS
cord-315453-mbv8vb2r	116	19	of	of	IN
cord-315453-mbv8vb2r	116	20	COVID-19	covid-19	NN
cord-315453-mbv8vb2r	116	21	:	:	:
cord-315453-mbv8vb2r	116	22	A	a	DT
cord-315453-mbv8vb2r	116	23	systematic	systematic	JJ
cord-315453-mbv8vb2r	116	24	review	review	NN
cord-315453-mbv8vb2r	116	25	and	and	CC
cord-315453-mbv8vb2r	116	26	meta	meta	NNP
cord-315453-mbv8vb2r	116	27	-	-	HYPH
cord-315453-mbv8vb2r	116	28	analysis	analysis	NN
cord-315453-mbv8vb2r	116	29	Coronavirus	Coronavirus	NNP
cord-315453-mbv8vb2r	116	30	disease	disease	NN
cord-315453-mbv8vb2r	116	31	2019	2019	CD
cord-315453-mbv8vb2r	116	32	(	(	-LRB-
cord-315453-mbv8vb2r	116	33	COVID-19	COVID-19	NNP
cord-315453-mbv8vb2r	116	34	)	)	-RRB-
cord-315453-mbv8vb2r	116	35	:	:	:
cord-315453-mbv8vb2r	117	1	A	a	DT
cord-315453-mbv8vb2r	117	2	literature	literature	NN
cord-315453-mbv8vb2r	117	3	review	review	NN
cord-315453-mbv8vb2r	117	4	Coronaviruses	Coronaviruses	NNP
cord-315453-mbv8vb2r	117	5	-drug	-drug	NNP
cord-315453-mbv8vb2r	117	6	discovery	discovery	NN
cord-315453-mbv8vb2r	117	7	and	and	CC
cord-315453-mbv8vb2r	117	8	therapeutic	therapeutic	JJ
cord-315453-mbv8vb2r	117	9	options	option	NNS
cord-315453-mbv8vb2r	117	10	••	••	''
cord-315453-mbv8vb2r	118	1	An	an	DT
cord-315453-mbv8vb2r	118	2	important	important	JJ
cord-315453-mbv8vb2r	118	3	review	review	NN
cord-315453-mbv8vb2r	118	4	addressing	address	VBG
cord-315453-mbv8vb2r	118	5	the	the	DT
cord-315453-mbv8vb2r	118	6	drugs	drug	NNS
cord-315453-mbv8vb2r	118	7	with	with	IN
cord-315453-mbv8vb2r	118	8	potential	potential	JJ
cord-315453-mbv8vb2r	118	9	activities	activity	NNS
cord-315453-mbv8vb2r	118	10	against	against	IN
cord-315453-mbv8vb2r	118	11	coronaviruses	coronaviruse	NNS
cord-315453-mbv8vb2r	118	12	Therapeutic	therapeutic	JJ
cord-315453-mbv8vb2r	118	13	options	option	NNS
cord-315453-mbv8vb2r	118	14	for	for	IN
cord-315453-mbv8vb2r	118	15	the	the	DT
cord-315453-mbv8vb2r	118	16	2019	2019	CD
cord-315453-mbv8vb2r	118	17	novel	novel	NN
cord-315453-mbv8vb2r	118	18	coronavirus	coronavirus	NN
cord-315453-mbv8vb2r	118	19	(	(	-LRB-
cord-315453-mbv8vb2r	118	20	2019-nCoV	2019-ncov	CD
cord-315453-mbv8vb2r	118	21	)	)	-RRB-
cord-315453-mbv8vb2r	118	22	Compassionate	compassionate	JJ
cord-315453-mbv8vb2r	118	23	use	use	NN
cord-315453-mbv8vb2r	118	24	of	of	IN
cord-315453-mbv8vb2r	118	25	remdesivir	remdesivir	NNS
cord-315453-mbv8vb2r	118	26	for	for	IN
cord-315453-mbv8vb2r	118	27	patients	patient	NNS
cord-315453-mbv8vb2r	118	28	with	with	IN
cord-315453-mbv8vb2r	118	29	severe	severe	JJ
cord-315453-mbv8vb2r	118	30	Covid-19	covid-19	NN
cord-315453-mbv8vb2r	118	31	Address	Address	NNP
cord-315453-mbv8vb2r	118	32	the	the	DT
cord-315453-mbv8vb2r	118	33	treatment	treatment	NN
cord-315453-mbv8vb2r	118	34	experience	experience	NN
cord-315453-mbv8vb2r	118	35	of	of	IN
cord-315453-mbv8vb2r	118	36	remdesivir	remdesivir	NNP
cord-315453-mbv8vb2r	118	37	on	on	IN
cord-315453-mbv8vb2r	118	38	patients	patient	NNS
cord-315453-mbv8vb2r	118	39	with	with	IN
cord-315453-mbv8vb2r	118	40	COVID-19	COVID-19	NNP
cord-315453-mbv8vb2r	118	41	in	in	IN
cord-315453-mbv8vb2r	118	42	details	detail	NNS
cord-315453-mbv8vb2r	118	43	Comparative	comparative	JJ
cord-315453-mbv8vb2r	118	44	effectiveness	effectiveness	NN
cord-315453-mbv8vb2r	118	45	of	of	IN
cord-315453-mbv8vb2r	118	46	combined	combine	VBN
cord-315453-mbv8vb2r	118	47	favipiravir	favipiravir	NNS
cord-315453-mbv8vb2r	118	48	and	and	CC
cord-315453-mbv8vb2r	118	49	oseltamivir	oseltamivir	NNP
cord-315453-mbv8vb2r	118	50	therapy	therapy	NNP
cord-315453-mbv8vb2r	118	51	versus	versus	IN
cord-315453-mbv8vb2r	118	52	oseltamivir	oseltamivir	NNP
cord-315453-mbv8vb2r	118	53	monotherapy	monotherapy	IN
cord-315453-mbv8vb2r	118	54	in	in	IN
cord-315453-mbv8vb2r	118	55	critically	critically	RB
cord-315453-mbv8vb2r	118	56	ill	ill	JJ
cord-315453-mbv8vb2r	118	57	patients	patient	NNS
cord-315453-mbv8vb2r	118	58	with	with	IN
cord-315453-mbv8vb2r	118	59	influenza	influenza	NN
cord-315453-mbv8vb2r	118	60	virus	virus	NN
cord-315453-mbv8vb2r	118	61	infection	infection	NN
cord-315453-mbv8vb2r	118	62	Novel	Novel	NNP
cord-315453-mbv8vb2r	118	63	coronavirus	coronavirus	NN
cord-315453-mbv8vb2r	118	64	pneumonia	pneumonia	NN
cord-315453-mbv8vb2r	118	65	diagnosis	diagnosis	NN
cord-315453-mbv8vb2r	118	66	and	and	CC
cord-315453-mbv8vb2r	118	67	treatment	treatment	NN
cord-315453-mbv8vb2r	118	68	plan	plan	NN
cord-315453-mbv8vb2r	118	69	(	(	-LRB-
cord-315453-mbv8vb2r	118	70	provisional	provisional	JJ
cord-315453-mbv8vb2r	118	71	7th	7th	JJ
cord-315453-mbv8vb2r	118	72	edition	edition	NN
cord-315453-mbv8vb2r	118	73	,	,	,
cord-315453-mbv8vb2r	118	74	in	in	IN
cord-315453-mbv8vb2r	118	75	Chinese	Chinese	NNP
cord-315453-mbv8vb2r	118	76	)	)	-RRB-
cord-315453-mbv8vb2r	119	1	Treatment	treatment	NN
cord-315453-mbv8vb2r	119	2	with	with	IN
cord-315453-mbv8vb2r	119	3	lopinavir	lopinavir	NNS
cord-315453-mbv8vb2r	119	4	/	/	SYM
cord-315453-mbv8vb2r	119	5	ritonavir	ritonavir	NNS
cord-315453-mbv8vb2r	119	6	or	or	CC
cord-315453-mbv8vb2r	119	7	interferon	interferon	NN
cord-315453-mbv8vb2r	119	8	-	-	HYPH
cord-315453-mbv8vb2r	119	9	β1b	β1b	NNP
cord-315453-mbv8vb2r	119	10	improves	improve	VBZ
cord-315453-mbv8vb2r	119	11	outcome	outcome	NN
cord-315453-mbv8vb2r	119	12	of	of	IN
cord-315453-mbv8vb2r	119	13	MERS	MERS	NNP
cord-315453-mbv8vb2r	119	14	-	-	HYPH
cord-315453-mbv8vb2r	119	15	CoV	cov	NN
cord-315453-mbv8vb2r	119	16	infection	infection	NN
cord-315453-mbv8vb2r	119	17	in	in	IN
cord-315453-mbv8vb2r	119	18	a	a	DT
cord-315453-mbv8vb2r	119	19	nonhuman	nonhuman	NN
cord-315453-mbv8vb2r	119	20	primate	primate	NN
cord-315453-mbv8vb2r	119	21	model	model	NN
cord-315453-mbv8vb2r	119	22	of	of	IN
cord-315453-mbv8vb2r	119	23	common	common	JJ
cord-315453-mbv8vb2r	119	24	marmoset	marmoset	JJ
cord-315453-mbv8vb2r	119	25	Role	role	NN
cord-315453-mbv8vb2r	119	26	of	of	IN
cord-315453-mbv8vb2r	119	27	lopinavir	lopinavir	NNP
cord-315453-mbv8vb2r	119	28	/	/	SYM
cord-315453-mbv8vb2r	119	29	ritonavir	ritonavir	NNS
cord-315453-mbv8vb2r	119	30	in	in	IN
cord-315453-mbv8vb2r	119	31	the	the	DT
cord-315453-mbv8vb2r	119	32	treatment	treatment	NN
cord-315453-mbv8vb2r	119	33	of	of	IN
cord-315453-mbv8vb2r	119	34	SARS	SARS	NNP
cord-315453-mbv8vb2r	119	35	:	:	:
cord-315453-mbv8vb2r	119	36	initial	initial	JJ
cord-315453-mbv8vb2r	119	37	virological	virological	JJ
cord-315453-mbv8vb2r	119	38	and	and	CC
cord-315453-mbv8vb2r	119	39	clinical	clinical	JJ
cord-315453-mbv8vb2r	119	40	findings	finding	NNS
cord-315453-mbv8vb2r	120	1	A	a	DT
cord-315453-mbv8vb2r	120	2	trial	trial	NN
cord-315453-mbv8vb2r	120	3	of	of	IN
cord-315453-mbv8vb2r	120	4	lopinavir	lopinavir	NNS
cord-315453-mbv8vb2r	120	5	-	-	HYPH
cord-315453-mbv8vb2r	120	6	ritonavir	ritonavir	NNS
cord-315453-mbv8vb2r	120	7	in	in	IN
cord-315453-mbv8vb2r	120	8	adults	adult	NNS
cord-315453-mbv8vb2r	120	9	hospitalized	hospitalize	VBN
cord-315453-mbv8vb2r	120	10	with	with	IN
cord-315453-mbv8vb2r	120	11	severe	severe	JJ
cord-315453-mbv8vb2r	120	12	COVID-19	COVID-19	NNP
cord-315453-mbv8vb2r	120	13	•	•	NN
cord-315453-mbv8vb2r	121	1	An	an	DT
cord-315453-mbv8vb2r	121	2	important	important	JJ
cord-315453-mbv8vb2r	121	3	database	database	NN
cord-315453-mbv8vb2r	121	4	issuing	issue	VBG
cord-315453-mbv8vb2r	121	5	the	the	DT
cord-315453-mbv8vb2r	121	6	role	role	NN
cord-315453-mbv8vb2r	121	7	of	of	IN
cord-315453-mbv8vb2r	121	8	monotherapy	monotherapy	NN
cord-315453-mbv8vb2r	121	9	with	with	IN
cord-315453-mbv8vb2r	121	10	lopinavir	lopinavir	NNS
cord-315453-mbv8vb2r	121	11	/	/	SYM
cord-315453-mbv8vb2r	121	12	ritonavir	ritonavir	NNP
cord-315453-mbv8vb2r	121	13	failure	failure	NN
cord-315453-mbv8vb2r	121	14	of	of	IN
cord-315453-mbv8vb2r	121	15	achieving	achieve	VBG
cord-315453-mbv8vb2r	121	16	the	the	DT
cord-315453-mbv8vb2r	121	17	success	success	NN
cord-315453-mbv8vb2r	121	18	of	of	IN
cord-315453-mbv8vb2r	121	19	treatment	treatment	NN
cord-315453-mbv8vb2r	121	20	against	against	IN
cord-315453-mbv8vb2r	121	21	COVID-19	COVID-19	NNP
cord-315453-mbv8vb2r	121	22	Consensus	Consensus	NNP
cord-315453-mbv8vb2r	121	23	Guidelines	Guidelines	NNPS
cord-315453-mbv8vb2r	121	24	for	for	IN
cord-315453-mbv8vb2r	121	25	the	the	DT
cord-315453-mbv8vb2r	121	26	Treatment	Treatment	NNP
cord-315453-mbv8vb2r	121	27	of	of	IN
cord-315453-mbv8vb2r	121	28	COVID-19	COVID-19	NNP
cord-315453-mbv8vb2r	122	1	••	••	CD
cord-315453-mbv8vb2r	123	1	An	an	DT
cord-315453-mbv8vb2r	123	2	important	important	JJ
cord-315453-mbv8vb2r	123	3	consensus	consensus	NN
cord-315453-mbv8vb2r	123	4	of	of	IN
cord-315453-mbv8vb2r	123	5	reference	reference	NN
cord-315453-mbv8vb2r	123	6	for	for	IN
cord-315453-mbv8vb2r	123	7	COVID-19	covid-19	JJ
cord-315453-mbv8vb2r	123	8	treatment	treatment	NN
cord-315453-mbv8vb2r	123	9	Chloroquine	Chloroquine	NNP
cord-315453-mbv8vb2r	123	10	is	be	VBZ
cord-315453-mbv8vb2r	123	11	a	a	DT
cord-315453-mbv8vb2r	123	12	potent	potent	JJ
cord-315453-mbv8vb2r	123	13	inhibitor	inhibitor	NN
cord-315453-mbv8vb2r	123	14	of	of	IN
cord-315453-mbv8vb2r	123	15	SARS	SARS	NNP
cord-315453-mbv8vb2r	123	16	coronavirus	coronavirus	NN
cord-315453-mbv8vb2r	123	17	infection	infection	NN
cord-315453-mbv8vb2r	123	18	and	and	CC
cord-315453-mbv8vb2r	123	19	spread	spread	VBD
cord-315453-mbv8vb2r	123	20	Chloroquine	Chloroquine	NNP
cord-315453-mbv8vb2r	123	21	and	and	CC
cord-315453-mbv8vb2r	123	22	hydroxychloroquine	hydroxychloroquine	NN
cord-315453-mbv8vb2r	123	23	in	in	IN
cord-315453-mbv8vb2r	123	24	covid-19	covid-19	NNP
cord-315453-mbv8vb2r	123	25	Use	Use	NNP
cord-315453-mbv8vb2r	123	26	of	of	IN
cord-315453-mbv8vb2r	123	27	these	these	DT
cord-315453-mbv8vb2r	123	28	drugs	drug	NNS
cord-315453-mbv8vb2r	123	29	is	be	VBZ
cord-315453-mbv8vb2r	123	30	premature	premature	JJ
cord-315453-mbv8vb2r	123	31	and	and	CC
cord-315453-mbv8vb2r	123	32	potentially	potentially	RB
cord-315453-mbv8vb2r	123	33	harmful	harmful	JJ
cord-315453-mbv8vb2r	124	1	In	in	IN
cord-315453-mbv8vb2r	124	2	vitro	vitro	FW
cord-315453-mbv8vb2r	124	3	antiviral	antiviral	JJ
cord-315453-mbv8vb2r	124	4	activity	activity	NN
cord-315453-mbv8vb2r	124	5	and	and	CC
cord-315453-mbv8vb2r	124	6	projection	projection	NN
cord-315453-mbv8vb2r	124	7	of	of	IN
cord-315453-mbv8vb2r	124	8	optimized	optimize	VBN
cord-315453-mbv8vb2r	124	9	dosing	dosing	NN
cord-315453-mbv8vb2r	124	10	design	design	NN
cord-315453-mbv8vb2r	124	11	of	of	IN
cord-315453-mbv8vb2r	124	12	hydroxychloroquine	hydroxychloroquine	NN
cord-315453-mbv8vb2r	124	13	for	for	IN
cord-315453-mbv8vb2r	124	14	the	the	DT
cord-315453-mbv8vb2r	124	15	treatment	treatment	NN
cord-315453-mbv8vb2r	124	16	of	of	IN
cord-315453-mbv8vb2r	124	17	severe	severe	JJ
cord-315453-mbv8vb2r	124	18	acute	acute	JJ
cord-315453-mbv8vb2r	124	19	respiratory	respiratory	JJ
cord-315453-mbv8vb2r	124	20	syndrome	syndrome	NN
cord-315453-mbv8vb2r	124	21	coronavirus	coronavirus	NN
cord-315453-mbv8vb2r	124	22	2	2	CD
cord-315453-mbv8vb2r	125	1	(	(	-LRB-
cord-315453-mbv8vb2r	125	2	SARS	SARS	NNP
cord-315453-mbv8vb2r	125	3	-	-	HYPH
cord-315453-mbv8vb2r	125	4	CoV-2	CoV-2	NNP
cord-315453-mbv8vb2r	125	5	)	)	-RRB-
cord-315453-mbv8vb2r	126	1	•	•	NNP
cord-315453-mbv8vb2r	127	1	Issue	issue	VB
cord-315453-mbv8vb2r	127	2	the	the	DT
cord-315453-mbv8vb2r	127	3	physiological	physiological	JJ
cord-315453-mbv8vb2r	127	4	dose	dose	NN
cord-315453-mbv8vb2r	127	5	of	of	IN
cord-315453-mbv8vb2r	127	6	hydroxychloroquine	hydroxychloroquine	NN
cord-315453-mbv8vb2r	127	7	in	in	IN
cord-315453-mbv8vb2r	127	8	treatment	treatment	NN
cord-315453-mbv8vb2r	127	9	of	of	IN
cord-315453-mbv8vb2r	127	10	SARS	SARS	NNP
cord-315453-mbv8vb2r	127	11	-	-	HYPH
cord-315453-mbv8vb2r	127	12	CoV-2	CoV-2	NNP
cord-315453-mbv8vb2r	127	13	infection	infection	NN
cord-315453-mbv8vb2r	127	14	19	19	CD
cord-315453-mbv8vb2r	127	15	update	update	NN
cord-315453-mbv8vb2r	127	16	:	:	:
cord-315453-mbv8vb2r	127	17	hydroxychloroquine	hydroxychloroquine	NNP
cord-315453-mbv8vb2r	127	18	&	&	CC
cord-315453-mbv8vb2r	127	19	recovery	recovery	NNP
cord-315453-mbv8vb2r	127	20	time	time	NN
cord-315453-mbv8vb2r	127	21	/	/	SYM
cord-315453-mbv8vb2r	127	22	home	home	NN
cord-315453-mbv8vb2r	127	23	face	face	NN
cord-315453-mbv8vb2r	127	24	masks	mask	NNS
cord-315453-mbv8vb2r	127	25	at	at	IN
cord-315453-mbv8vb2r	127	26	work	work	NN
cord-315453-mbv8vb2r	127	27	/	/	SYM
cord-315453-mbv8vb2r	127	28	reusing	reuse	VBG
cord-315453-mbv8vb2r	127	29	respirators	respirator	NNS
cord-315453-mbv8vb2r	127	30	Efficacy	Efficacy	NNP
cord-315453-mbv8vb2r	127	31	of	of	IN
cord-315453-mbv8vb2r	127	32	hydroxychloroquine	hydroxychloroquine	NN
cord-315453-mbv8vb2r	127	33	in	in	IN
cord-315453-mbv8vb2r	127	34	patients	patient	NNS
cord-315453-mbv8vb2r	127	35	with	with	IN
cord-315453-mbv8vb2r	127	36	COVID-19	covid-19	NN
cord-315453-mbv8vb2r	127	37	:	:	:
cord-315453-mbv8vb2r	127	38	results	result	NNS
cord-315453-mbv8vb2r	127	39	of	of	IN
cord-315453-mbv8vb2r	127	40	a	a	DT
cord-315453-mbv8vb2r	127	41	randomized	randomized	JJ
cord-315453-mbv8vb2r	127	42	clinical	clinical	JJ
cord-315453-mbv8vb2r	127	43	trial	trial	NN
cord-315453-mbv8vb2r	127	44	(	(	-LRB-
cord-315453-mbv8vb2r	127	45	preprint	preprint	NN
cord-315453-mbv8vb2r	127	46	)	)	-RRB-
cord-315453-mbv8vb2r	127	47	.	.	.
cord-315453-mbv8vb2r	128	1	MedRxIV	MedRxIV	NNP
cord-315453-mbv8vb2r	128	2	Hydroxychloroquine	Hydroxychloroquine	NNP
cord-315453-mbv8vb2r	128	3	and	and	CC
cord-315453-mbv8vb2r	128	4	azithromycin	azithromycin	NNP
cord-315453-mbv8vb2r	128	5	as	as	IN
cord-315453-mbv8vb2r	128	6	a	a	DT
cord-315453-mbv8vb2r	128	7	treatment	treatment	NN
cord-315453-mbv8vb2r	128	8	of	of	IN
cord-315453-mbv8vb2r	128	9	COVID-19	covid-19	NN
cord-315453-mbv8vb2r	128	10	:	:	:
cord-315453-mbv8vb2r	128	11	results	result	NNS
cord-315453-mbv8vb2r	128	12	of	of	IN
cord-315453-mbv8vb2r	128	13	an	an	DT
cord-315453-mbv8vb2r	128	14	open	open	JJ
cord-315453-mbv8vb2r	128	15	-	-	HYPH
cord-315453-mbv8vb2r	128	16	label	label	NN
cord-315453-mbv8vb2r	128	17	non	non	JJ
cord-315453-mbv8vb2r	128	18	-	-	JJ
cord-315453-mbv8vb2r	128	19	randomized	randomized	JJ
cord-315453-mbv8vb2r	128	20	clinical	clinical	JJ
cord-315453-mbv8vb2r	128	21	trial	trial	NN
cord-315453-mbv8vb2r	128	22	Address	Address	NNP
cord-315453-mbv8vb2r	128	23	the	the	DT
cord-315453-mbv8vb2r	128	24	efficacy	efficacy	NN
cord-315453-mbv8vb2r	128	25	of	of	IN
cord-315453-mbv8vb2r	128	26	hydroxychloroquine	hydroxychloroquine	NNP
cord-315453-mbv8vb2r	128	27	plus	plus	CC
cord-315453-mbv8vb2r	128	28	azithromycin	azithromycin	NNP
cord-315453-mbv8vb2r	128	29	in	in	IN
cord-315453-mbv8vb2r	128	30	treatment	treatment	NN
cord-315453-mbv8vb2r	128	31	of	of	IN
cord-315453-mbv8vb2r	128	32	COVID-19	covid-19	CD
cord-315453-mbv8vb2r	128	33	in	in	IN
cord-315453-mbv8vb2r	128	34	terms	term	NNS
cord-315453-mbv8vb2r	128	35	of	of	IN
cord-315453-mbv8vb2r	128	36	clinical	clinical	JJ
cord-315453-mbv8vb2r	128	37	condition	condition	NN
cord-315453-mbv8vb2r	128	38	and	and	CC
cord-315453-mbv8vb2r	128	39	viral	viral	JJ
cord-315453-mbv8vb2r	128	40	loading	loading	NN
cord-315453-mbv8vb2r	128	41	FDA	FDA	NNP
cord-315453-mbv8vb2r	128	42	approves	approve	VBZ
cord-315453-mbv8vb2r	128	43	COVACTA	COVACTA	NNP
cord-315453-mbv8vb2r	128	44	trial	trial	NN
cord-315453-mbv8vb2r	128	45	for	for	IN
cord-315453-mbv8vb2r	128	46	RA	RA	NNP
cord-315453-mbv8vb2r	128	47	drug	drug	NN
cord-315453-mbv8vb2r	128	48	Actemra	Actemra	NNP
cord-315453-mbv8vb2r	128	49	in	in	IN
cord-315453-mbv8vb2r	128	50	COVID-19	COVID-19	NNP
cord-315453-mbv8vb2r	128	51	patients	patient	NNS
cord-315453-mbv8vb2r	128	52	Treatment	Treatment	NNP
cord-315453-mbv8vb2r	128	53	of	of	IN
cord-315453-mbv8vb2r	128	54	coronavirus	coronavirus	NN
cord-315453-mbv8vb2r	128	55	disease	disease	NN
cord-315453-mbv8vb2r	128	56	2019	2019	CD
cord-315453-mbv8vb2r	129	1	(	(	-LRB-
cord-315453-mbv8vb2r	129	2	COVID-19	COVID-19	NNP
cord-315453-mbv8vb2r	129	3	)	)	-RRB-
cord-315453-mbv8vb2r	129	4	:	:	:
cord-315453-mbv8vb2r	129	5	investigational	investigational	JJ
cord-315453-mbv8vb2r	129	6	drugs	drug	NNS
cord-315453-mbv8vb2r	129	7	and	and	CC
cord-315453-mbv8vb2r	129	8	other	other	JJ
cord-315453-mbv8vb2r	129	9	therapies	therapy	NNS
cord-315453-mbv8vb2r	129	10	:	:	:
cord-315453-mbv8vb2r	129	11	introduction	introduction	NN
cord-315453-mbv8vb2r	129	12	,	,	,
cord-315453-mbv8vb2r	129	13	investigational	investigational	JJ
cord-315453-mbv8vb2r	129	14	antiviral	antiviral	JJ
cord-315453-mbv8vb2r	129	15	agents	agent	NNS
cord-315453-mbv8vb2r	129	16	,	,	,
cord-315453-mbv8vb2r	129	17	immunomodulators	immunomodulator	NNS
cord-315453-mbv8vb2r	129	18	and	and	CC
cord-315453-mbv8vb2r	129	19	other	other	JJ
cord-315453-mbv8vb2r	129	20	investigational	investigational	JJ
cord-315453-mbv8vb2r	129	21	therapies	therapy	NNS
cord-315453-mbv8vb2r	130	1	Incyte	Incyte	NNP
cord-315453-mbv8vb2r	130	2	announces	announce	VBZ
cord-315453-mbv8vb2r	130	3	plans	plan	NNS
cord-315453-mbv8vb2r	130	4	to	to	TO
cord-315453-mbv8vb2r	130	5	initiate	initiate	VB
cord-315453-mbv8vb2r	130	6	a	a	DT
cord-315453-mbv8vb2r	130	7	phase	phase	NN
cord-315453-mbv8vb2r	130	8	3	3	CD
cord-315453-mbv8vb2r	130	9	clinical	clinical	JJ
cord-315453-mbv8vb2r	130	10	trial	trial	NN
cord-315453-mbv8vb2r	130	11	of	of	IN
cord-315453-mbv8vb2r	130	12	ruxolitinib	ruxolitinib	NNP
cord-315453-mbv8vb2r	130	13	(	(	-LRB-
cord-315453-mbv8vb2r	131	1	Jakafi	Jakafi	NNP
cord-315453-mbv8vb2r	131	2	®	®	.
cord-315453-mbv8vb2r	131	3	)	)	-RRB-
cord-315453-mbv8vb2r	131	4	as	as	IN
cord-315453-mbv8vb2r	131	5	a	a	DT
cord-315453-mbv8vb2r	131	6	treatment	treatment	NN
cord-315453-mbv8vb2r	131	7	for	for	IN
cord-315453-mbv8vb2r	131	8	patients	patient	NNS
cord-315453-mbv8vb2r	131	9	with	with	IN
cord-315453-mbv8vb2r	131	10	COVID-19	covid-19	JJ
cord-315453-mbv8vb2r	131	11	associated	associated	JJ
cord-315453-mbv8vb2r	131	12	cytokine	cytokine	NN
cord-315453-mbv8vb2r	131	13	storm	storm	NN
cord-315453-mbv8vb2r	132	1	Teicoplanin	Teicoplanin	NNS
cord-315453-mbv8vb2r	132	2	inhibits	inhibit	VBZ
cord-315453-mbv8vb2r	132	3	Ebola	Ebola	NNP
cord-315453-mbv8vb2r	132	4	pseudovirus	pseudovirus	JJ
cord-315453-mbv8vb2r	132	5	infection	infection	NN
cord-315453-mbv8vb2r	132	6	in	in	IN
cord-315453-mbv8vb2r	132	7	cell	cell	NN
cord-315453-mbv8vb2r	132	8	culture	culture	NN
cord-315453-mbv8vb2r	133	1	Glycopeptide	Glycopeptide	NNP
cord-315453-mbv8vb2r	133	2	antibiotics	antibiotic	NNS
cord-315453-mbv8vb2r	133	3	potently	potently	RB
cord-315453-mbv8vb2r	133	4	inhibit	inhibit	VBP
cord-315453-mbv8vb2r	133	5	cathepsin	cathepsin	NN
cord-315453-mbv8vb2r	133	6	L	l	NN
cord-315453-mbv8vb2r	133	7	in	in	IN
cord-315453-mbv8vb2r	133	8	the	the	DT
cord-315453-mbv8vb2r	133	9	late	late	JJ
cord-315453-mbv8vb2r	133	10	endosome	endosome	NN
cord-315453-mbv8vb2r	133	11	/	/	SYM
cord-315453-mbv8vb2r	133	12	lysosome	lysosome	NN
cord-315453-mbv8vb2r	133	13	and	and	CC
cord-315453-mbv8vb2r	133	14	block	block	VB
cord-315453-mbv8vb2r	133	15	the	the	DT
cord-315453-mbv8vb2r	133	16	entry	entry	NN
cord-315453-mbv8vb2r	133	17	of	of	IN
cord-315453-mbv8vb2r	133	18	Ebola	Ebola	NNP
cord-315453-mbv8vb2r	133	19	virus	virus	NN
cord-315453-mbv8vb2r	133	20	,	,	,
cord-315453-mbv8vb2r	133	21	Middle	Middle	NNP
cord-315453-mbv8vb2r	133	22	East	East	NNP
cord-315453-mbv8vb2r	133	23	respiratory	respiratory	JJ
cord-315453-mbv8vb2r	133	24	syndrome	syndrome	NN
cord-315453-mbv8vb2r	133	25	coronavirus	coronavirus	NN
cord-315453-mbv8vb2r	133	26	(	(	-LRB-
cord-315453-mbv8vb2r	133	27	MERS	MERS	NNP
cord-315453-mbv8vb2r	133	28	-	-	HYPH
cord-315453-mbv8vb2r	133	29	CoV	CoV	NNP
cord-315453-mbv8vb2r	133	30	)	)	-RRB-
cord-315453-mbv8vb2r	133	31	,	,	,
cord-315453-mbv8vb2r	133	32	and	and	CC
cord-315453-mbv8vb2r	133	33	Severe	severe	JJ
cord-315453-mbv8vb2r	133	34	Acute	acute	JJ
cord-315453-mbv8vb2r	133	35	Respiratory	Respiratory	NNP
cord-315453-mbv8vb2r	133	36	Syndrome	Syndrome	NNP
cord-315453-mbv8vb2r	133	37	coronavirus	coronavirus	NN
cord-315453-mbv8vb2r	133	38	(	(	-LRB-
cord-315453-mbv8vb2r	133	39	SARS	SARS	NNP
cord-315453-mbv8vb2r	133	40	-	-	HYPH
cord-315453-mbv8vb2r	133	41	CoV	CoV	NNP
cord-315453-mbv8vb2r	133	42	)	)	-RRB-
cord-315453-mbv8vb2r	134	1	••	••	CD
cord-315453-mbv8vb2r	135	1	An	an	DT
cord-315453-mbv8vb2r	135	2	important	important	JJ
cord-315453-mbv8vb2r	135	3	study	study	NN
cord-315453-mbv8vb2r	135	4	issuing	issue	VBG
cord-315453-mbv8vb2r	135	5	the	the	DT
cord-315453-mbv8vb2r	135	6	in	in	FW
cord-315453-mbv8vb2r	135	7	vitro	vitro	FW
cord-315453-mbv8vb2r	135	8	efficacy	efficacy	NN
cord-315453-mbv8vb2r	135	9	of	of	IN
cord-315453-mbv8vb2r	135	10	teicoplanin	teicoplanin	NNP
cord-315453-mbv8vb2r	135	11	on	on	IN
cord-315453-mbv8vb2r	135	12	SARS	SARS	NNP
cord-315453-mbv8vb2r	135	13	-	-	HYPH
cord-315453-mbv8vb2r	135	14	CoV	CoV	NNP
cord-315453-mbv8vb2r	135	15	and	and	CC
cord-315453-mbv8vb2r	135	16	MERS	MERS	NNP
cord-315453-mbv8vb2r	135	17	-	-	HYPH
cord-315453-mbv8vb2r	135	18	CoV	CoV	NNP
cord-315453-mbv8vb2r	135	19	Teicoplanin	Teicoplanin	NNPS
cord-315453-mbv8vb2r	135	20	:	:	:
cord-315453-mbv8vb2r	135	21	an	an	DT
cord-315453-mbv8vb2r	135	22	alternative	alternative	JJ
cord-315453-mbv8vb2r	135	23	drug	drug	NN
cord-315453-mbv8vb2r	135	24	for	for	IN
cord-315453-mbv8vb2r	135	25	the	the	DT
cord-315453-mbv8vb2r	135	26	treatment	treatment	NN
cord-315453-mbv8vb2r	135	27	of	of	IN
cord-315453-mbv8vb2r	135	28	coronavirus	coronavirus	NN
cord-315453-mbv8vb2r	136	1	COVID-19	covid-19	VB
cord-315453-mbv8vb2r	136	2	?	?	.
cord-315453-mbv8vb2r	137	1	The	the	DT
cord-315453-mbv8vb2r	137	2	pharmacokinetics	pharmacokinetic	NNS
cord-315453-mbv8vb2r	137	3	and	and	CC
cord-315453-mbv8vb2r	137	4	interactions	interaction	NNS
cord-315453-mbv8vb2r	137	5	of	of	IN
cord-315453-mbv8vb2r	137	6	ivermectin	ivermectin	NNP
cord-315453-mbv8vb2r	137	7	in	in	IN
cord-315453-mbv8vb2r	137	8	humans	human	NNS
cord-315453-mbv8vb2r	137	9	-	-	:
cord-315453-mbv8vb2r	137	10	a	a	DT
cord-315453-mbv8vb2r	137	11	mini	mini	JJ
cord-315453-mbv8vb2r	137	12	-	-	NN
cord-315453-mbv8vb2r	137	13	review	review	NN
cord-315453-mbv8vb2r	137	14	Immunomodulatory	immunomodulatory	JJ
cord-315453-mbv8vb2r	137	15	effect	effect	NN
cord-315453-mbv8vb2r	137	16	of	of	IN
cord-315453-mbv8vb2r	137	17	various	various	JJ
cord-315453-mbv8vb2r	137	18	anti	anti	NNS
cord-315453-mbv8vb2r	137	19	-	-	NNS
cord-315453-mbv8vb2r	137	20	parasitics	parasitic	NNS
cord-315453-mbv8vb2r	137	21	:	:	:
cord-315453-mbv8vb2r	137	22	a	a	DT
cord-315453-mbv8vb2r	137	23	review	review	NN
cord-315453-mbv8vb2r	138	1	An	an	DT
cord-315453-mbv8vb2r	138	2	AlphaScreen	AlphaScreen	NNP
cord-315453-mbv8vb2r	138	3	®	®	POS
cord-315453-mbv8vb2r	138	4	-based	-based	JJ
cord-315453-mbv8vb2r	138	5	assay	assay	NN
cord-315453-mbv8vb2r	138	6	for	for	IN
cord-315453-mbv8vb2r	138	7	high	high	JJ
cord-315453-mbv8vb2r	138	8	-	-	HYPH
cord-315453-mbv8vb2r	138	9	throughput	throughput	NN
cord-315453-mbv8vb2r	138	10	screening	screening	NN
cord-315453-mbv8vb2r	138	11	for	for	IN
cord-315453-mbv8vb2r	138	12	specific	specific	JJ
cord-315453-mbv8vb2r	138	13	inhibitors	inhibitor	NNS
cord-315453-mbv8vb2r	138	14	of	of	IN
cord-315453-mbv8vb2r	138	15	nuclear	nuclear	JJ
cord-315453-mbv8vb2r	138	16	import	import	NN
cord-315453-mbv8vb2r	139	1	The	the	DT
cord-315453-mbv8vb2r	139	2	FDA	FDA	NNP
cord-315453-mbv8vb2r	139	3	-	-	HYPH
cord-315453-mbv8vb2r	139	4	approved	approve	VBN
cord-315453-mbv8vb2r	139	5	drug	drug	NN
cord-315453-mbv8vb2r	139	6	ivermectin	ivermectin	NNP
cord-315453-mbv8vb2r	139	7	inhibits	inhibit	VBZ
cord-315453-mbv8vb2r	139	8	the	the	DT
cord-315453-mbv8vb2r	139	9	replication	replication	NN
cord-315453-mbv8vb2r	139	10	of	of	IN
cord-315453-mbv8vb2r	139	11	SARS	SARS	NNP
cord-315453-mbv8vb2r	139	12	-	-	HYPH
cord-315453-mbv8vb2r	139	13	CoV-2	CoV-2	NNP
cord-315453-mbv8vb2r	139	14	in	in	IN
cord-315453-mbv8vb2r	139	15	vitro	vitro	FW
cord-315453-mbv8vb2r	140	1	Issuing	issue	VBG
cord-315453-mbv8vb2r	140	2	an	an	DT
cord-315453-mbv8vb2r	140	3	important	important	JJ
cord-315453-mbv8vb2r	140	4	finding	finding	NN
cord-315453-mbv8vb2r	140	5	,	,	,
cord-315453-mbv8vb2r	140	6	validated	validate	VBN
cord-315453-mbv8vb2r	140	7	by	by	IN
cord-315453-mbv8vb2r	140	8	US	US	NNP
cord-315453-mbv8vb2r	140	9	FDA	FDA	NNP
cord-315453-mbv8vb2r	140	10	,	,	,
cord-315453-mbv8vb2r	140	11	about	about	IN
cord-315453-mbv8vb2r	140	12	the	the	DT
cord-315453-mbv8vb2r	140	13	in	in	FW
cord-315453-mbv8vb2r	140	14	vitro	vitro	FW
cord-315453-mbv8vb2r	140	15	efficacy	efficacy	NN
cord-315453-mbv8vb2r	140	16	of	of	IN
cord-315453-mbv8vb2r	140	17	ivermectin	ivermectin	NNP
cord-315453-mbv8vb2r	140	18	on	on	IN
cord-315453-mbv8vb2r	140	19	reducing	reduce	VBG
cord-315453-mbv8vb2r	140	20	SARS	SARS	NNP
cord-315453-mbv8vb2r	140	21	-	-	HYPH
cord-315453-mbv8vb2r	140	22	CoV-2	CoV-2	NNP
cord-315453-mbv8vb2r	140	23	loading	load	VBG
cord-315453-mbv8vb2r	140	24	Nuclear	nuclear	JJ
cord-315453-mbv8vb2r	140	25	trafficking	trafficking	NN
cord-315453-mbv8vb2r	140	26	of	of	IN
cord-315453-mbv8vb2r	140	27	proteins	protein	NNS
cord-315453-mbv8vb2r	140	28	from	from	IN
cord-315453-mbv8vb2r	140	29	RNA	RNA	NNP
cord-315453-mbv8vb2r	140	30	viruses	virus	NNS
cord-315453-mbv8vb2r	140	31	:	:	:
cord-315453-mbv8vb2r	140	32	potential	potential	JJ
cord-315453-mbv8vb2r	140	33	target	target	NN
cord-315453-mbv8vb2r	140	34	for	for	IN
cord-315453-mbv8vb2r	140	35	antivirals	antiviral	NNS
cord-315453-mbv8vb2r	140	36	?	?	.
cord-315453-mbv8vb2r	141	1	Serious	serious	JJ
cord-315453-mbv8vb2r	141	2	neurological	neurological	JJ
cord-315453-mbv8vb2r	141	3	adverse	adverse	JJ
cord-315453-mbv8vb2r	141	4	events	event	NNS
cord-315453-mbv8vb2r	141	5	after	after	IN
cord-315453-mbv8vb2r	141	6	ivermectin	ivermectin	NNP
cord-315453-mbv8vb2r	141	7	-	-	:
cord-315453-mbv8vb2r	141	8	Do	do	VBP
cord-315453-mbv8vb2r	141	9	they	-PRON-	PRP
cord-315453-mbv8vb2r	141	10	occur	occur	VB
cord-315453-mbv8vb2r	141	11	beyond	beyond	IN
cord-315453-mbv8vb2r	141	12	the	the	DT
cord-315453-mbv8vb2r	141	13	Indication	indication	NN
cord-315453-mbv8vb2r	141	14	of	of	IN
cord-315453-mbv8vb2r	141	15	onchocerciasis	onchocerciasis	NN
cord-315453-mbv8vb2r	141	16	?	?	.
cord-315453-mbv8vb2r	142	1	•	•	NNP
cord-315453-mbv8vb2r	143	1	A	a	DT
cord-315453-mbv8vb2r	143	2	detailed	detailed	JJ
cord-315453-mbv8vb2r	143	3	study	study	NN
cord-315453-mbv8vb2r	143	4	addressing	address	VBG
cord-315453-mbv8vb2r	143	5	the	the	DT
cord-315453-mbv8vb2r	143	6	potentially	potentially	RB
cord-315453-mbv8vb2r	143	7	adverse	adverse	JJ
cord-315453-mbv8vb2r	143	8	effects	effect	NNS
cord-315453-mbv8vb2r	143	9	about	about	IN
cord-315453-mbv8vb2r	143	10	ivermectin	ivermectin	NN
cord-315453-mbv8vb2r	143	11	treatment	treatment	NN
cord-315453-mbv8vb2r	143	12	on	on	IN
cord-315453-mbv8vb2r	143	13	patients	patient	NNS
cord-315453-mbv8vb2r	143	14	with	with	IN
cord-315453-mbv8vb2r	143	15	scabies	scabie	NNS
cord-315453-mbv8vb2r	143	16	,	,	,
cord-315453-mbv8vb2r	143	17	many	many	JJ
cord-315453-mbv8vb2r	143	18	helminth	helminth	JJ
cord-315453-mbv8vb2r	143	19	infestations	infestation	NNS
cord-315453-mbv8vb2r	143	20	Safety	Safety	NNP
cord-315453-mbv8vb2r	143	21	of	of	IN
cord-315453-mbv8vb2r	143	22	high	high	JJ
cord-315453-mbv8vb2r	143	23	-	-	HYPH
cord-315453-mbv8vb2r	143	24	dose	dose	NN
cord-315453-mbv8vb2r	143	25	ivermectin	ivermectin	NNP
cord-315453-mbv8vb2r	143	26	:	:	:
cord-315453-mbv8vb2r	143	27	a	a	DT
cord-315453-mbv8vb2r	143	28	systematic	systematic	JJ
cord-315453-mbv8vb2r	143	29	review	review	NN
cord-315453-mbv8vb2r	143	30	and	and	CC
cord-315453-mbv8vb2r	143	31	meta	meta	NNP
cord-315453-mbv8vb2r	143	32	-	-	HYPH
cord-315453-mbv8vb2r	143	33	analysis	analysis	NN
cord-315453-mbv8vb2r	143	34	Exploring	explore	VBG
cord-315453-mbv8vb2r	143	35	the	the	DT
cord-315453-mbv8vb2r	143	36	safe	safe	JJ
cord-315453-mbv8vb2r	143	37	dose	dose	NN
cord-315453-mbv8vb2r	143	38	of	of	IN
cord-315453-mbv8vb2r	143	39	ivermectin	ivermectin	NNP
cord-315453-mbv8vb2r	143	40	in	in	IN
cord-315453-mbv8vb2r	143	41	human	human	JJ
cord-315453-mbv8vb2r	143	42	treatment	treatment	NN
cord-315453-mbv8vb2r	143	43	double	double	RB
cord-315453-mbv8vb2r	143	44	-	-	HYPH
cord-315453-mbv8vb2r	143	45	blind	blind	JJ
cord-315453-mbv8vb2r	143	46	,	,	,
cord-315453-mbv8vb2r	143	47	placebo	placebo	NN
cord-315453-mbv8vb2r	143	48	-	-	HYPH
cord-315453-mbv8vb2r	143	49	controlled	control	VBN
cord-315453-mbv8vb2r	143	50	study	study	NN
cord-315453-mbv8vb2r	143	51	to	to	TO
cord-315453-mbv8vb2r	143	52	investigate	investigate	VB
cord-315453-mbv8vb2r	143	53	the	the	DT
cord-315453-mbv8vb2r	143	54	efficacy	efficacy	NN
cord-315453-mbv8vb2r	143	55	of	of	IN
cord-315453-mbv8vb2r	143	56	tradipitant	tradipitant	JJ
cord-315453-mbv8vb2r	143	57	in	in	IN
cord-315453-mbv8vb2r	143	58	treating	treat	VBG
cord-315453-mbv8vb2r	143	59	inflammatory	inflammatory	JJ
cord-315453-mbv8vb2r	143	60	lung	lung	NN
cord-315453-mbv8vb2r	143	61	injury	injury	NN
cord-315453-mbv8vb2r	143	62	and	and	CC
cord-315453-mbv8vb2r	143	63	improving	improve	VBG
cord-315453-mbv8vb2r	143	64	clinical	clinical	JJ
cord-315453-mbv8vb2r	143	65	outcomes	outcome	NNS
cord-315453-mbv8vb2r	143	66	associated	associate	VBN
cord-315453-mbv8vb2r	143	67	with	with	IN
cord-315453-mbv8vb2r	143	68	severe	severe	JJ
cord-315453-mbv8vb2r	143	69	or	or	CC
cord-315453-mbv8vb2r	143	70	critical	critical	JJ
cord-315453-mbv8vb2r	143	71	COVID-19	covid-19	NN
cord-315453-mbv8vb2r	143	72	.	.	.
cord-315453-mbv8vb2r	144	1	(	(	-LRB-
cord-315453-mbv8vb2r	144	2	ClinicalTrials.gov	ClinicalTrials.gov	NNP
cord-315453-mbv8vb2r	145	1	NCT04326426	NCT04326426	NNP
cord-315453-mbv8vb2r	145	2	)	)	-RRB-
cord-315453-mbv8vb2r	146	1	Inhalation	inhalation	NN
cord-315453-mbv8vb2r	146	2	of	of	IN
cord-315453-mbv8vb2r	146	3	nitric	nitric	NN
cord-315453-mbv8vb2r	146	4	oxide	oxide	NN
cord-315453-mbv8vb2r	146	5	in	in	IN
cord-315453-mbv8vb2r	146	6	the	the	DT
cord-315453-mbv8vb2r	146	7	treatment	treatment	NN
cord-315453-mbv8vb2r	146	8	of	of	IN
cord-315453-mbv8vb2r	146	9	severe	severe	JJ
cord-315453-mbv8vb2r	146	10	acute	acute	JJ
cord-315453-mbv8vb2r	146	11	respiratory	respiratory	JJ
cord-315453-mbv8vb2r	146	12	syndrome	syndrome	NN
cord-315453-mbv8vb2r	146	13	:	:	:
cord-315453-mbv8vb2r	146	14	a	a	DT
cord-315453-mbv8vb2r	146	15	rescue	rescue	NN
cord-315453-mbv8vb2r	146	16	trial	trial	NN
cord-315453-mbv8vb2r	146	17	in	in	IN
cord-315453-mbv8vb2r	146	18	Beijing	Beijing	NNP
cord-315453-mbv8vb2r	146	19	Society	Society	NNP
cord-315453-mbv8vb2r	146	20	of	of	IN
cord-315453-mbv8vb2r	146	21	critical	critical	JJ
cord-315453-mbv8vb2r	146	22	care	care	NN
cord-315453-mbv8vb2r	146	23	medicine	medicine	NN
cord-315453-mbv8vb2r	146	24	Treating	treat	VBG
cord-315453-mbv8vb2r	146	25	the	the	DT
cord-315453-mbv8vb2r	146	26	host	host	NN
cord-315453-mbv8vb2r	146	27	response	response	NN
cord-315453-mbv8vb2r	146	28	to	to	IN
cord-315453-mbv8vb2r	146	29	emerging	emerge	VBG
cord-315453-mbv8vb2r	146	30	virus	virus	NN
cord-315453-mbv8vb2r	146	31	diseases	disease	NNS
cord-315453-mbv8vb2r	146	32	:	:	:
cord-315453-mbv8vb2r	146	33	lessons	lesson	NNS
cord-315453-mbv8vb2r	146	34	learned	learn	VBN
cord-315453-mbv8vb2r	146	35	from	from	IN
cord-315453-mbv8vb2r	146	36	sepsis	sepsis	NN
cord-315453-mbv8vb2r	146	37	,	,	,
cord-315453-mbv8vb2r	146	38	pneumonia	pneumonia	NN
cord-315453-mbv8vb2r	146	39	,	,	,
cord-315453-mbv8vb2r	146	40	influenza	influenza	NN
cord-315453-mbv8vb2r	146	41	and	and	CC
cord-315453-mbv8vb2r	146	42	Ebola	Ebola	NNP
cord-315453-mbv8vb2r	146	43	Hiding	hide	VBG
cord-315453-mbv8vb2r	146	44	in	in	IN
cord-315453-mbv8vb2r	146	45	plain	plain	JJ
cord-315453-mbv8vb2r	146	46	sight	sight	NN
cord-315453-mbv8vb2r	146	47	:	:	:
cord-315453-mbv8vb2r	146	48	an	an	DT
cord-315453-mbv8vb2r	146	49	approach	approach	NN
cord-315453-mbv8vb2r	146	50	to	to	IN
cord-315453-mbv8vb2r	146	51	treating	treat	VBG
cord-315453-mbv8vb2r	146	52	patients	patient	NNS
cord-315453-mbv8vb2r	146	53	with	with	IN
cord-315453-mbv8vb2r	146	54	severe	severe	JJ
cord-315453-mbv8vb2r	146	55	COVID-19	covid-19	JJ
cord-315453-mbv8vb2r	146	56	infection	infection	NN
cord-315453-mbv8vb2r	146	57	Treatment	Treatment	NNP
cord-315453-mbv8vb2r	146	58	options	option	NNS
cord-315453-mbv8vb2r	146	59	for	for	IN
cord-315453-mbv8vb2r	146	60	COVID-19	covid-19	VB
cord-315453-mbv8vb2r	146	61	:	:	:
cord-315453-mbv8vb2r	146	62	the	the	DT
cord-315453-mbv8vb2r	146	63	reality	reality	NN
cord-315453-mbv8vb2r	146	64	and	and	CC
cord-315453-mbv8vb2r	146	65	challenges	challenge	NNS
cord-315453-mbv8vb2r	146	66	Issuing	issue	VBG
cord-315453-mbv8vb2r	146	67	many	many	JJ
cord-315453-mbv8vb2r	146	68	potentially	potentially	RB
cord-315453-mbv8vb2r	146	69	effective	effective	JJ
cord-315453-mbv8vb2r	146	70	drugs	drug	NNS
cord-315453-mbv8vb2r	146	71	against	against	IN
cord-315453-mbv8vb2r	146	72	SARS	SARS	NNP
cord-315453-mbv8vb2r	146	73	-	-	HYPH
cord-315453-mbv8vb2r	146	74	CoV-2	CoV-2	NNP
cord-315453-mbv8vb2r	146	75	and	and	CC
cord-315453-mbv8vb2r	146	76	other	other	JJ
cord-315453-mbv8vb2r	146	77	practical	practical	JJ
cord-315453-mbv8vb2r	146	78	therapies	therapy	NNS
cord-315453-mbv8vb2r	146	79	in	in	IN
cord-315453-mbv8vb2r	146	80	treatment	treatment	NN
cord-315453-mbv8vb2r	146	81	of	of	IN
cord-315453-mbv8vb2r	146	82	critical	critical	JJ
cord-315453-mbv8vb2r	146	83	COVID-19	COVID-19	NNP
cord-315453-mbv8vb2r	146	84	in	in	IN
cord-315453-mbv8vb2r	146	85	detail	detail	NN